Canopy Growth (CGC) 10-K 31 May 22 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - CAD ($) $ in Billions	12 Months Ended
	Mar. 31, 2022	May 26, 2022	Sep. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Canopy Growth Corporation
Entity Central Index Key	0001737927
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Well Known Seasoned Issuer	Yes
Entity Public Float			$ 5.5
Entity Common Stock, Shares Outstanding		402,858,012
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	CGC
Security Exchange Name	NASDAQ
Entity File Number	001-38496
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	1 Hershey Drive
Entity Address, City or Town	Smiths Falls
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	K7A 0A8
City Area Code	855
Local Phone Number	558-9333
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Auditor Firm ID	85
Auditor Name	KPMG LLP
Auditor Location	Ottawa, Canada
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Part III of this annual report on Form 10-K incorporates certain information by reference from the registrant’s definitive proxy statement with respect to its 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year.

Consolidated Balance Sheets

Consolidated Balance Sheets - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 776,005	$ 1,154,653
Short-term investments	595,651	1,144,563
Restricted short-term investments	12,216	11,332
Amounts receivable, net	96,443	92,435
Inventory	204,387	367,979
Prepaid expenses and other assets	52,700	67,232
Total current assets	1,737,402	2,838,194
Other financial assets	800,328	708,167
Property, plant and equipment	942,780	1,074,537
Intangible assets	252,695	308,167
Goodwill	1,866,503	1,889,354
Other assets	15,342	5,061
Total assets	5,615,050	6,823,480
Current liabilities:
Accounts payable	64,270	67,262
Other accrued expenses and liabilities	75,278	100,813
Current portion of long-term debt	9,296	9,827
Other liabilities	64,054	106,428
Total current liabilities	212,898	284,330
Long-term debt	1,491,695	1,573,136
Deferred income tax liabilities	15,991	21,379
Liability arising from Acreage Arrangement	47,000	600,000
Warrant derivative liability	26,920	615,575
Other liabilities	190,049	107,240
Total liabilities	1,984,553	3,201,660
Commitments and contingencies
Redeemable noncontrolling interest	36,200	135,300
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 394,422,604 shares and 382,875,179 shares, respectively	7,482,809	7,168,557
Additional paid-in capital	2,519,766	2,415,650
Accumulated other comprehensive loss	(42,282)	(34,240)
Deficit	(6,370,337)	(6,068,156)
Total Canopy Growth Corporation shareholders' equity	3,589,956	3,481,811
Noncontrolling interests	4,341	4,709
Total shareholders' equity	3,594,297	3,486,520
Total liabilities and shareholders' equity	$ 5,615,050	$ 6,823,480

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Mar. 31, 2022	Mar. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, shares issued	394,422,604	382,875,179

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 582,218	$ 607,198	$ 439,626
Excise taxes	61,893	60,549	40,854
Net revenue	520,325	546,649	398,772
Cost of goods sold	713,379	479,689	430,456
Gross margin	(193,054)	66,960	(31,684)
Operating expenses
Selling, general and administrative expenses	472,756	575,389	693,737
Share-based compensation	47,525	91,149	320,276
Expected credit losses on financial assets and related charges	0	109,480	0
Asset impairment and restructuring costs	369,339	534,398	623,266
Total operating expenses	889,620	1,310,416	1,637,279
Operating loss	(1,082,674)	(1,243,456)	(1,668,963)
Loss from equity method investments	(100)	(52,629)	(64,420)
Other income (expense), net	753,341	(387,876)	224,329
Loss before income taxes	(329,433)	(1,683,961)	(1,509,054)
Income tax recovery	8,948	13,141	121,614
Net loss	(320,485)	(1,670,820)	(1,387,440)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	(18,304)	74,100	(66,114)
Net loss attributable to Canopy Growth Corporation	$ (302,181)	$ (1,744,920)	$ (1,321,326)
Basic and diluted loss per share	$ (0.77)	$ (4.69)	$ (3.80)
Basic and diluted weighted average common shares outstanding	391,324,285	371,662,296	348,038,163
Comprehensive loss:
Net loss	$ (320,485)	$ (1,670,820)	$ (1,387,440)
Other comprehensive income (loss), net of income tax effect
Fair value changes of own credit risk of financial liabilities	21,180	(100,170)	141,306
Foreign currency translation	(45,352)	(154,969)	85,498
Total other comprehensive income (loss), net of income tax effect	(24,172)	(255,139)	226,804
Comprehensive loss	(344,657)	(1,925,959)	(1,160,636)
Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest	(18,304)	74,100	(66,114)
Comprehensive loss attributable to Canopy Growth Corporation	$ (326,353)	$ (2,000,059)	$ (1,094,522)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - CAD ($) $ in Thousands	Total	Common Shares	Additional Paid-in capitalShare-based Reserve	Additional Paid-in capitalWarrants	Additional Paid-in capitalOwnership Changes	Additional Paid-in capitalRedeemable Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)	Deficit	Noncontrolling Interests
Beginning balance at Mar. 31, 2019	$ 7,065,708	$ 6,029,222	$ 505,172	$ 1,589,925	$ (500,963)	$ (2,110)	$ (5,905)	$ (835,118)	$ 285,485
Other issuances of common shares and warrants	91	271,966	(272,234)	359
Exercise of warrants	446	932		(486)
Exercise of Omnibus Plan stock options	41,413	69,951	(28,538)
Share-based compensation	$ 312,929		$ 312,929
Issuance of replacement equity instruments	1,885		1,885
Issuance and vesting of restricted share units		1,473	$ (1,473)
CBI warrant modification	$ (1,117,639)			1,049,153				(2,166,792)
Changes in redeemable noncontrolling interest	(44,513)					(38,024)			(6,489)
Ownership changes relating to noncontrolling interests	8,436				(440)				8,876
Comprehensive loss	(1,160,636)						226,804	(1,321,326)	(66,114)
Ending balance at Mar. 31, 2020	5,108,120	6,373,544	517,741	2,638,951	(501,403)	(40,134)	220,899	(4,323,236)	221,758
Other issuances of common shares and warrants	27,856	61,809	(33,953)
Exercise of warrants	245,186	315,699		(70,513)
Exercise of Omnibus Plan stock options	156,897	244,170	(87,273)
Share-based compensation	87,322		87,322
Issuance and vesting of restricted share units		3,051	(3,051)
Completion of plan of arrangement with RIV Capital	(153,935)	170,284			(10,976)				(313,243)
Changes in redeemable noncontrolling interest	(65,550)					(83,627)			18,077
Ownership changes relating to noncontrolling interests	6,583				39	2,527			4,017
Comprehensive loss	(1,925,959)						(255,139)	(1,744,920)	74,100
Ending balance at Mar. 31, 2021	3,486,520	7,168,557	480,786	2,568,438	(512,340)	(121,234)	(34,240)	(6,068,156)	4,709
Other issuances of common shares and warrants	267,688	298,145	(30,457)
Replacement equity instruments from the acquisition of Supreme Cannabis	18,916		5,566	13,350
Exercise of Omnibus Plan stock options	5,567	8,855	(3,288)
Share-based compensation	46,686		46,686
Issuance and vesting of restricted share units		7,252	(7,252)
Changes in redeemable noncontrolling interest	99,100					82,003			17,097
Ownership changes relating to noncontrolling interests	839								839
Redemption of redeemable noncontrolling interest	(2,492)				2,617	(5,109)
Disposal of consolidated entities	16,130						16,130
Comprehensive loss	(344,657)						(24,172)	(302,181)	(18,304)
Ending balance at Mar. 31, 2022	$ 3,594,297	$ 7,482,809	$ 492,041	$ 2,581,788	$ (509,723)	$ (44,340)	$ (42,282)	$ (6,370,337)	$ 4,341

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (320,485)	$ (1,670,820)	$ (1,387,440)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment	76,247	70,914	73,716
Amortization of intangible assets	38,171	56,204	51,297
Share of loss on equity method investments	100	52,629	64,420
Share-based compensation	47,525	91,149	320,276
Asset impairment and restructuring costs	332,949	519,209	571,719
Expected credit losses on financial assets and related charges	0	109,480	0
Income tax recovery	(8,948)	(13,141)	(121,614)
Non-cash fair value adjustments	(866,739)	380,758	(103,027)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable	3,741	(11,994)	20,979
Inventory	173,189	23,107	(33,952)
Prepaid expenses and other assets	24,472	77	(26,917)
Accounts payable and accrued liabilities	(35,844)	16,542	(11,222)
Other, including non-cash foreign currency	(10,189)	(89,843)	(190,870)
Net cash used in operating activities	(545,811)	(465,729)	(772,635)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment	(36,684)	(164,502)	(704,944)
Purchases of intangible assets	(11,429)	(9,639)	(16,957)
Proceeds on sale of property, plant and equipment	27,279	45,921	0
Proceeds on sale of intangible assets	0	18,337	0
Redemption (purchases) of short-term investments	545,991	(459,834)	1,427,482
Cash outflow on completion of RIV Arrangement	0	(152,801)	0
Net cash proceeds on sale of subsidiaries	118,149	0	0
Sale of (investments in) equity method investments	0	7,000	(5,135)
Investment in other financial assets	(379,414)	(44,721)	(129,590)
Investment in Acreage Arrangement	0	(49,849)	(395,190)
Loan advanced to Acreage Hempco	0	(66,995)	0
Net cash outflow on acquisition of subsidiaries	(14,947)	0	(498,838)
Other investing activities	(18,126)	(7,022)	(24,482)
Net cash provided by (used in) investing activities	230,819	(884,105)	(347,654)
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants	2,700	0	0
Proceeds from exercise of stock options	5,567	156,897	41,413
Proceeds from exercise of warrants	0	245,186	446
Issuance of long-term debt	0	893,160	14,761
Repayment of long-term debt	(50,763)	(15,619)	(114,953)
Other financing activities	(3,037)	(14,855)	1,172
Net cash (used in) provided by financing activities	(45,533)	1,264,769	(57,161)
Effect of exchange rate changes on cash and cash equivalents	(18,123)	(63,458)	(204)
Net decrease in cash and cash equivalents	(378,648)	(148,523)	(1,177,654)
Cash and cash equivalents, beginning of period	1,154,653	1,303,176	2,480,830
Cash and cash equivalents, end of period	776,005	1,154,653	1,303,176
Cash received during the period:
Income taxes	1,299	4,068	0
Interest	16,175	26,279	66,327
Cash paid during the period:
Income taxes	2,641	22,769	5,460
Interest	119,249	25,649	25,472
Noncash investing and financing activities
Additions to property, plant and equipment	$ 1,408	$ 9,962	$ 44,573

Description of Business

Description of Business	12 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1 Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References in these consolidated financial statements to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult recreational and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act, In the year ended March 31, 2020, the Company commenced an organizational and strategic review of its business which resulted in a restructuring of the Company’s global operations, including the closure of certain of the Company’s production facilities and other organizational and operational changes. The Company’s restructuring actions continued during the years ended March 31, 2021 and March 31, 2022. Please refer to Note 5 for further details regarding these restructuring actions. On February 23, 2021, the Company completed a plan of arrangement with its partially-owned subsidiary RIV Capital Inc. (formerly Canopy Rivers Inc.) (“RIV Capital”) and its wholly-owned subsidiary, RIV Capital Corporation (formerly Canopy Rivers Corporation) (“RCC”). As a result of this transaction, the Company no longer controlled RIV Capital and derecognized RIV Capital’s consolidated assets and liabilities from its consolidated financial statements. Refer to Note 6 for a description of the plan of arrangement with RIV Capital.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2 The consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under Accounting Standards Codification (“ASC”) 810 – Consolidations Equity method investments Investments accounted for using the equity method include those investments where the Company (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods. Use of estimates The preparation of these consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3 Foreign currency translation In preparing the financial statements of individual entities, transactions in currencies other than the entity’s functional currency are recognized at exchange rates in effect on the date of the transactions. At each reporting date monetary assets and liabilities denominated in foreign currencies are re-translated at the exchange rates applicable at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary assets and liabilities that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Realized and unrealized exchange gains and losses are recognized through net income (loss). For the purposes of presenting consolidated financial statements, the assets and liabilities of foreign operations are translated into Canadian dollars at the exchange rates applicable at the balance sheet date. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in accumulated other comprehensive income (loss). Cash equivalents and short-term investments Cash equivalents consist of highly liquid investments with original maturities of three months or less. Investments with maturities greater than 90 days but less than one year at the date of purchase are included in short-term investments. The Company’s investments in debt securities, which consist primarily of U.S. government securities and U.S. commercial paper, have been classified and accounted for using the fair value option. Unrealized gains and losses on debt securities are recognized in net income (loss). All other short-term investments are recorded at fair value with gains or losses recognized in net income (loss). Inventory Inventory consists of raw materials, supplies and consumables used in the inventory process, merchandise for sale, finished goods and work-in-process such as pre-harvested cannabis plants, by-products to be extracted, oils, gel capsules and edible products. Inventory is valued at the lower of cost and net realizable value. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead costs. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, age of inventory, historical experience and application of the specific identification method. The Company classifies cannabis inventory as a current asset, although part of such inventory, because of the duration of the cultivation, drying, and conversion process, ordinarily would not be utilized within one year. Property, plant and equipment Property, plant and equipment is recorded at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in net income (loss). Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 Estimates of useful life and residual value, and the method of depreciation, are reviewed only when events or changes in circumstances indicate that the current estimates or depreciation method are no longer appropriate. Any changes are accounted for on a prospective basis as a change in estimate. Intangible assets Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 8 Software and domain names 3 - 5 Brands 2 - 5 The estimated useful life and amortization method are reviewed at the end of each reporting year, with the effect of any changes in estimate being accounted for on a prospective basis. Goodwill and indefinite lived intangible assets Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company reviews goodwill and indefinite lived intangible assets annually for impairment in the fourth quarter, or sooner, if events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If factors indicate this is the case, then a quantitative test is performed and an impairment is recorded for any excess carrying value above the reporting unit’s fair value, not to exceed the amount of goodwill. Until the three months ended March 31, 2021, the Company had two operating segments, which were also its reportable segments: (i) cannabis, hemp and other consumer products; and (ii) RIV Capital. The goodwill associated with all acquisitions was allocated to the one reporting unit within the cannabis, hemp and other consumer products operating and reportable segment, as this reporting unit held the acquired entities. The Company changed the structure of its internal management reporting in the fourth quarter of the year ended March 31, 2021 (refer to Note 35), and accordingly, identified two operating and reportable segments: (i) global cannabis; and (ii) other consumer products. The reorganization of the Company’s reporting structure changed the composition of its reporting units and required that goodwill be reassigned to the reporting units using a relative fair value allocation approach. Assets and liabilities were also reassigned to the reporting units affected based on the assets that would be employed in, or the liabilities related to, the operations of each reporting unit, and the assets or liabilities that would be considered in determining the fair value of each reporting unit. After this reorganization, the Company’s reporting units with goodwill in the global cannabis segment included (i) cannabis operations, and (ii) C 3 3 In the three months ended March 31, 2022, the Company further changed the composition of its reporting units within the global cannabis segment as a result of (i) the completion of the Company’s divestiture (the “C 3 3 The Company performed its annual goodwill impairment test in the fourth quarter of the year ended March 31, 2022, and recognized an impairment loss in relation to its KeyLeaf and This Works reporting units. Refer to Note 15 for further details. Indefinite lived intangible assets are comprised of certain acquired brand names and operating licenses, which are carried at cost less accumulated impairment losses. The Company reviews the classification each reporting period to decide whether the assessment made about the useful life as indefinite or finite is still appropriate. Any change is accounted for on a prospective basis as a change in estimate. Impairment of long-lived assets The Company evaluates the recoverability of long-lived assets, including property, plant and equipment and finite lived intangible assets whenever events or changes in circumstances indicate a potential impairment exists. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. When indicators of potential impairment are present the Company prepares a projected undiscounted cash flow analysis for the respective asset or asset group. If the sum of the undiscounted cash flow is less than the carrying value of the asset or asset group, an impairment loss is recognized equal to the excess of the carrying value over the fair value, if any. Restricted short-term investments The Company considers short-term investments to be restricted when withdrawal or general use is legally restricted. The Company records restricted short-term investments as current or non-current in the consolidated balance sheets based on the classification of the underlying securities. Redeemable noncontrolling interest Redeemable noncontrolling interest is presented as mezzanine equity. The balance of the redeemable noncontrolling interest is reported at the greater of the initial carrying amount adjusted for the redeemable noncontrolling interest's share of earnings or losses and other comprehensive income or loss, or its estimated redemption value. The Company adjusts the carrying amount of the redeemable interest to the redemption amount each period, assuming the interest was redeemable at the balance sheet date with changes in fair value recorded in equity. Revenue recognition The Company’s cannabis revenue is comprised of sales of (i) recreational cannabis products in Canada, either to government agencies or third-party retailers under a “business-to-business” wholesale model, or directly to consumers through the Company’s network of retail stores and e-commerce platforms; and (ii) medical and other cannabis products in Canada and certain other countries. The Company’s other revenue is comprised of sales of vaporizers, beauty, wellness and sleep products, sports nutrition beverages, merchandise, and revenue from other sources. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. In accordance with contracts with certain of the Company’s Canadian provincial customers, the Company fulfills its obligations only when the customer transfers control of the product to the end consumer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts, most notably those with the Canadian provincial and territorial agencies, may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. The Company estimates this variable consideration by taking into account factors such as historical information, current trends, forecasts, provincial and territorial inventory levels, availability of actual results and expectations of demand. The Company recognizes a liability for sales refunds within other current liabilities, and an asset for the value of inventory which is expected to be returned is recognized within prepaid expenses and other assets on the consolidated balance sheets. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data. Cost of goods sold The types of costs included in cost of goods sold are raw materials, packaging materials, manufacturing costs, plant facilities administrative support and overheads, and freight and warehouse costs, including distribution costs. Advertising Advertising costs are expensed as incurred. Advertising expenses totaled $104,221, $72,377 and $78,474 in the years ended March 31, 2022, 2021, and 2020, respectively. Research and development Research and development costs are expensed as incurred. Research and development expenses totaled $32,344, $57,582, and $61,812 in the years ended March 31, 2022, 2021, and 2020, respectively. Asset impairment and restructuring costs Asset impairment and restructuring costs consist of property, plant and equipment, intangible asset and goodwill impairment charges, asset abandonment costs, contractual and other settlement costs, and employee-related and other restructuring costs recognized in connection with (i) the restructuring of the Company’s global operations that commenced in the year ended March 31, 2020 and continued during the years ended March 31, 2021 and March 31, 2022; and (ii) other impairments. When a long-lived asset is abandoned its carrying amount is adjusted to its salvage value, if any. In determining the salvage value of our long-lived assets, management considers information from manufacturers, historical data, and industry standards. In certain cases, management may obtain third party appraisals to estimate salvage value. Share-based compensation The Company accounts for share-based compensation using the fair value method. With the exception of a limited number of share-based awards subject to market-based performance conditions that are valued using the Monte Carlo simulation model, the fair value of awards granted is estimated at the date of grant using the Black-Scholes model. The share-based compensation expense is based on the fair value of share-based awards at the grant date and the expense is recognized over the related service period following a graded vesting expense schedule. Forfeitures are estimated at the time of grant and revised in subsequent periods if there is a difference in actual forfeitures and the estimate. Effective April 1, 2018, the Company early-adopted ASU 2018-07 – Compensation - Stock Compensation (Topic 718) For awards with service and/or non-market based performance conditions, the amount of compensation expense recognized is based on the number of awards expected to vest, reflecting estimated expected forfeitures, and is adjusted to reflect those awards that do ultimately vest. For awards with performance conditions, the Company recognizes the compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of achieving the performance condition at each reporting date. Restricted stock units (“RSUs”) that are settled in cash or common stock at the election of the employee are remeasured to fair value at the end of each reporting period until settlement. This fair value is based on the closing price of the Company's common shares on the last business day before each period end. Income taxes Income taxes are comprised of current and deferred taxes. These taxes are accounted for using the liability method. Current tax is recognized in connection with income for tax purposes, unrealized tax benefits and the recovery of tax paid in a prior period and measured using the enacted tax rates and laws applicable to the taxation period during which the income for tax purposes arose. Deferred tax is recognized on the difference between the carrying amount of an asset or a liability, as reflected in the financial statements, and the corresponding tax base, used in the computation of income for tax purposes (“temporary difference”) and measured using the enacted tax rates and laws as at the balance sheet date that are expected to apply to the income that the Company expects to arise for tax purposes in the period during which the difference is expected to reverse. Management assesses the likelihood that a deferred tax asset will be realized and a valuation allowance is provided to the extent that it is more likely than not that all or a portion of a deferred tax asset will not be realized. The determination of both current and deferred taxes reflects the Company's interpretation of the relevant tax rules and judgement. An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs. Income taxes are recognized in the consolidated statement of operations, except when they relate to a pre-tax item that is recognized in other comprehensive income (loss) or directly in equity, respectively. Income taxes recognized in other comprehensive income (loss) or equity are reclassified to the consolidated statement of operations if the corresponding pre-tax item is reclassified to the consolidated statement of operations. Where income taxes arise from the initial accounting for a business combination, these are embedded in the pre-tax accounting for the business combination. Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense. Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share is computed by dividing earnings (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common shares of the Company during the reporting periods. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of warrants, vested share options, RSUs and the incremental shares issuable upon conversion of the convertible senior notes. As at March 31, 2022, March 31, 2021, and March 31, 2020, all instruments were anti-dilutive. Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company calculates the estimated fair value of financial instruments using quoted market prices whenever available. When quoted market prices are not available, the Company uses standard pricing models. For other financial assets measured at fair value that earn interest, the Company has elected to present interest income as part of the fair value change in other income (expense), net. COVID-19 estimation uncertainty In March 2020, the World Health Organization recognized the outbreak of COVID-19 as a global pandemic. Government measures to limit the spread of COVID-19, including the closure of non-essential businesses, did not materially impact the Company’s operations during the years ended March 31, 2022, March 31, 2021 and March 31, 2020. The production and sale of cannabis have been recognized as essential services in Canada and across Europe. Due to the rapid developments and uncertainty surrounding COVID-19, it is not possible to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in the future. Additionally, it is possible that estimates in the Company’s consolidated financial statements will change in the near term as a result of COVID-19. The Company is closely monitoring the impact of the pandemic on all aspects of its business.

New Accounting Policies

New Accounting Policies	12 Months Ended
	Mar. 31, 2022
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
New Accounting Policies	4. NEW ACCOUNTING POLICIES Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Accounting Guidance not yet adopted Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020.

Asset Impairment and Restructur

Asset Impairment and Restructuring Costs	12 Months Ended
	Mar. 31, 2022
Restructuring And Related Activities [Abstract]
Asset Impairment and Restructuring Costs	5. ASSET IMPAIRMENT AND RESTRUCTURING COSTS Year Ended March 31, 2022 Restructuring and other charges In the year ended March 31, 2022, the Company recorded charges associated with operational changes resulting from its continuing strategic review of its business. The Company recorded charges in the three months ended June 30, 2021 related to a strategic review of the business conducted as a result of acquisitions completed in that period (see Note 29), which resulted in the closure of the Company’s Niagara-on-the-Lake, Ontario and Langley, British Columbia facilities. In the three months ended March 31, 2022, the Company recorded further charges related to further restructuring actions aligned to its strategic review of the business, which included (i) reducing cultivation costs in the Canadian recreational cannabis business through cultivation-related efficiencies and facility improvements; (ii) implementing a flexible manufacturing platform, including contract manufacturing for certain product formats; (iii) right-sizing indirect costs and generating efficiencies across the Company’s supply chain and procurement; (iv) aligning general and administrative costs with short-term business expectations; and (v) further streamlining the organization to drive process-related efficiencies. The Company also recorded charges associated with changes in the estimated fair value of certain of the Company’s Canadian sites that were closed in December 2020, and costs associated with the closure of those sites. Refer to discussion below for restructuring actions in the year ended March 31, 2021. The Company recorded total inventory write-downs and associated restructuring charges of $123,669 in the year ended March 31, 2022, related primarily to (i) the aforementioned strategic changes to our business, including the shift to a contract manufacturing model for certain product formats and the closure of certain of our production facilities; and (ii) amounts deemed excess based on current and projected market demand. As a result of these actions, the Company recognized aggregate pre-tax charges of $429,810 in the year ended March 31, 2022, and reduced headcount by approximately 250 full-time positions. Other impairments Goodwill The Company performed its annual goodwill impairment test in the three months ended March 31, 2022, and recognized impairment losses totaling $40,748, of which $22,355 relates to the KeyLeaf reporting unit and $18,393 relates to the This Works reporting unit. Refer to Note 15 for further details. Intangible assets In the year ended March 31, 2022, the Company recognized asset impairment charges totaling $26,065 related to certain of its acquired brands and operating licenses. These impairment charges were identified by the Company during its annual impairment testing process, which was conducted in the three months ended March 31, 2022, and reflected in asset impairment and restructuring costs. These other impairment charges related to goodwill and intangible assets are in addition to the restructuring and impairment costs described above and which are associated with the Company’s restructuring actions. A summary of the pre-tax charges totaling $496,623 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2022 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 123,669 $ - $ 123,669 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 224,726 - 224,726 Impairment and abandonment of intangible assets 41,404 26,065 67,469 Impairment of goodwill - 40,748 40,748 Contractual and other settlement obligations 6,610 - 6,610 Employee-related and other restructuring costs 29,786 - 29,786 Asset impairment and restructuring costs 302,526 66,813 369,339 Acceleration of share-based compensation expense related to acquisition milestones 3,615 - 3,615 Share-based compensation expense 3,615 - 3,615 Total restructuring, asset impairments and related costs $ 429,810 $ 66,813 $ 496,623 Costs recorded in cost of goods sold In the year ended March 31, 2022, the Company recognized charges of $123,669 relating to inventory write-downs and associated restructuring charges, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $302,526 in the year ended March 31, 2022 as a result of the restructuring actions described above. The Company impaired and abandoned certain production facilities and brand and intellectual property intangible assets, and a loss totaling $266,130 was recognized in the year ended March 31, 2022, representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $224,726 related to property, plant and equipment, and related primarily to buildings and greenhouses, and production and warehouse equipment, and $41,404 related to brand and intellectual property intangible assets. In the year ended March 31, 2022, the Company recognized contractual and other settlement obligations of $6,610 and employee-related and other restructuring costs of $29,786. In the year ended March 31, 2022, as a result of the restructuring actions described above, the Company accelerated share-based compensation expense relating to the unvested milestones associated with acquisitions completed in prior fiscal years. Accordingly, the Company recognized share-based compensation expense of $3,615 in the year ended March 31, 2022. Year Ended March 31, 2021 Restructuring and other charges In the three months ended June 30, 2020, the Company completed certain of the restructuring actions that had commenced in the year ended March 31, 2020 (refer to discussion below for restructuring actions in the year ended March 31, 2020), including completing the exit of the Company’s operations in South Africa and Lesotho, and the Company recorded final adjustments related to changes in certain estimates recorded at March 31, 2020. In addition, the Company incurred additional costs related primarily to the rationalization of its marketing organization in April 2020. In the three months ended September 30, 2020, the Company recorded (i) adjustments related to changes in the estimated fair value of certain of its Canadian production facilities from March 31, 2020, and (ii) charges related to rationalizing certain research and development activities. In December 2020, as the partial outcome of an ongoing end-to-end strategic review of its operations, the Company announced a series of Canadian operational changes designed to streamline its operations and further improve its gross margins. The Company has ceased operations at its sites in St. John’s, Newfoundland and Labrador; Fredericton, New Brunswick; Edmonton, Alberta; Bowmanville, Ontario; as well as its outdoor cannabis grow operations in Saskatchewan. As a result of these restructuring actions, the Company reduced headcount by approximately 220 full-time positions, and abandoned or impaired certain of its production facilities and intangible assets. Additionally, the Company (i) completed the sale of its production facilities in Aldergrove and Delta, British Columbia in December 2020 and January 2021, respectively, for combined proceeds of $40,650; and (ii) recorded additional charges related to the shifting of the Company’s strategy in Latin America, which the Company commenced in the three months ended March 31, 2020. In addition to recording adjustments associated with changes in certain estimates related to the closure of its Canadian production facilities, in the three months ended March 31, 2021, the Company recognized costs associated with the closure of the production facilities, and rationalizing certain licensing arrangements. This included (i) the impairment of the Company’s equity method investment in More Life in the amount of $10,300; (ii) the difference between the termination payment made by the Company to More Life, and the remaining minimum royalty obligations owing to More Life that were derecognized (refer to Note 29(d); and (iii) charges associated with terminating a licensing agreement with a third party (which included derecognizing the remaining minimum royalty obligations owing to the third party in the amount of $18,810). The Company recorded total inventory write-downs of $25,985 in the year ended March 31, 2021 related to the closure of certain of its Canadian and international production facilities. As a result of these actions the Company recognized aggregate pre-tax charges of $564,049 in the year ended March 31, 2021. Other impairments In the year ended March 31, 2021, the Company recognized licensed brand intangible asset impairment charges totaling $6,634, which were identified during its annual impairment testing process and reflected in asset impairment and restructuring costs. These other impairment charges are in addition to the restructuring and impairment costs described above and associated with the Company’s restructuring actions. A summary of the pre-tax charges totaling $570,683 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2021 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 25,985 $ - $ 25,985 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 426,748 - 426,748 Impairment and abandonment of intangible assets 54,511 6,634 61,145 Contractual and other settlement obligations 22,352 - 22,352 Employee-related and other restructuring costs 24,153 - 24,153 Asset impairment and restructuring costs 527,764 6,634 534,398 Costs recorded in loss from equity method investments: Impairment of equity method investments 10,300 - 10,300 Total restructuring, asset impairments and related costs $ 564,049 $ 6,634 $ 570,683 Costs recorded in cost of goods sold In the year ended March 31, 2021, the Company recognized charges of $25,985 relating to inventory write-downs associated with its restructuring activities, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $527,764 in the year ended March 31, 2021 as a result of the restructuring actions described above. As a result of the restructuring actions described above the Company impaired and abandoned certain production facilities, and operating license intangible assets. A loss totaling $481,259 was recognized in the year ended March 31, 2021 representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $426,748 related to property, plant and equipment and $54,511 related to facility operating license intangible assets. The losses relating to property, plant and equipment were primarily attributable to buildings and greenhouses, and production and warehouse equipment. In the year ended March 31, 2021, the Company recognized contractual and other settlement obligations of $22,352 and employee-related and other restructuring costs of $24,153, which included costs associated with the remediation of damages caused by the fire at the Delta facility in November, the closure of the Canadian facilities as described above, and the sale of the British Columbia facilities. Year Ended March 31, 2020 Restructuring and other charges In the three months ended March 31, 2020, the Company commenced an organizational and strategic review of its business which resulted in the following restructuring actions designed to improve organizational focus, streamline operations and align the Company’s production capability with projected demand: (i) the closure of certain of the Company’s greenhouses as they are no longer essential to our Canadian cannabis cultivation footprint; (ii) exiting non-strategic geographies, including South Africa and Lesotho and the Company’s hemp farming operations in New York, and shifting the Company’s strategy in Colombia; and (iii) rationalizing certain marketing and research and development activities. The Company recorded a write-down of inventory in the amount of $55,890 related to these restructuring actions, as well as additional amounts totaling $76,199 deemed excess based on current and projected market demand. As a result of these actions the Company recognized aggregate pre-tax charges of $742,929 in the year ended March 31, 2020 and reduced headcount by approximately 600 full-time positions. Other impairments In the year ended March 31, 2020, the Company recognized contractual and other settlement obligations and brand and license impairment charges totaling $60,020, which were identified during its annual impairment testing process. These charges are reflected in asset impairment and restructuring costs. Additionally, the Company recognized impairment charges relating to certain of its equity method investments totaling $40,326. These charges are recorded in other income (expense), net within the consolidated statements of operations . These other impairment charges are in addition to the restructuring and impairment costs described above and associated with the Company’s restructuring actions . A summary of the pre-tax charges totaling $843,275 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2020 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 132,089 $ - $ 132,089 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 334,964 - 334,964 Impairment and abandonment of intangible assets 192,987 54,020 247,007 Contractual and other settlement obligations 18,712 6,000 24,712 Employee-related and other restructuring costs 16,583 - 16,583 Asset impairment and restructuring costs 563,246 60,020 623,266 Acceleration of share-based compensation expense related to acquisition milestones 32,694 - 32,694 Share-based compensation expense 32,694 - 32,694 Costs recorded in loss from equity method investments: Impairment of equity method investments 14,900 40,326 55,226 Total restructuring, asset impairments and related costs $ 742,929 $ 100,346 $ 843,275 Costs recorded in cost of goods sold In the year ended March 31, 2020, the Company recognized charges of $132,089 relating to restructuring charges and inventory write-downs, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $563,246 in the year ended March 31, 2020 as a result of the restructuring actions described above. As a result of the restructuring actions described above the Company impaired and abandoned certain production facilities, operating licenses and other intangible assets. A loss totaling $527,951 was recognized in the year ended March 31, 2020 representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $334,964 related to property, plant and equipment and $192,987 related to brand, intellectual property and license intangible assets. The losses relating to property, plant and equipment were primarily attributable to buildings and greenhouses, and production and warehouse equipment. In the year ended March 31, 2020, the Company recognized contractual and other settlement obligations of $18,712 and employee-related and other restructuring costs of $16,583. In the year ended March 31, 2020, as a result of the restructuring of our operations in Colombia and Lesotho, the Company accelerated share-based compensation expense relating to the unvested milestones associated with the acquisitions of Spectrum Cannabis Colombia S.A.S. (“Spectrum Colombia”), Canindica Capital Ltd. (“Canindica”), and DaddyCann Lesotho PTY Limited (“DCL”) in the year ended March 31, 2019. Accordingly, the Company recognized share-based compensation expense of $32,694 in the year ended March 31, 2020.

Plan Of Arrangement With Riv Ca

Plan Of Arrangement With Riv Capital	12 Months Ended
	Mar. 31, 2022
Divestiture [Abstract]
Plan Of Arrangement With Riv Capital	6. PLAN OF ARRANGEMENT WITH RIV CAPITAL On December 21, 2020, the Canopy Growth entered into an arrangement agreement (the “RIV Arrangement Agreement”) with its wholly-owned subsidiary The Tweed Tree Lot Inc. (“Tweed NB”), RIV Capital and its wholly-owned subsidiary RCC, pursuant to which Canopy Growth acquired certain assets from RCC, as set out below, in exchange for cash, Canopy Growth common shares and the surrender of all shares in the capital of RIV Capital held by Canopy Growth in accordance with a plan of arrangement under the Business Corporations Act Pursuant to the RIV Arrangement, Canopy Growth increased its conditional ownership interest in TerrAscend Corp. (“TerrAscend”) through the acquisition of (i) 19,445,285 exchangeable shares in the capital of TerrAscend (the “TerrAscend Exchangeable Shares”) held by RCC; (ii) 2,225,714 common share purchase warrants in the capital of TerrAscend with an exercise price of $5.95 per share held by RCC; (iii) 333,723 common share purchase warrants in the capital of TerrAscend with an exercise price of $6.49 per share held by RCC; and (iv) a loan receivable owing by TerrAscend Canada Inc. (“TerrAscend Canada”) to RCC. The securities in the capital of TerrAscend held by Canopy Growth are not currently convertible or exercisable and will not be convertible or exercisable until federal laws in the United States with respect to marijuana are amended. Pursuant to the RIV Arrangement, Canopy Growth also acquired (i) all of the Class A preferred shares in the capital of Les Serres Vert Cannabis Inc. (“Vert Mirabel”) held by RCC; and (vi) 143 common shares in the capital of Vert Mirabel, thereby increasing Canopy Growth’s ownership of the issued and outstanding common shares in the capital of Vert Mirabel to approximately 55%. In addition, all of the obligations of Tweed NB owing to RCC pursuant to a royalty agreement between the parties were terminated. In exchange for the foregoing, Canopy Growth (i) surrendered 36,468,318 Class B multiple voting shares (“MVS”) and 15,223,938 Class A subordinate voting shares (“SVS”) in the capital of RIV Capital; (ii) made a cash payment to RCC of $115,000; and (iii) issued 3,647,902 Canopy Growth common shares to RCC. As a result, following completion of the RIV Arrangement, Canopy Growth no longer had any equity, debt or other interest in RIV Capital, and no longer had any representation on the RIV Capital board of directors. Following completion of the RIV Arrangement, Canopy Growth now owns 38,890,570 TerrAscend Exchangeable Shares, an aggregate of 22,474,130 common share purchase warrants in the capital of TerrAscend (the “TerrAscend warrants”) and is deemed to own an aggregate of 1,072,450 common shares of TerrAscend that are subject to an option agreement entered into in January 2021 (the “TerrAscend Option”). Canopy Growth beneficially owns, and exercise control or direction over approximately 15% of the issued and outstanding TerrAscend common shares on a fully-diluted basis. Following this transaction, Canopy Growth no longer controls RIV Capital, and Canopy Growth derecognized the consolidated assets and liabilities of RIV Capital from its consolidated financial statements at their carrying amounts. The derecognized assets and liabilities on February 23, 2021, were as follows: Acquired assets TerrAscend Exchangeable Shares $ 291,500 TerrAscend warrants 32,000 Preferred shares in Vert Mirabel 22,600 Settlement of Tweed NB obligations to RCC 15,000 TerrAscend loan 10,000 Common shares in Vert Mirabel 9,075 Total acquired assets $ 380,175 Consideration paid in shares (170,284 ) Consideration paid in cash (115,000 ) $ 94,891 Derecognition of RIV Capital net assets Cash and cash equivalents $ 37,801 Amounts receivable, net 4,327 Prepaid expenses and other assets 995 Equity method investments 5,114 Other financial assets 417,256 Property, plant and equipment 729 Intangible assets 86 Accounts payable (22,038 ) Other accrued expenses and liabilities (1,703 ) Other current liabilities (32,653 ) Other long-term liabilities (303 ) Noncontrolling interests and other (315,144 ) $ 94,467 Gain on completion of RIV Arrangement $ 424 The gain calculated on the derecognition of RIV Capital’s assets and liabilities is the difference between the carrying amounts of the derecognized assets and liabilities of RIV Capital and the fair value of the consideration transferred, being the cash payment made to RCC in the amount of $115,000, the fair value of the Canopy Growth common shares issued to RCC, and the assets acquired.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Mar. 31, 2022
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	7. CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: March 31, March 31, 2022 2021 Cash $ 470,682 $ 436,588 Cash equivalents 305,323 718,065 $ 776,005 $ 1,154,653

Short-term Investments

Short-term Investments	12 Months Ended
	Mar. 31, 2022
Short Term Investments [Abstract]
Short-term Investments	8. SHORT-TERM INVESTMENTS The components of short-term investments are as follows: March 31, March 31, 2022 2021 Term deposits $ 319,092 $ 463,824 Government securities 22,253 136,620 Asset-backed securities 21,905 16,342 Commercial paper and other 232,401 527,777 $ 595,651 $ 1,144,563 The amortized cost of short-term investments at March 31, 2022 is $599,862 (March 31, 2021 – $1,145,364).

Amounts Receivable, Net

Amounts Receivable, Net	12 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Amounts Receivable, Net	9. AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: March 31, March 31, 2022 2021 Accounts receivable, net $ 78,059 $ 67,106 Indirect taxes receivable 7,524 8,281 Interest receivable 4,406 5,140 Other receivables 6,454 11,908 $ 96,443 $ 92,435 Included in the accounts receivable, net balance at March 31, 2022 is an allowance for doubtful accounts of $4,764 (March 31, 2021 – $1,411).

Inventory

Inventory	12 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	10. INVENTORY The components of inventory are as follows: March 31, March 31, 2022 2021 Raw materials, packaging supplies and consumables $ 26,821 $ 55,554 Work in progress 65,245 223,652 Finished goods 112,321 88,773 $ 204,387 $ 367,979 In the year ended March 31, 2022, the Company recorded write-downs related to inventory in cost of goods sold of $237,147 (year ended March 31, 2021 – $79,859), including charges of $116,770 (year ended March 31, 2021 – $25,985) associated with the strategic review, as described in Note 5.

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets	12 Months Ended
	Mar. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Assets	11. PREPAID EXPENSES AND OTHER ASSETS The components of prepaid and other assets are as follows: March 31, March 31, 2022 2021 Prepaid expenses $ 23,041 $ 28,349 Deposits 10,145 18,316 Prepaid inventory 449 1,496 Other assets 19,065 19,071 $ 52,700 $ 67,232

Other Financial Assets

Other Financial Assets	12 Months Ended
	Mar. 31, 2022
Schedule Of Investments [Abstract]
Other Financial Assets	12. OTHER FINANCIAL ASSETS The following tables outline changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 24. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal March 31, Entity Instrument 2021 Additions changes adjustments income of shares 2022 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ (156,000 ) $ - $ - $ - $ 229,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 835 - (795 ) - 10,280 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - (1,528 ) - (4,912 ) - 49,890 Arise Bioscience Term loan / debenture 13,077 - 308 (42 ) - - 13,343 TerrAscend - October 2019 Warrants 17,250 - (13,520 ) - - - 3,730 TerrAscend - March 2020 Warrants 152,910 - (92,170 ) - - - 60,740 TerrAscend - December 2020 Warrants 13,240 - (9,780 ) - - - 3,460 TerrAscend Option 10,600 - (4,300 ) - - - 6,300 Wana Option - 442,227 (74,639 ) 4,755 - - 372,343 Acreage Hempco 1 Debenture 27,448 - 5,337 (94 ) (3,867 ) - 28,824 Other - at fair value through net income (loss) Various 14,887 6,457 (10,652 ) (204 ) - (92 ) 10,396 Other - classified as held for investment Loan receivable 7,185 5,000 - - - (163 ) 12,022 $ 708,167 $ 453,684 $ (356,109 ) $ 4,415 $ (9,574 ) $ (255 ) $ 800,328 1 Exercise of Foreign options / Balance at currency Allowance disposal Derecognition Balance at March 31, Fair value translation for expected of shares / of March 31, Entity Instrument 2020 Additions changes adjustments credit losses repayments RIV Capital 1 2021 TerrAscend Exchangeable Shares Exchangeable shares $ 47,000 $ - $ 338,000 $ - $ - $ - $ - $ 385,000 TerrAscend Canada - October 2019 Term loan / debenture 9,520 8,579 (7,859 ) - - - - 10,240 TerrAscend Canada - March 2020 Term loan / debenture 44,300 - 16,942 - - (4,912 ) - 56,330 Arise Bioscience Term loan / debenture - 11,758 1,489 (170 ) - - - 13,077 TerrAscend - October 2019 Warrants 804 4,315 12,131 - - - - 17,250 TerrAscend - March 2020 Warrants 24,200 - 128,710 - - - - 152,910 TerrAscend - December 2020 Warrants - 13,720 (480 ) - - - - 13,240 TerrAscend Option - 13,445 (2,845 ) - - - - 10,600 Acreage Hempco 2 Debenture - 66,995 (37,026 ) (2,521 ) - - - 27,448 SLANG Warrants 3,500 - 5,900 - - - - 9,400 PharmHouse 3 Loan receivable 40,000 - - - (40,000 ) - - - ZeaKal Shares 14,186 - (1,486 ) - - - (12,700 ) - Agripharm Royalty interest 12,600 - (7,200 ) - - - (5,400 ) - Greenhouse Convertible debenture 10,517 - (4,117 ) - - (1,300 ) (5,100 ) - Other - at fair value through net income (loss) Various 28,478 11,251 (7,052 ) - - (4,234 ) (22,956 ) 5,487 Other - classified as held for investment Loan receivable 14,148 11,106 - - (12,956 ) (5,113 ) - 7,185 $ 249,253 $ 141,169 $ 435,107 $ (2,691 ) $ (52,956 ) $ (15,559 ) $ (46,156 ) $ 708,167 1 2 3 Wana On October 14, 2021, the Company and Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana” and each, a “Wana Entity”) entered into definitive agreements (the “Wana Agreements”) providing the Company with the right, upon the occurrence or waiver (at the Company’s discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”), to acquire 100% of the outstanding membership interests of Wana. Wana manufactures and sells gummies in the state of Colorado and licenses its intellectual property to partners, who manufacture, distribute, and sell Wana-branded gummies across the United States and Canada. The Wana Agreements are structured as three separate option agreements whereby the Company has a call option (the “Call Option”) to acquire 100% of the membership interests in each Wana Entity. As consideration for entering into the Wana Agreements, the Company made an upfront cash payment (the “Upfront Payment”) in the aggregate amount of $368,067 (US$297,500). Upon the Company’s exercise of its right to acquire Wana, the Company will make payments equal to 15% of the fair market value of Wana at the time the options are exercised (the “Call Option Payments”). As additional consideration for the right to acquire Wana, the Company expects to make additional deferred payments (the “Deferred Payments”) in respect of Wana as of the 2.5- and 5-year anniversary of the Upfront Payment, computed based on a pre-determined contractual formula as follows: • Deferred Payment 1: 25% of the amount computed as the estimated fair value of Wana at the 2.5-year anniversary, less (i) the Upfront Payment, (ii) Wana debt, and (iii) certain other deductions; plus Wana cash, all at the 2.5-year anniversary. • Deferred Payment 2: 25% of the amount computed as the estimated fair value of Wana at the 5-year anniversary, less (i) the greater of (a) the Upfront Payment and (b) the estimated fair value of Wana at the 2.5-year anniversary, (ii) Wana debt, and (iii) certain other deductions, all at the 5-year anniversary; plus the difference in Wana cash between the 5-year and 2.5-year anniversaries. Payment of the Deferred Payments is not contingent upon the occurrence or waiver (at the Company’s discretion) of the Triggering Event or the exercise of the Call Option. At the Company’s option, the Call Option Payments and the Deferred Payments may be satisfied in cash, common shares or a combination thereof at the Company’s sole discretion. Until such time as the Company exercises its right to acquire Wana, the Company will have no economic or voting interest in Wana, the Company will not control Wana, and the Company and Wana will continue to operate independently. Upon initial recognition, the Company estimated the fair value of the Wana financial instrument to be $442,227, consisting of (i) the Upfront Payment as noted above; and (ii) the present value of the estimated Deferred Payments, totaling $74,160 (see Note 18). The Wana financial instrument, in effect, represents a call option to purchase 100% of Wana for a payment equal to 15% of Wana’s fair market value at the time the option is exercised. At March 31, 2022, the estimated fair value of the Wana financial instrument was $372,343, with the change from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the Wana financial instrument is calculated on a recurring basis. TerrAscend Exchangeable Shares TerrAscend is a publicly traded licensed producer. The TerrAscend Exchangeable Shares will only become convertible into common shares following changes in U.S. federal laws regarding the cultivation, distribution or possession of cannabis, the compliance of TerrAscend with such laws and the approval of the various securities exchanges upon which the issuer’s securities are listed (the “TerrAscend Triggering Event”). The TerrAscend Exchangeable Shares are not transferrable or monetizable until exchanged into common shares. In the interim, the Company will not be entitled to voting rights, dividends or other rights upon dissolution of TerrAscend. As a result, the Company does not have significant influence over TerrAscend and accounts for the TerrAscend Exchangeable Shares as a financial asset at estimated fair value with any changes recorded in other income (expense), net. See Note 6 for information regarding the completion of the plan of arrangement with RIV Capital, which included the acquisition, by Canopy Growth, of the TerrAscend Exchangeable Shares held by RCC. At March 31, 2022 the estimated fair value of the Company’s investment in the TerrAscend Exchangeable Shares was estimated to be $229,000 (March 31, 2021 – $385,000). See Note 24 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis. TerrAscend Canada Term Loan, Debenture, and Warrants – October 2019 On October 2, 2019, RIV Capital completed a $13,243 (US$10,000) investment in TerrAscend Canada, a wholly-owned subsidiary of TerrAscend, which included a term loan with an estimated fair value of $10,853 and TerrAscend warrants with an estimated fair value of $2,390. As part of the completion of the plan of arrangement with RIV Capital, as described in Note 6, Canopy Growth acquired these securities from RCC. The non-cash additions in respect to these investments represents the inherent deferred tax liability on the initial acquisition of the assets from RIV Capital, as the accounting carrying value of the assets exceeds the tax basis. The Company accounts for these instruments as financial assets at estimated fair value, with any changes recorded in other income (expense), net. As of March 31, 2022 , the estimated fair value of the term loan was $10,280 ( March 31, 2021 – $ 10,240 ), and the estimated fair value of the warrants was $3,730 ( March 31, 2021 – $ 17,250 ). See Note 24 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis. TerrAscend Canada Term Loan, Debenture, and TerrAscend Warrants – March 2020 On March 11, 2020, Canopy Growth completed an $80,526 investment in TerrAscend Canada. The investment includes a secured debenture (the “debenture”) for $80,526, that matures the earliest of (i) March 10, 2030 and (ii) the later of March 10, 2025 and the date that is 24 months following the date that is the TerrAscend Triggering Event. The debenture bears interest at a rate of 6.1% and is payable annually. As additional consideration, TerrAscend issued 17,808,975 common share purchase warrants (collectively, the “TerrAscend Warrants”). The TerrAscend Warrants consist of two tranches. The first tranche TerrAscend Warrants total 15,656,242 and are exercisable at a price of $5.41 per common share. They are exercisable upon the occurrence or waiver of TerrAscend the Triggering Event until the earliest of (i) March 10, 2030 and (ii) the later of (A) March 10, 2025 and (B) the date that is 24 months following the occurrence of the TerrAscend Triggering Event. The second tranche TerrAscend Warrants total of 2,152,733 and are exercisable at a price of $3.74 per common share. They are exercisable upon the occurrence or waiver of the TerrAscend Triggering Event until the earliest of (i) March 10, 2031 and (ii) the later of (A) March 10, 2026 and (B) the date that is 36 months following the occurrence of the TerrAscend Triggering Event. Canopy Growth has the right to set-off the applicable exercise price payable for the exercise of the TerrAscend Warrants against any amounts owing by TerrAscend, or any amounts owing under the Loan by TerrAscend Canada. The Company accounts for these instruments as financial assets at estimated fair value, with any changes recorded in other income (expense), net. At issuance, the term loan had an estimated fair value of $54,800 and the TerrAscend Warrants had an estimated fair value of $25,626 with $100 of related transaction costs expensed. As of March 31, 2022, the estimated fair value of the debenture was $49,890 (March 31, 2021 – $56,330) and the Warrants had an estimated fair value of $60,740 (March 31, 2021 – $152,910). See Note 24 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis. Arise Bioscience and Additional TerrAscend Warrants – December 2020 On December 10, 2020, the Company entered into a loan financing agreement with Arise Bioscience, Inc. (“Arise Bioscience”), a wholly owned subsidiary of TerrAscend. The investment is in the amount of US$20,000 ($25,478) (the “Loan”) pursuant to a secured debenture (the “Arise Debenture”). The Arise Debenture bears interest at a rate of 6.1% and is payable beginning in the fourth year after its issuance. The Arise Debenture will mature on December 10, 2030. In connection with the Loan, TerrAscend issued 2,105,718 common share purchase warrants to the Company (the “Additional TerrAscend Warrants”). 1,926,983 Additional TerrAscend Warrants are exercisable at a price of $15.28 per share, and expire on December 10, 2030. 178,735 Additional TerrAscend Warrants are exercisable at a price of $17.19 per share, and expire on December 10, 2031. The Additional TerrAscend Warrants will be exercisable by the Company following the TerrAscend Triggering Event. The Loan is repayable by Arise Bioscience at any time. The Company accounts for these instruments as financial assets at estimated fair value, with any changes recorded in other income (expense), net. At issuance, the Arise Debenture had an estimated fair value of $11,758 and the Additional TerrAscend Warrants had an estimated fair value of $13,720. As of March 31, 2022, the Arise Debenture had an estimated fair value of $13,343 and the Additional TerrAscend Warrants had an estimated fair value of $3,460 (March 31, 2021 – $13,077 and $13,240, respectively). See Note 24 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis. TerrAscend Option On January 13, 2021, the Company entered into the TerrAscend Option to purchase 1,072,450 common shares of TerrAscend for aggregate consideration of US$10,529 ($13,445). The Company accounts for this instrument as a financial asset at estimated fair value, with any changes recorded in other income (expense), net. At March 31, 2022 the estimated fair value of the TerrAscend Option was $6,300 (March 31, 2021 – $10,600). See Note 24 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	13. PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: March 31, March 31, 2022 2021 Buildings and greenhouses $ 766,931 $ 651,166 Production and warehouse equipment 159,314 216,925 Leasehold improvements 69,304 106,837 Office and lab equipment 29,879 30,546 Computer equipment 22,293 26,431 Land 18,917 34,747 Right-of-use-assets Buildings and greenhouses 89,228 100,517 Production and warehouse equipment 55 530 Assets in process 19,771 129,428 1,175,692 1,297,127 Less: Accumulated depreciation (232,912 ) (222,590 ) $ 942,780 $ 1,074,537 Depreciation expense included in cost of goods sold for the year ended March 31, 2022 is $50,200 (year ended March 31, 2021 – $51,737; year ended March 31, 2020 – $52,249). Depreciation expense included in selling, general and administrative expenses for the year ended March 31, 2022 is $26,047 (year ended March 31, 2021 – $19,177, year ended March 31, 2020 – $21,467). See Note 5 for information on the impairment and abandonment of property, plant and equipment that resulted in charges in the amount of $224,726 that the Company recognized as part of its restructuring actions in the year ended March 31, 2022 (year ended March 31, 2021 – $426,748; year ended March 31, 2020 – $334,964).

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	14. INTANGIBLE ASSETS The components of intangible assets are as follows: March 31, 2022 March 31, 2021 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 138,170 $ 97,638 $ 212,100 $ 168,655 Distribution channel 72,642 24,834 73,756 35,176 Operating licenses 24,400 22,052 - - Software and domain names 29,822 14,206 27,836 18,149 Brands 5,547 3,680 21,812 8,894 Amortizable intangibles in process 5,476 5,476 1,952 1,952 Total $ 276,057 $ 167,886 $ 337,456 $ 232,826 Indefinite lived intangible assets Acquired brands $ 74,809 $ 67,341 Operating licenses 10,000 8,000 Total intangible assets $ 252,695 $ 308,167 Amortization expense included in cost of goods sold for the year ended March 31, 2022 is $81 (year ended March 31, 2021 – $80; year ended March 31, 2020 – $1,030 (year ended March 31, 2021 – $56,124; year ended March 31, 2020 – $50,267 Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows: 2023 $ 25,318 2024 $ 24,660 2025 $ 21,040 2026 $ 18,472 2027 $ 17,727 Thereafter $ 60,669 See Note 5 for information on (i) the impairment and abandonment of intangible assets that resulted in charges in the amount of $41,404 that the Company recognized as part of its restructuring actions in the year ended March 31, 2022 (year ended March 31, 2021 – $54,511; year ended March 31, 2020 – $192,987) and (ii) impairment charges of $26,065 in the year ended March 31, 2022 (year ended March 31, 2021 – $6,634; year ended March 31, 2020 – $54,020)

Goodwill

Goodwill	12 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	15. GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2020 $ 1,954,471 Foreign currency translation adjustments (65,117 ) Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities (58,786 ) Impairment losses (40,748 ) Foreign currency translation adjustments (28,640 ) Balance, March 31, 2022 $ 1,866,503 At March 31, 2022, the Company performed its annual goodwill impairment analysis using the quantitative assessment. The Company concluded that the carrying values of its KeyLeaf and This Works reporting units were higher than their respective estimated fair values as determined using the income valuation method, and a goodwill impairment loss totaling $40,748 was recognized in the year ended March 31, 2022 (year ended March 31, 2021 - $nil). The goodwill impairment loss was comprised of (i) $22,355 related to the KeyLeaf reporting unit, representing the entirety of the goodwill assigned to the KeyLeaf reporting unit; and (ii) $18,393 related to the This Works reporting unit. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the KeyLeaf and This Works reporting units. No impairment was noted for any of the Company’s other reporting units, as the estimated fair value of each of the other reporting units with goodwill exceeded their carrying value. The estimated fair value of the cannabis operations reporting unit in the global cannabis segment was determined using the market valuation method, with the most significant assumptions used in applying this method being (i) the price of the Company’s common shares; and (ii) the estimated control premium associated with ownership of the Company’s common shares. The estimated fair values of all other reporting units (KeyLeaf, This Works, BioSteel and Storz & Bickel) were determined using the income valuation method, with the most significant assumptions used in applying this method being (i) the discount rate; (ii) the expected long-term growth rate; and (iii) the annual cash flow projections. These methodologies are consistent with those used by the Company for its annual impairment test conducted at March 31, 2021, and for the quantitative interim goodwill assessment conducted by the Company for the cannabis operations reporting unit at December 31, 2021. The carrying value, at March 31, 2022, of the goodwill associated with the Company’s cannabis operations reporting unit was $1,727,848. For the cannabis operations reporting unit, if all other assumptions were held constant and the estimated control premium was decreased by 500 basis points, the estimated fair value would decrease by 7% and result in an impairment charge. If all other assumptions were held constant and the share price decreased by 10%, the estimated fair value would decrease by 15% and result in an impairment charge. The carrying value, at March 31, 2022, of the goodwill associated with the Company’s BioSteel reporting unit was $57,339. For the BioSteel reporting unit, if all other assumptions were held constant and the discount rate was increased by 50 basis points, the estimated fair value would decrease by 8%. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease by 3%. If all other assumptions were held constant and the annual cash flow projections were decreased by 250 basis points, the estimated fair value would decrease by 5%. The carrying value, at March 31, 2022, of the goodwill associated with the Company’s Storz & Bickel reporting unit was $79,027. For the Storz & Bickel reporting unit, if all other assumptions were held constant and the discount rate was increased by 50 basis points, the estimated fair value would decrease by 6%. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease by 4%. If all other assumptions were held constant and the annual cash flow projections were decreased by 250 basis points, the estimated fair value would decrease by 3%. At March 31, 2022, the fair value of the cannabis operations reporting unit to which goodwill is assigned exceeded its carrying value by approximately 5% to 10%. Accordingly, the goodwill assigned to the cannabis operations reporting unit is at risk for impairment in future periods. The Company may be required to perform a quantitative goodwill impairment assessment in future periods for the cannabis operations reporting unit, to the extent the Company continues to experience declines in the price of its common shares from March 31, 2022, reductions in the estimated control premium associated with ownership of the Company’s common shares, or other indicators of impairment arise. The carrying value, at March 31, 2022, of the goodwill associated with the Company’s This Works reporting unit was $2,289.

Other Accrued Expenses and Liab

Other Accrued Expenses and Liabilities	12 Months Ended
	Mar. 31, 2022
Accounts Payable And Accrued Liabilities Current [Abstract]
Other Accrued Expenses and Liabilities	16. OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: March 31, March 31, 2022 2021 Employee compensation $ 24,873 $ 47,237 Inventory 10,096 5,426 Professional fees 7,640 11,544 Taxes and government fees 7,144 13,550 Other 25,525 23,056 $ 75,278 $ 100,813

Debt

Debt	12 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	17. DEBT The components of debt are as follows: March 31, March 31, Maturity Date 2022 2021 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 5,958 5,664 Non-credit risk fair value adjustment 7,140 109,710 Credit risk fair value adjustment (49,140 ) (27,960 ) 563,958 687,414 Convertible debentures September 10, 2025 32,858 - Accretion debentures September 10, 2025 7,720 - Credit facility March 18, 2026 893,647 891,677 Other revolving debt facility, loan, and financings 2,808 3,872 1,500,991 1,582,963 Less: current portion (9,296 ) (9,827 ) Long-term portion $ 1,491,695 $ 1,573,136 Credit Facility On March 18, 2021, the Company entered into a credit agreement (the “Credit Agreement”) providing for a five-year The Credit Facility has no principal payments, matures on March 18, 2026, has a coupon of LIBOR plus 8.50% and is subject to a LIBOR floor of 1.00%. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of these assets, including material real property, of the borrowers and each of the guarantors. The C redit A greement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$ 200,000 at the end of each fiscal quarter. The proceeds from the Credit Facility were $893,160, and the carrying amount is reflected net of financing costs. Convertible Notes On June 20, 2018, the Company issued convertible senior notes (the “Notes”) with an aggregate principal amount of $600,000. The Notes bear interest at a rate of 4.25% per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019. The Notes will mature on July 15, 2023. The Notes are subordinated in right of payment to any existing and future senior indebtedness, including indebtedness under the revolving debt facility with FCC (as defined below). The Notes will rank senior in right of payment to any future subordinated borrowings. The Notes are effectively junior to any secured indebtedness and the Notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Holders of the Notes may convert the Notes at their option at any time from January 15, 2023 to the maturity date. The Notes will be convertible, at the holder’s option, at a conversion rate of 20.7577 common shares for every $1 principal amount of Notes (equal to an initial conversion price of approximately $48.18 per common share), subject to adjustments in certain events. In addition, the holder has the right to exercise the conversion option from September 30, 2018 to January 15, 2023, if (i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith. The Company may, upon conversion by the holder, elect to settle in either cash, common shares, or a combination of cash and common shares, subject to certain circumstances. Under the terms of the indenture if a Fundamental Change occurs and a holder elects to convert its Notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company may be required to increase the conversion rate for the Notes surrendered for conversion by a number of additional common shares. Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law. On or after July 20, 2021, the Company could redeem for cash, subject to certain conditions, any or all of the Notes, at its option, if the last reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130% of the conversion price on each applicable trading day. The Company may also redeem the Notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of Notes in either case shall be at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. For accounting purposes, the equity conversion feature did not meet the equity classification guidance, therefore the Company elected the fair value option under ASC 825 – Financial Instruments The overall change in fair value of the Notes during the years ended March 31, 2022 and March 31, 2021 was a decrease of $123,456 and an increase of $237,210, respectively, which included contractual interest of $25,794 and $25,710, respectively. Refer to Note 24 for additional details on how the fair value of the Notes is calculated. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, Supreme Cannabis (as defined below) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $100,000. On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of $63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to $0.285. In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of $36,500 to a maximum of $13,500, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into Supreme Shares (as defined below). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0 % per month over the 24 months prior to maturity. As a result of the Supreme Arrangement (as defined below), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures are not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. Other revolving debt facility, loans, and financings On August 13, 2019 the Company, through its wholly owned subsidiary, Tweed Inc., entered into a $40,000 revolving debt facility with Farm Credit Canada (“FCC”). The facility is secured by the Company’s property in Niagara-on-the-Lake. The extinguishment of $4,912 in previous FCC debt resulted in no gain or loss. The current outstanding balance of the FCC debt facility is $nil (March 31, 2021 – $nil) with an interest rate of 3.70%, or FCC prime rate plus 1.0%. The facility expires on September 3, 2024. Debt payments As of March 31, 2022, the required principal repayments under long-term debt obligations for each of the five succeeding fiscal years and thereafter are as follows: 2023 $ 865 2024 603,865 2025 6,865 2026 966,470 2027 - Thereafter - $ 1,578,065

Other Liabilities

Other Liabilities	12 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	18. OTHER LIABILITIES The components of other liabilities are as follows: As at March 31, 2022 As at March 31, 2021 Current Long-term Total Current Long-term Total Lease liabilities $ 38,035 $ 101,125 $ 139,160 $ 42,061 $ 94,164 $ 136,225 Acquisition consideration and other investment related liabilities 4,020 77,834 81,854 16,577 7,808 24,385 Refund liability 3,437 - 3,437 6,441 - 6,441 Settlement liabilities and other 18,562 11,090 29,652 41,349 5,268 46,617 $ 64,054 $ 190,049 $ 254,103 $ 106,428 $ 107,240 $ 213,668 On October 14, 2021, upon entering into the Wana Agreements, the Company recognized the present value of the estimated Deferred Payments associated with the Wana financial instrument within acquisition consideration and other investment related liabilities, in the amount of $74,160 (see Note 12). At March 31, 2022, the estimated fair value of the Deferred Payments was $70,066, with the change from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the estimated Deferred Payments are calculated on a recurring basis.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	12 Months Ended
	Mar. 31, 2022
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	19. REDEEMABLE NONCONTROLLING INTEREST The net change in the redeemable noncontrolling interests is as follows: Vert Mirabel BioSteel Total As at March 31, 2019 $ 6,400 $ - $ 6,400 Initial recognition of noncontrolling interest - 18,733 18,733 Income (loss) attributable to noncontrolling interest 8,220 (1,731 ) 6,489 Adjustments to redemption amount 5,630 32,498 38,128 As at March 31, 2020 20,250 49,500 69,750 Net loss attributable to redeemable noncontrolling interest (11,906 ) (6,171 ) (18,077 ) Adjustments to redemption amount 3,156 80,471 83,627 As at March 31, 2021 11,500 123,800 135,300 Net loss attributable to redeemable noncontrolling interest (3,165 ) (13,932 ) (17,097 ) Adjustments to redemption amount (7,335 ) (69,559 ) (76,894 ) Redemption of redeemable noncontrolling interest - (5,109 ) (5,109 ) As at March 31, 2022 $ 1,000 $ 35,200 $ 36,200

Share Capital

Share Capital	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Share Capital	20. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the years ended March 31, 2022, March 31, 2021 and March 31, 2020. (ii) Other issuances of common shares During the year ended March 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 (29,721 ) Other issuances 492,741 8,201 (736 ) Total 10,801,426 $ 298,145 $ (30,457 ) During the year ended March 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Completion of acquisition milestones 2,598,978 $ 46,903 $ (19,059 ) Other issuances 449,729 14,906 (14,894 ) Total 3,048,707 $ 61,809 $ (33,953 ) During the year ended March 31, 2020, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Acquisition of BC Tweed NCI release from escrow 6,940,531 $ 223,036 $ (223,036 ) Completion of acquisition milestones 1,121,605 29,561 (29,687 ) Other issuances 597,936 19,369 (19,511 ) Total 8,660,072 $ 271,966 $ (272,234 ) (iii) Warrants Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2019 107,848,322 $ 43.80 $ 1,589,925 Tranche A warrant modification - - 1,049,153 Issuance of Tranche B warrants 38,454,444 76.68 - Other issuance of warrants 9,200 32.83 359 Exercise of warrants (12,523 ) 35.55 (486 ) Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,882,927 ) 12.98 (70,513 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants (145,831 ) 32.61 - Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 1 RIV CAPITAL Completion of RIV Arrangement As described in Note 6, the RIV Arrangement was completed on February 23, 2021. Pursuant to the RIV Arrangement, Canopy Growth surrendered 36,468,318 MVS and 15,223,938 SVS in the capital of RIV Capital and as a result held no MVS (March 31, 2020 – 36,468,318) and no SVS (March 31, 2020 – 15,223,938). The Company’s MVS and SVS holdings at March 31, 2020 represented a 27.3% ownership interest and 84.4% voting interest in RIV Capital at that time. The voting rights allowed the Company to direct the relevant activities of RIV Capital such that the Company had control over RIV Capital until the completion of the RIV Arrangement on February 23, 2021, and RIV Capital was consolidated in these financial statements until that date. Upon completion of the RIV Arrangement, the Company no longer controlled RIV Capital, and the Company derecognized RIV Capital’s consolidated assets and liabilities from its consolidated financial statements. Share buyback On April 2, 2020, RIV Capital received approval from the Toronto Stock Exchange (“TSX”) to commence a normal course issuer bid (“NCIB”) to purchase up to 10,409,961 SVS, representing 10% of RIV Capital’s issued and outstanding SVS, in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. The NCIB expired on April 1, 2021. Daily purchases were limited to 70,653 SVS, representing 25% of the average daily trading volume on the TSX over a specified period. The NCIB was utilized at the sole discretion of RIV Capital, with no contractual obligation to purchase any specified number of shares. All SVS purchases made by RIV Capital under the NCIB were funded out of RIV Capital’s working capital and were cancelled immediately. During the period from April 1, 2020 to February 23, 2021, RIV Capital repurchased and cancelled a total of 273,300 SVS under the NCIB program for $307, at a weighted average acquisition price of $1.11 per share. Financings Period from April 1, 2020 to February 23, 2021 There were no financings during the period from April 1, 2020 to February 23, 2021. Year ended March 31, 2020 There were no financings during the year ended March 31, 2020.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	21. SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth's eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directors of the Company approved certain amendments to the Omnibus Plan in order to reduce the maximum number of shares available for issuance under the Omnibus Plan from 15% of the issued and outstanding shares to 10% of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. The maximum number of common shares reserved for Awards is 39,442,260 at March 31, 2022 (March 31, 2021 – 57,431,277). As of March 31, 2022, the only Awards issued have been options, RSUs, and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board of Directors of the Company (the “CGC&N Committee”) which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Awards under the Omnibus Plan generally vest in increments with 1/3 Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,000, and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000. As of March 31, 2022, the Company has issued a total of 235,813 common shares under the Purchase Plan (March 31, 2021 – 37,312) with 198,501 being issued in the current fiscal year (March 31, 2021 – 37,312). The following is a summary of the changes in the Company’s Omnibus Plan employee options during the years ended March 31, 2020, 2021 and 2022: Options issued Weighted average exercise price Balance outstanding at March 31, 2019 32,831,895 $ 34.10 Options granted 9,454,714 33.87 Options exercised (3,900,032 ) 10.63 Options forfeited/cancelled (5,878,182 ) 44.95 Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 478,215 28.15 Options exercised (7,062,317 ) 22.22 Options forfeited (8,219,982 ) 41.27 Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,537,290 17.40 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised (445,680 ) 12.27 Options forfeited (3,153,118 ) 42.03 Balance outstanding at March 31, 2022 16,782,962 $ 33.89 The following is a summary of the outstanding stock options as at March 31, 2022: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices March 31, 2022 (years) March 31, 2022 (years) $0.06 - $24.62 3,705,144 4.05 1,312,215 2.12 $24.63 - $33.53 4,036,819 3.25 2,285,789 2.68 $33.54 - $36.80 2,984,264 2.24 2,984,264 2.24 $36.81 - $42.84 2,641,567 2.85 2,488,993 2.65 $42.85 - $67.64 3,415,168 2.88 3,005,487 2.83 16,782,962 3.11 12,076,748 2.54 At March 31, 2022, the weighted average exercise price of options outstanding and options exercisable was $33.89 and $38.33, respectively (March 31, 2021 – $36.79 and $36.97, respectively). The Company recorded $27,163 in share-based compensation expense related to Options issued to employees and contractors for the year ended March 31, 2022 (for the year ended March 31, 2021 – $67,737, for the year ended March 31, 2020 – $248,450). The share-based compensation expense for the year ended March 31, 2022 includes an amount related to 1,336,249 options being provided in exchange for services which are subject to performance conditions (for the year ended March 31, 2021 – 2,152,938, for the year ended March 31, 2020 – 2,160,068). The Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis (Note 29) and during the year ended March 31, 2022, recorded share-based compensation expense $823. With the exception of nil options which are subject to market-based performance conditions (March 31, 2021 – 17,559, March 31, 2020 – 571,689) and valued using the Monte Carlo simulation model, the Company uses the Black-Scholes option pricing model to establish the fair value of options granted during the years ended March 31, 2022, 2021 and 2020 on their measurement date by applying the following assumptions: March 31, March 31, March 31, 2022 2021 2020 Risk-free interest rate 1.09% 0.36% 1.38% Expected life of options (years) 3 - 5 1 - 7 3 - 5 Expected volatility 75% 76% 73% Expected forfeiture rate 18% 17% 12% Expected dividend yield nil nil nil Black-Scholes value of each option $9.69 $15.24 $19.83 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the year ended March 31, 2022, 445,680 Options were exercised ranging in price from $0.06 to $36.34 for gross proceeds of $5,567 (for the year ended March 31, 2021 – 7,062,317 Options were exercised ranging in price from $0.06 to $67.64 for gross proceeds of $156,897, for the year ended March 31, 2020 – 3,900,032 Options were exercised ranging in prices from $0.06 to $40.68 for gross proceeds of $41,413). For the year ended March 31, 2022, the Company recorded $10,709 in share-based compensation expense related to RSUs and PSUs (for the year ended March 31, 2021 – $11,448, for the year ended March 31, 2020 – $2,308). The following is a summary of changes in the Company’s RSUs during the years ended March 31, 2020, 2021 and 2022: Number of RSUs and PSUs Balance outstanding at March 31, 2019 137,228 RSUs granted 875,673 RSUs released (29,892 ) RSUs cancelled and forfeited (100,000 ) Balance outstanding at March 31, 2020 883,009 RSUs granted 142,826 RSUs released (120,399 ) RSUs cancelled and forfeited (152,126 ) Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 3,253,671 RSUs and PSUs released (300,319 ) RSUs and PSUs cancelled and forfeited (229,370 ) Balance outstanding at March 31, 2022 3,477,292 During the year ended March 31, 2022, the Company recorded $7,991 in share-based compensation expense related to acquisition milestones (for the year ended March 31, 2021 – $8,136, for the year ended March 31, 2020 – $62,172). During the year ended March 31, 2022, 1,295,285 shares (during the year ended March 31, 2021 – 2,598,978, during the year ended March 31, 2020 – 1,121,605) were released on completion of acquisition milestones. At March 31, 2022, there were up to 275,468 shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of shares has been estimated assuming the milestones were met at March 31, 2022. The number of shares excludes shares that were to be issued on July 4, 2023 to the previous shareholders of Spectrum Colombia and Canindica based on the fair market value of the Company’s Latin American business on that date. In the year ended March 31, 2020, as a result of the restructuring of our operations in Colombia and Lesotho, the Company accelerated share-based compensation expense relating to the unvested milestones associated with the acquisitions of Spectrum Colombia, Canindica, and DCL in the year ended March 31, 2019. Accordingly, the Company recognized share-based compensation expense of $32,694 in the year ended March 31, 2020. See Note 5 for further information. BioSteel share-based payments On October 1, 2019, the Company purchased 72% of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”) (see Note 29(c)(iii)). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at March 31, 2022, the Company had 1,565,300 (March 31, 2021 – 1,581,000, March 31, 2020 – 1,008,000) options outstanding which vest in equal tranches over a 5-year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $839 of share-based compensation expense related to the BioSteel options during the year ended March 31, 2022 with a corresponding increase in noncontrolling interest (year ended March 31, 2021 – $1,169, March 31, 2020 – $489). RIV Capital Inc. (“RIV Capital”) share-based payments For the period from April 1, 2020 to February 23, 2021, the Company recorded $2,659 in share-based compensation expense related to its former subsidiary, RIV Capital (year ended March 31, 2020 – $6,857). As described in Note 6, the Company disposed of its investment in RIV Capital on February 23, 2021.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	22. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2019 $ 41,225 $ (47,130 ) $ (5,905 ) Other comprehensive income 85,498 175,260 260,758 Income tax expense - (33,954 ) (33,954 ) As at March 31, 2020 126,723 94,176 220,899 Other comprehensive loss (154,969 ) (100,170 ) (255,139 ) As at March 31, 2021 (28,246 ) (5,994 ) (34,240 ) Disposal of consolidated entities 16,130 - 16,130 Other comprehensive income (loss) (45,352 ) 21,180 (24,172 ) As at March 31, 2022 $ (57,468 ) $ 15,186 $ (42,282 )

Noncontrolling Interests

Noncontrolling Interests	12 Months Ended
	Mar. 31, 2022
Noncontrolling Interest [Abstract]
Noncontrolling Interests	23. NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: RIV Capital Vert Mirabel BioSteel Other Total As at March 31, 2019 $ 280,012 $ 2,422 $ - $ 3,051 $ 285,485 Comprehensive (loss) income (77,313 ) 12,930 (1,731 ) - (66,114 ) Net (loss) income loss attributable to redeemable noncontrolling interest - (8,220 ) 1,731 - (6,489 ) Share-based compensation 6,857 - 489 - 7,346 Ownership changes 1,530 - - - 1,530 As at March 31, 2020 211,086 7,132 489 3,051 221,758 Comprehensive income (loss) 94,532 (14,261 ) (6,171 ) - 74,100 Net loss attributable to redeemable noncontrolling interest - 11,906 6,171 - 18,077 Share-based compensation 2,659 - 1,169 - 3,828 Ownership changes (308,527 ) (4,777 ) - - (313,304 ) Warrants 250 - - - 250 As at March 31, 2021 - - 1,658 3,051 4,709 Comprehensive loss - (3,165 ) (13,932 ) (1,207 ) (18,304 ) Net loss attributable to redeemable noncontrolling interest - 3,165 13,932 - 17,097 Share-based compensation - - 839 - 839 Ownership changes - - - - - Warrants - - - - - As at March 31, 2022 $ - $ - $ 2,497 $ 1,844 $ 4,341 1

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	24. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 - defined as observable inputs such as quoted prices in active markets; • Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and, accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. We determine the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Convertible senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066 March 31, 2021 Assets: Short-term investments $ 1,144,563 $ - $ - $ 1,144,563 Restricted short-term investments 11,332 - - 11,332 Other financial assets 254 - 700,728 700,982 Liabilities: Convertible senior notes - 687,414 - 687,414 Liability arising from Acreage Arrangement - - 600,000 600,000 Warrant derivative liability - - 615,575 615,575 See Note 5 for further details regarding the abandonment and impairment of long-lived assets as a result of the Company’s restructuring of its global operations and its annual impairment testing for the years ended March 31, 2022, 2021 and 2020. The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior notes Convertible note pricing model Quoted prices in over-the-counter broker market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - October 2019, March 2020 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Arise Bioscience term loan, TerrAscend Canada term loan - Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value October 2019, March 2020 Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Call Option Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue

Revenue	12 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	25. REVENUE Revenue is dissaggregated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Canadian recreational cannabis net revenue Business-to-business 1 $ 143,732 $ 163,585 $ 121,605 Business-to-consumer 61,570 66,016 52,044 205,302 229,601 173,649 Canadian medical cannabis net revenue 2 52,608 55,448 51,647 257,910 285,049 225,296 International and other revenue C 3 36,113 62,335 53,770 Other 43,193 31,296 15,869 79,306 93,631 69,639 Global cannabis net revenue 337,216 378,680 294,935 Other consumer products Storz & Bickel 85,410 80,998 48,329 This Works 32,296 33,314 24,725 BioSteel 44,626 28,530 4,589 Other 20,777 25,127 26,194 Other consumer products revenue 183,109 167,969 103,837 Net revenue $ 520,325 $ 546,649 $ 398,772 1 - $54,928, and year ended March 31, 2020 - $35,649). 2 The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $21,464 for the year ended March 31, 2022 (year ended March 31, 2021 – $23,935, and year ended March 31, 2020 – $51,500). As of March 31, 2022, the liability for estimated returns and price adjustments was $3,437 (March 31, 2021 – $6,441).

Pharmhouse

Pharmhouse	12 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Pharmhouse	26. PHARMHOUSE PharmHouse Inc. (“PharmHouse”), a joint venture formed on May 7, 2018, between RIV Capital and 2615975 Ontario Limited (the “PharmHouse JV Partner”), is a company licensed to cultivate cannabis under the Cannabis Act. Upon completion of the RIV Arrangement on February 23, 2021, the Company no longer controlled RIV Capital and RIV Capital’s consolidated assets and liabilities were derecognized from the Company’s consolidated financial statements. The assets and liabilities that were derecognized include those described below in relation to RIV Capital’s investments in, and obligations with respect to, PharmHouse. Refer to Note 6 for further details on the RIV Arrangement. CCAA Proceedings During the year ended March 31, 2021, PharmHouse determined that the previously anticipated timeline to generate cash flows from its offtake agreements with the Company and TerrAscend Canada would not be met, and the ultimate timing and receipt of cash inflows pursuant to these agreements became uncertain. As a result of this, as well as broader sector-wide challenges impacting the Canadian cannabis industry, PharmHouse did not have sufficient liquidity and capital resources to meet its business objectives and became unable to meet its financial obligations as they became due. Accordingly, on September 15, 2020, PharmHouse obtained an order (the “Initial Order”) from the Ontario Superior Court of Justice (the “Court”) granting PharmHouse creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”) (the “CCAA Proceedings”). The Court appointed an independent professional services firm to act as the Monitor of PharmHouse in the CCAA Proceedings while PharmHouse explored a restructuring of its business and operations (the “Restructuring”). On October 29, 2020, PharmHouse received approval from the Court to commence its Sale and Investor Solicitation Process (“SISP”). The SISP process concluded in March 2021, subsequent to the completion of the RIV Arrangement, when PharmHouse entered into a binding asset purchase agreement to sell various operating assets including its facility and certain equipment at the facility. The asset purchase agreement was approved by the Court in March 2021 . PharmHouse Recoverability Assessment As a result of the CCAA Proceedings and the Restructuring, RIV Capital determined that there were indicators of impairment present for its investments in various PharmHouse-related financial assets. RIV Capital performed impairment testing for its various PharmHouse-related financial assets by estimating the fair value of PharmHouse en bloc. Due to the lack of profitable operating history for PharmHouse as a cannabis entity, RIV Capital estimated the fair value of PharmHouse en bloc using an asset-based approach to value PharmHouse’s assets under an orderly liquidation scenario where cannabis operations are not continued at PharmHouse’s facility and the greenhouse is sold for purposes other than cannabis cultivation. This amount was then compared to the carrying values of the various PharmHouse-related financial instruments held by RIV Capital, in sequence based on the priority of claims on PharmHouse’s assets (the “PharmHouse Recoverability Assessment”). The significant components of this fair value analysis included PharmHouse’s greenhouse facility and retrofits, separable machinery and equipment, saleable inventory, and cash. Significant unobservable inputs used by RIV Capital to determine the fair value of PharmHouse’s assets include the selling price per square foot for PharmHouse’s greenhouse facility; the recoverability percentage on the liquidation of PharmHouse’s property, plant and equipment; the selling price per gram of PharmHouse’s existing cannabis inventory; and adjustments for the risk of fair value changes and liquidity. Based on the foregoing, the Company estimated the recoverable value of PharmHouse’s assets in an orderly liquidation scenario to be approximately $57,500. The impact of the PharmHouse Recoverability Assessment on RIV Capital’s various PharmHouse-related financial instruments is described below. PharmHouse Financial Guarantee Prior to February 23, 2021, PharmHouse had entered into a syndicated credit agreement (as amended, the “PharmHouse Credit Agreement”) with a number of Canadian banks (the “PharmHouse Lenders”) to provide PharmHouse with a committed, non-revolving credit facility (the “PharmHouse Credit Facility”) with a maximum principal amount of $90,000, which was fully drawn. The obligations of PharmHouse under the PharmHouse Credit Facility were secured by guarantees of RIV Capital and RCC, and a pledge by RCC of all of the shares of PharmHouse held by it (the “PharmHouse Financial Guarantee”). Accordingly, if PharmHouse was unable to generate sufficient cash flows to service its obligations pursuant to the PharmHouse Credit Facility, RIV Capital and RCC were required to compensate the PharmHouse Lenders for their loss incurred on the PharmHouse Credit Facility. The PharmHouse Credit Agreement also contains other covenants applicable to RIV Capital and RCC. Based on the PharmHouse Recoverability Assessment described above, the Company determined that the fair value of PharmHouse’s assets under an orderly liquidation scenario where the facility is not used for cannabis operations may be less than the principal amount owed by PharmHouse pursuant to the PharmHouse Credit Facility. Accordingly, the Company estimated that, prior to February 23, 2021, it had a financial liability related to the PharmHouse Financial Guarantee, reflecting the estimated shortfall between the recoverable amount of PharmHouse en bloc and the Company’s exposure to the PharmHouse Credit Facility. As at February 23, 2021, the Company estimated the current expected credit loss related to its contingent obligation under the PharmHouse Financial Guarantee to be $32,500, and recognized a financial liability for this amount in the consolidated balance sheet (March 31, 2020 – $nil). Upon completion of the RIV Arrangement on February 23, 2021, this liability was derecognized from the Company’s consolidated balance sheet. During the year ended March 31, 2021, the Company recognized an associated current expected credit loss of $32,500 in net income (loss) (year ended March 31, 2020 – $nil). Other financial assets, including loans receivable Prior to February 23, 2021, RCC had advanced to PharmHouse (i) $40,000 of secured debt financing pursuant to a shareholder loan agreement (March 31, 2020 – $40,000); (ii) $2,450 pursuant to a secured demand promissory note (March 31, 2020 – $2,450); and (iii) $1,206 between August 4, 2020, and September 8, 2020 pursuant to an unsecured promissory note. The Company recognized these instruments as financial assets, initially recorded them at fair value and subsequently measured them at amortized cost. Additionally, pursuant to the Initial Order, RCC entered into an agreement to provide a super-priority, debtor-in-possession interim, non-revolving credit facility to PharmHouse (the “DIP Financing”), with a maximum principal amount available to be drawn by PharmHouse of $9,700, and a maturity date of February 28, 2021. As at February 23, 2021, RCC had advanced $9,300 pursuant to the DIP Financing. As a result of the PharmHouse Recoverability Assessment described above, the Company recognized a current expected credit loss of $32,500 in the year ended March 31, 2021, related to its contingent obligation under the PharmHouse Financial Guarantee that existed prior to the completion of the RIV Arrangement on February 23, 2021 and the resulting derecognition of RIV Capital’s consolidated assets and liabilities. The Company also concluded that the following amounts, as described above, may not be recoverable: (i) $ 9,300 advanced pursuant to DIP Financing; (ii) $ 40,000 advanced under the shareholder loan agreement; (iii) $ 2,450 advanced under the secured demand promissory note; (iv) $ 1,206 advanced under the unsecured demand promissory note; and (v) $ 8,989 in interest receivable in relation to these financial instruments. Additionally, it was determined that certain advances in the amount of $ 15,000 provided to PharmHouse by the Company may not be recoverable, and costs of $ 35 were incurred associated with the Restructuring in the year ended March 31, 2021. Accordingly, the Company recorded expected credit losses on financial assets and related charges of $ 109,480 for the year ended March 31, 2021 (year ended March 31, 2020 – $ nil ). PharmHouse equity method investment As at February 23, 2021, RCC owned 10,998,660 common shares of PharmHouse (March 31, 2020 – 10,998,660 common shares), representing a 49% equity interest on a non-diluted basis. RCC had not yet received any distributions on account of its common share investment in PharmHouse. As a result of the PharmHouse Recoverability Assessment described above, the Company determined that there was an other-than-temporary-impairment and recognized an impairment charge for the full amount of its equity method investment of $32,369.

Other Income (Expense), Net

Other Income (Expense), Net	12 Months Ended
	Mar. 31, 2022
Other Income And Expenses [Abstract]
Other Income (Expense), Net	27. OTHER INCOME (EXPENSE), NET Other income (expense), net is dissaggregated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Fair value changes on other financial assets (356,109 ) $ 435,107 $ (243,965 ) Fair value changes on liability arising from Acreage Arrangement 553,000 (399,849 ) (645,190 ) Fair value changes on convertible senior notes 76,776 (162,540 ) 184,740 Fair value changes on warrant derivative liability 588,655 (293,084 ) 795,149 Fair value changes on acquisition related contingent consideration and other 4,417 39,608 12,293 Interest income 6,601 21,367 66,327 Interest expense (103,944 ) (8,459 ) (6,716 ) Foreign currency gain (loss) 5,415 (18,013 ) (1,245 ) (Loss) gain on disposal/acquisition of consolidated entity (6,762 ) 634 61,775 Other income (expense), net (14,708 ) (2,647 ) 1,161 $ 753,341 $ (387,876 ) $ 224,329

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	28. INCOME TAXES Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Domestic - Canada $ (163,888 ) $ (1,611,210 ) $ (1,167,000 ) Foreign - outside of Canada (165,545 ) (72,751 ) (342,054 ) $ (329,433 ) $ (1,683,961 ) $ (1,509,054 ) The income tax recovery consists of the following: Years ended March 31, March 31, March 31, 2022 2021 2020 Current Domestic - Canada $ 895 $ (19,318 ) $ (12,342 ) Foreign - outside of Canada 1,476 (2,091 ) (4,356 ) $ 2,371 $ (21,409 ) $ (16,698 ) Deferred Domestic - Canada $ 6,353 $ 36,505 $ 78,624 Foreign - outside of Canada 224 (1,955 ) 59,688 6,577 34,550 138,312 Income tax recovery $ 8,948 $ 13,141 $ 121,614 As more fully described in Note 3, income taxes that are required to be reflected in equity, instead of in the consolidated statements of operations, are included in the consolidated statements of shareholders’ equity, if applicable. Current and deferred income tax referred to above is recognized based on the Company’s best estimate of the tax rates expected to apply to the income, loss or temporary difference. The Company is subject to income tax in numerous jurisdictions with varying tax rates. During the current year ended, there were no material changes to the enacted statutory tax rates in the jurisdictions where the majority of the Company’s income for tax purposes was earned or where its material temporary differences or losses are expected to be realized or settled, however the impact of commercial decisions and market forces result in changes to the distribution of income for tax purposes amongst taxing jurisdictions that may result in a change of the effective tax rate applicable to such income, loss or temporary difference. A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5% for each of the three years ended March 31, 2022, 2021 and 2020 is as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Net loss before income taxes $ (329,433 ) $ (1,683,961 ) $ (1,509,054 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 87,300 446,250 399,899 Non-deductible and non-taxable items 17,557 81,883 22,947 Fair value changes on Acreage Arrangement 146,545 (105,960 ) (170,975 ) Fair value changes on warrant derivative liability 155,964 (77,663 ) 210,715 Share-based compensation (9,908 ) (21,121 ) (84,873 ) Change in valuation allowance (361,283 ) (358,964 ) (215,975 ) Effect of tax rates outside of Canada 8,459 10,870 (3,248 ) Non-taxable portion of capital gains and losses (38,440 ) 38,705 (34,961 ) Other 2,754 (859 ) (1,915 ) Income tax recovery $ 8,948 $ 13,141 $ 121,614 Current income taxes payable in the amount of $1,927 (March 31, 2021 – $5,267) is included in accounts payable and current income taxes receivable in the amount of $6,018 (March 31, 2021 – $5,259) is included in other accounts receivable. The Company continues to believe the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the year in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company's estimate, such difference will impact the Company's income taxes in the year during which such determination is made. Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2022 2021 Deferred income tax assets Property, plant and equipment $ 78,023 $ 74,603 Intangible assets 671 5,063 Inventory reserves and write-downs 40,324 39,893 Other reserves and accruals 5,939 7,957 Losses carried forward 917,283 608,002 Equity method investments and other financial assets 10,512 14,900 Deferred financing costs 2,740 3,587 Other 5,635 6,226 Gross deferred income tax assets 1,061,127 760,231 Valuation allowances (1,039,130 ) (677,847 ) Total deferred income tax assets, net $ 21,997 $ 82,384 Deferred income tax liabilities Property, plant and equipment $ (4,182 ) $ (25,864 ) Intangible assets (29,832 ) (43,449 ) Equity method investments and other financial assets - (31,176 ) Deferred financing costs (3,353 ) (2,785 ) Other (621 ) (489 ) Total deferred income tax liabilities (37,988 ) (103,763 ) Net deferred income tax assets (liabilities) $ (15,991 ) $ (21,379 ) In evaluating whether it is more likely than not that all or a portion of a deferred income tax asset will be realized consideration is given to the estimated reversal of deferred income tax liabilities and future taxable income. The Company has recognized valuation allowances for operating losses carried forward, capital losses carried forward and other deferred income tax assets when it is believed that it is more likely than not that these items will not be realized. As at March 31, 2022, the Company had temporary differences associated with investments in foreign subsidiaries for which no deferred income tax liabilities have been recognized, as the Company is able to control the timing of the reversal of these temporary differences and material undistributed earnings are considered permanently invested. Determination of the amount of the unrecognized deferred income tax liability is not practicable due to the inherent complexity of the multi-jurisdictional operations of the Company. As at March 31, 2022 the Company has the following losses carried forward available to reduce future years' taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 1,031 Expiring between 10 and 15 years 156,420 Expiring between 15 and 20 years 2,394,542 Indefinite 377,120 $ 2,929,113 Total in Canada $ 2,547,844 Total in United States 278,458 Total in Europe 55,440 Total in other jurisdictions 47,371 $ 2,929,113 Total operating losses $ 2,929,113 Total capital losses (carried forward indefinitely) 892,360 $ 3,821,473

Acquisitions

Acquisitions	12 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Acquisitions	29. ACQUISITIONS (a) Year ended March 31, 2022 The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities (1,724 ) (12,935 ) (30 ) (14,689 ) Debt and other liabilities - (88,324 ) (1,037 ) (89,361 ) Deferred income tax liabilities (1,899 ) (5,545 ) (540 ) (7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired (1,544 ) (41,306 ) (1,227 ) (44,077 ) Net cash outflow (inflow) $ 50,292 $ (41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Except for some of the goodwill arising in respect of the Ace Valley and Supreme Cannabis acquisition, none of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021, the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100% of the issued and outstanding shares of Ace Valley for cash consideration of $51,836. Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. In the year ended March 31, 2022, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. (ii) Supreme Cannabis On June 22, 2021, the Company and The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100% of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of recreational, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $260,668 and made a cash payment of $84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $13,350 using a Black-Scholes model. The replacement options’ fair value totaled $1,452, calculated using a Black-Scholes model, of which $629 was included in consideration paid as it related to pre-combination services and the residual $823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659. The fair value of these convertible debentures on June 22, 2021 was estimated to be $36,593, of which $4,937 was allocated to the conversion feature and $31,656 to the debt component. Due to the timing of this acquisition, the purchase price allocation for the acquisition of Supreme Cannabis is provisional. The fair value assigned to the consideration paid, intangible assets and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (b) Acquisitions completed in the year ended March 31, 2021 There were no acquisitions during the year ended March 31, 2021. (c) Acquisitions completed in the year ended March 31, 2020 The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2020: Spectrum Storz & C 3 This Works BioSteel BCT UK Bickel (i) (ii) (iii) (iv) (iv) 30(c)(v) Total Cash and cash equivalents $ 2,818 $ 1,619 $ 225 $ 7,886 $ - $ - $ 12,548 Other current assets 15,140 8,239 12,972 2,296 67 - 38,714 Property, plant and equipment 8,345 478 391 5 895 - 10,114 Intangible assets Brands 10,613 22,114 3,600 - - - 36,327 Distribution channel 4,058 12,988 14,700 - - - 31,746 Operating licenses - - - - 1,158 - 1,158 Intellectual property 36,520 16,848 20,900 5,267 - 24,990 104,525 Software and domain names 8 176 541 - - - 725 Goodwill 287,010 22,214 35,939 85,700 12,861 (24,990 ) 418,734 Accounts payable and other accrued expenses and liabilities (3,652 ) (4,100 ) (3,852 ) (2,176 ) (922 ) - (14,702 ) Debt and other liabilities (3,942 ) - (3,659 ) - - - (7,601 ) Deferred income tax liabilities (11,219 ) (7,911 ) (3,817 ) (838 ) (36 ) - (23,821 ) Net assets $ 345,699 $ 72,665 $ 77,940 $ 98,140 $ 14,023 $ - $ 608,467 Noncontrolling interests - - (18,733 ) - - - (18,733 ) Net assets acquired $ 345,699 $ 72,665 $ 59,207 $ 98,140 $ 14,023 $ - $ 589,734 Consideration paid in cash $ 345,699 $ 72,665 $ 47,924 $ 45,098 $ - $ - $ 511,386 Fair value of previously held equity interest - - - 37,919 14,023 - 51,942 Replacement options - - - 1,885 - - 1,885 Other consideration - - 11,283 13,238 - - 24,521 Total consideration $ 345,699 $ 72,665 $ 59,207 $ 98,140 $ 14,023 $ - $ 589,734 Consideration paid in cash $ 345,699 $ 72,665 $ 47,924 $ 45,098 $ - $ - $ 511,386 Less: Cash and cash equivalents acquired (2,818 ) (1,619 ) (225 ) (7,886 ) - - (12,548 ) Net cash outflow $ 342,881 $ 71,046 $ 47,699 $ 37,212 $ - $ - $ 498,838 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Except for the goodwill arising in respect of the Storz & Bickel GmbH & Co., KG (“Storz & Bickel”) acquisition, none of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) C 3 On April 30, 2019, the Company acquired 100% of the shares of C 3 3 five-year 3 In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Distribution channel $ 4,058 10 Income approach Intellectual property 36,520 10 Relief-from-royalty Licensed brands 10,613 2 Relief-from-royalty Other adjustments Inventory step-up 1,814 Deferred income tax liabilities (11,219 ) Net impact to goodwill $ (41,786 ) (ii) This Works On May 21, 2019, the Company acquired 100% of the shares of TWP UK Holdings Limited (“This Works”) and its subsidiary companies, This Works Products Limited, TWP USA Inc. and TWP IP Limited for total cash consideration of $72,665 (GBP 43,296). Based in London, United Kingdom, This Works is a natural skincare and sleep solutions company. In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Acquired brands $ 19,130 Indefinite Relief-from-royalty Distribution channel 12,988 10 Income approach using a multi-period excess earnings method Intellectual property 16,848 10 Replacement cost Licensed brands 2,984 5 Income approach using a multi-period excess earnings method Other adjustments Inventory step-up 1,755 Deferred income tax liabilities (7,911 ) Net Impact to Goodwill $ (45,794 ) (iii) BioSteel On October 1, 2019, the Company purchased 72% of the outstanding shares of BioSteel, a North America-based producer of sports nutrition products. Initial cash consideration was $50,707 subject to certain adjustments and holdbacks such that $47,924 was advanced on closing. The purchase price was to be further adjusted based on a multiple of BioSteel’s calendar 2019 net revenue. Management has concluded that this purchase price adjustment is nominal. Through its voting rights, the Company controls BioSteel and therefore, the acquisition was accounted for as a business combination. The noncontrolling interests of $18,733 recognized at acquisition date were recorded at their share of fair value. Prior to September 30, 2019, the Company had advanced a total of $8,500 to BioSteel under a secured loan agreement. The acquisition resulted in an effective settlement of the loan payable of $8,500 which has been recorded as other consideration. Immediately following the October 1 acquisition, the Company subscribed for additional shares of BioSteel for consideration of $14,000 which was funded through a cash advance of $10,000 and the conversion of $4,000 of the loan payable. After completing this investment, the Company’s ownership interest in BioSteel is 76.7%. The shares not purchased by the Company will be retained by certain current shareholders and management for a period of up to 5 years (the “Rollover Shareholders”). On the third anniversary of the closing Canopy Growth will have a right to purchase, and the Rollover Shareholders will have a right to sell one half of the remaining interest held by the Rollover Shareholders to Canopy Growth at a specified valuation based on a multiple of BioSteel’s net revenue. On the fifth anniversary of the closing Canopy Growth will have a right to purchase, and the Rollover Shareholders will have a right to sell the balance of the remaining interest held by the Rollover Shareholders to Canopy Growth at a valuation to be mutually agreed upon by the parties. The call and put options represent redeemable noncontrolling interest (“BioSteel Redeemable NCI”) and is recorded at fair value on initial recognition. See Note 19 for a continuity of the BioSteel Redeemable NCI. See Note 24 for additional details on how the fair value is calculated. In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Acquired brands $ 3,600 Indefinite Relief-from-royalty Distribution channel 14,700 11 Income approach using a multi-period excess earnings method Intellectual property 20,900 11 Relief-from-royalty, net of product migration Other adjustments Inventory step-up 2,710 Deferred income tax liabilities (3,817 ) Net impact to goodwill $ (38,093 ) (iv) BCT and Spectrum UK BCT is a cannabis research and development organization in the United Kingdom which was formed in fiscal 2018 through a collaboration agreement between CHI and Beckley Research and Innovations Limited. In the fourth quarter of fiscal 2019, the Company and BCT had formed another joint venture – Spectrum Biomedical UK (“Spectrum UK”). The purpose of Spectrum UK was to become the exclusive distributor of cannabis-based medicinal products made by the Company. Since their inception the Company had been accounting for its 42% interest in BCT and its 67% interest in Spectrum UK using the equity method. Though BCT and Spectrum UK are VIE’s, due to the fact that both entities are jointly controlled, Canopy Growth is not the primary beneficiary of either entity and therefore is not required to consolidate either entity. On October 11, 2019, the Company acquired all its unowned interest in BCT to increase its total ownership of BCT’s issued and outstanding shares to 100%. Following this transaction, the Company will control both BCT and Spectrum UK, and both BCT and Spectrum UK will be accounted for as wholly owned subsidiaries. Cash consideration for this transaction was $58,336 of which $45,098 was advanced on closing, $8,750 was paid during October 2020, and $5,861 was paid on October 1, 2021 and has a fair value of $5,746. Consideration also included 155,565 replacement options. The fair value of the replacement options was determined using a Black-Scholes model and $1,885 of the total fair value has been included as consideration paid to acquire BCT as it related to pre-combination vesting service and $1,987 of the fair value will be recognized as share-based compensation expense ratably over the post-combination vesting period. The acquisition of the unowned interests is accounted for as business combinations achieved in stages under ASC 805. The Company remeasured its 42% interest in BCT and its 67% interest in Spectrum UK to fair value and recognized a total gain of $39,485 which reflects the difference between the carrying value of $12,457 and the implied fair value $51,942. The fair value was estimated to be the transaction price less an estimated control premium of 5%. The consideration paid for BCT included $250 cash and 16,430 replacement options that were issued to a member of key management of the Company that was a shareholder and option holder in BCT. In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Intellectual property $ 5,267 1 Replacement cost Operating license 1,158 1 Replacement cost Other adjustments Deferred income tax liabilities (874 ) Net impact to goodwill $ (5,551 ) (d) More Life On November 7, 2019 the Company entered into agreements with certain entities that are controlled by Aubrey “Drake” Graham to launch the More Life Growth Company (“More Life”). Under the agreements Canopy Growth sold 100% of the shares of 1955625 Ontario Inc., a wholly owned subsidiary of Canopy Growth that holds the Health Canada license for a facility located in Scarborough, Ontario to More Life (“More Life Facility”) in exchange for a 40% interest in More Life. Certain entities that are controlled by Drake hold a 60% ownership interest in More Life. Following this transaction, the Company no longer controlled 1955625 Ontario Inc. and the Company derecognized the assets and liabilities of 1955625 Ontario Inc. from its consolidated financial statements at their carrying amounts. Management has concluded that the subsidiary does not meet the definition of an operation and no goodwill was allocated. The derecognized assets and liabilities on November 7, 2019, were as follows: Current assets $ 100 Intangible assets 2,810 Net assets disposed $ 2,910 Fair value of retained interest 25,200 Gain on disposal of consolidated entity $ 22,290 The gain calculated on the derecognition of 1955625 Ontario Inc.’s assets and liabilities was the difference between the carrying amounts of the derecognized assets and liabilities of 1955625 Ontario Inc. and the fair value of the consideration received, being the fair value of the Company’s interest in More Life. This gain was recognized in other income (expense), net, in the year ended March 31, 2020. The fair value of this interest on the transaction date was estimated to be $25,200 which was determined using a discounted cash flow approach. The most significant inputs to the fair value measurement are the discount rate and expectations about future royalties. As consideration for the 60% interest in More Life, certain entities that are controlled by Drake granted More Life the right to exclusively exploit certain intellectual property and brands in association with the growth, manufacture, production, marketing and sale of cannabis and cannabis-related products, accessories, merchandise and paraphernalia in Canada and internationally. More Life sublicensed such rights in Canada to Canopy Growth in exchange for royalty payments. On November 7, 2019, Canopy Growth recorded an intangible asset equal to the present value of the agreed minimum royalty payments. As part of the Company’s restructuring of its global operations in the year ended March 31, 2020, the Company recognized an impairment charge related to the remaining intangible assets in the amount of $32,717. The Company and More Life agreed to terminate the sublicense agreement between the two parties as of March 1, 2021, and as a result the Company derecognized the remaining minimum royalty obligations owing to More Life in the amount of $33,681. The difference between the termination payment made by the Company to More Life and the remaining minimum royalty obligations was recorded in asset impairment and restructuring costs; refer to Note 5. Through its ownership and other rights, the Company was determined to have significant influence over More Life and accounts for its interest in More Life using the equity method of accounting. The investment was initially recognized at its fair value of $25,200 and adjusted thereafter to recognize the Company’s share of net income (loss) and other comprehensive income (loss). The fair value of the Company’s interest in More Life was estimated to be $10,300 at March 31, 2020 using the same valuation techniques and inputs as described above. As at March 31, 2021, as a result of the termination of the sublicense agreement between the Company and More Life, the Company determined that the fair value of its’ interest in More Life was $nil, and accordingly, the Company recognized an impairment on its equity method investment in the amount of $10,300 in the year ended March 31, 2021 (year ended March 31, 2020 – $14,900) as part of the restructuring of its global operations. See Note 5 for further information.

C3 Divestiture

C3 Divestiture	12 Months Ended
	Mar. 31, 2022
Discontinued Operations And Disposal Groups [Abstract]
C3 Divestiture	30. C 3 On December 15, 2021, the Company entered into an agreement to divest all of its interest in C 3 3 The C 3 3 Following the C 3 3 3 3 Current assets 1 $ 44,568 Property, plant and equipment 9,216 Intangible assets 15,548 Goodwill 53,541 Current liabilities (3,089 ) Deferred income tax liabilities (6,029 ) Cumulative translation adjustment 19,178 Net assets disposed $ 132,933 Consideration received in cash $ 128,316 Future cash consideration 7,233 Costs to sell (1,153 ) Total consideration $ 134,396 Gain on disposal of consolidated entity $ 1,463 1 The gain calculated on the derecognition of C 3

Acreage Arrangement and Amendme

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	12 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	31. ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On September 23, 2020, the Company and Acreage Holdings, Inc. (“Acreage”) entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Acreage Arrangement Agreement”) and plan of arrangement (the “Original Acreage Arrangement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019. In connection with the Acreage Amending Agreement, the Company and Acreage implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”) on September 23, 2020. Pursuant to the terms of the Original Acreage Arrangement, shareholders of Acreage and holders of certain securities convertible into the existing Acreage subordinated voting shares as of June 26, 2019, received an immediate aggregate total payment of US$300,000 ($395,190) in exchange for granting Canopy Growth both the right and the obligation to acquire all of the issued and outstanding shares of Acreage following the occurrence or waiver of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement. The Acreage Amended Arrangement provides for, among other things, the following: • Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Class E subordinated voting shares (the “Fixed Shares”) based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right exercisable for a period of 30 days, to acquire all of the issued and outstanding Class D subordinated voting shares (the “Floating Shares”) for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$37,500 ($49,849); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. At March 31, 2022, the right and the obligation (the “Acreage financial instrument”) to acquire the Fixed Shares represents a financial liability of $47,000 (March 31, 2021 – $600,000), as the estimated fair value of the Acreage business is less than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes on the Acreage financial instrument are recognized in other income (expense), net; see Note 27. The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 24 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825. In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$50,000 ($66,995) to Universal Hemp, LLC, a wholly owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Hempco Debenture”). In accordance with the terms of the Hempco Debenture, the funds advanced to Acreage Hempco cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Hempco Debenture bears interest at a rate of 6.1% per annum and matures on September 23, 2030, or such earlier date in accordance with the terms of the Hempco Debenture. All interest payments made pursuant to the Hempco Debenture are payable in cash by Acreage Hempco. The Hempco Debenture is not convertible and is not guaranteed by Acreage. The amount advanced on September 23, 2020 pursuant to the Hempco Debenture has been recorded in other financial assets (see Note 12), and the Company has elected the fair value option under ASC 825 (see Note 24). At March 31, 2022, the estimated fair value of the Hempco Debenture issued to an affiliate of the Company by Acreage Hempco was $28,824 (March 31, 2021 – $27,448), measured using a discounted cash flow model (see Note 24). Refer to Note 12 for details on fair value changes, foreign currency translation adjustment, and interest received. An additional US$50,000 may be advanced pursuant to the Hempco Debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly owned subsidiaries of CBI and Canopy Growth entered into a second amended and restated investor rights agreement and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $50.40 per share (the “Tranche A Warrants”), to November 1, 2023; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • the Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,866 common shares; and (ii) common shares with a value of $1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at March 31, 2022. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging The Tranche B Warrants are accounted for as derivative instruments (the “warrant derivative liability”) measured at fair value in accordance with ASC 815. At March 31, 2022, the fair value of the warrant derivative liability was $26,920 (March 31, 2021 – $615,575), and fair value changes are recognized in other income (expense), net; see Note 27. See Note 24 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at March 31, 2022.

Leases

Leases	12 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Leases	32. LEASES The Company primarily leases office and production facilities, warehouses, production equipment and vehicles. The Company assesses service arrangements to determine if an asset is explicitly or implicitly specified in the agreement and if we have the right to control the use of the identified asset. The right-of-use asset is initially measured at cost, which is primarily comprised of the initial amount of the lease liability, plus initial direct costs and lease payments at or before the lease commencement date, less any lease incentives received, and is amortized on a straight-line basis over the remaining lease term. All right-of-use assets are reviewed periodically for impairment. The lease liability is initially measured at the present value of lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. We elected to recognize expenses for leases with a term of 12 months or less on a straight-line basis over the lease term and not to recognize these short-term leases on the balance sheet. Leases have varying terms with remaining lease terms of up to approximately 30 years Lease payments included in the measurement of the lease liability comprise (a) fixed payments, including in-substance fixed payments; (b) variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date; (c) amounts expected to be payable under a residual value guarantee; and (d) the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Company is reasonably certain not to terminate early. At inception or reassessment of a contract that contains lease and non-lease components, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. Balance sheet location A summary of lease right-of-use assets and liabilities are as follows: March 31, March 31, 2022 2021 Property, plant and equipment Operating lease $ 39,571 $ 47,522 Finance lease 34,333 39,427 $ 73,904 $ 86,949 Other current liabilities: Operating lease $ 11,752 $ 11,491 Finance lease 26,283 30,570 Other long-term liabilities: Operating lease 58,031 62,285 Finance lease 43,094 31,879 $ 139,160 $ 136,225 Lease expense The components of total lease expense are as follows: Years ended March 31, March 31, 2022 2021 Operating lease expense $ 5,245 $ 10,846 Finance lease expense: Amortization of right-of-use assets 3,883 2,303 Interest on lease liabilities 1,667 1,674 $ 10,795 $ 14,823 Lease maturities As of March 31, 2022, the minimum payments due for lease liabilities for each of the five succeeding fiscal years and thereafter are as follows: Operating Leases Finance Leases 2023 $ 12,004 $ 8,023 2024 11,402 8,116 2025 10,923 8,200 2026 9,892 38,476 2027 9,525 3,388 Thereafter 17,761 6,262 Total lease payments $ 71,507 $ 72,465 Less: Interest 1,724 3,088 Total lease liabilities $ 69,783 $ 69,377 As of March 31, 2022, we have additional operating leases that have not yet commenced with immaterial aggregated minimum payments on an undiscounted basis. Supplemental information Years ended March 31, March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,905 $ 18,792 Operating cash flows from finance leases 1,667 1,674 Financing cash flows from finance leases 1,494 2,303 Right-of-use assets obtained in exchange for new lease liabilities: Operating leases $ 9,019 $ 13,592 Finance leases 3,720 1,428 March 31, March 31, 2022 2021 Weighted-average remaining lease term: Operating leases 6 7 Finance leases 4 4 Weighted-average discount rate Operating leases 4.50 % 4.50 % Finance leases 4.50 % 4.50 %

Related Party

Related Party	12 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party	33. RELATED PARTY Year ended March 31, 2022 There were no reportable related party transactions in the year ended March 31, 2022. Year ended March 31, 2021 On February 23, 2021, the Company completed the RIV Arrangement with RIV Capital and RCC. Refer to Note 6 for a description of the RIV Arrangement. In connection with the Proposal Agreement entered into by the Company and Acreage on June 24, 2020 to amend the terms of the Original Acreage Arrangement, the Company entered into the Second Consent Agreement with CBI and its affiliates. Year ended March 31, 2020 In connection with the Acreage Arrangement Agreement, the Company entered into several agreements with CBI and its affiliates, including the New Investor Rights Agreement, the Consent Agreement and amendments to the Original Tranche B Warrants. See Note 31 for further information.

Commitments

Commitments	12 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments	34. COMMITMENTS The Company has entered into agreements in which it has committed to purchase a minimum amount of inventory, pay a minimum amount of royalty expenses, incur expenditures for property, plant and equipment and procure various other goods or services. The following summarizes the Company’s annual minimum commitments associated with its contractual agreements as of March 31, 2022. This amount excludes the Company’s debt and lease related commitments which are disclosed elsewhere in Notes 17 and 32, respectively in these consolidated financial statements. 2023 $ 130,453 2024 72,653 2025 33,641 2026 24,347 2027 16,936 Thereafter 57,773 $ 335,803

Segmented Information

Segmented Information	12 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segmented Information	35. SEGMENTED INFORMATION Reportable segments Prior to the fourth quarter of the year ended March 31, 2021, the Company had the following two operating segments, which were also its reportable segments: (i) cannabis, hemp, and other consumer products; and (ii) RIV Capital. Following the completion of the RIV Arrangement in February 2021 (refer to Note 6) and the completion of restructuring actions in the third and fourth quarters of the year ended March 31, 2021, associated with the end-to-end review of the Company’s operations (refer to Note 5), the Company changed the structure of its internal management financial reporting. Accordingly, in the fourth quarter of the year ended March 31, 2021, the Company began reporting its financial results for the following two operating segments, which are also its reportable segments: (i) global cannabis; and (ii) other consumer products. These segments reflect how the Company’s operations are managed, how the Company’s Chief Executive Officer, who is the chief operating decision maker (“CODM”), allocates resources and evaluates performance, and how the Company’s internal management financial reporting is structured. The Company’s global cannabis segment encompasses the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Company’s other consumer products segment comprises the production, distribution, and sale of consumer products, including (i) Storz & Bickel vaporizers; (ii) This Works beauty, skincare, wellness and sleep products; (iii) BioSteel sports nutrition beverages, mixes, protein, gum and mints; and (iv) other revenue sources. The Company’s CODM evaluates the performance of these two segments focusing on (i) segment net revenue, and (ii) segment gross margin and gross margin percentage as the measure of segment profit or loss. Accordingly, information regarding segment net revenue and segment gross margin for the year ended March 31, 2020 comparative period has been recast to reflect the aforementioned change in reportable segments. The accounting policies of each segment are the same as those disclosed in the summary of significant accounting policies in Note 3. Years ended March 31, March 31, March 31, 2022 2021 2020 Segmented net revenue Global cannabis $ 337,216 $ 378,680 $ 294,935 Other consumer products 183,109 167,969 103,837 $ 520,325 $ 546,649 $ 398,772 Segmented gross margin: Global cannabis $ (251,235 ) $ 7,045 $ (76,836 ) Other consumer products 58,181 59,915 45,152 (193,054 ) 66,960 (31,684 ) Selling, general and administrative expenses 472,756 575,389 693,737 Share-based compensation 47,525 91,149 320,276 Expected credit losses on financial assets and relates charges - 109,480 - Asset impairment and restructuring costs 369,339 534,398 623,266 Operating loss (1,082,674 ) (1,243,456 ) (1,668,963 ) Loss from equity method investments (100 ) (52,629 ) (64,420 ) Other income (expense), net 753,341 (387,876 ) 224,329 Loss before incomes taxes $ (329,433 ) $ (1,683,961 ) $ (1,509,054 ) Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: Years ended March 31, March 31, March 31, 2022 2021 2020 Canada $ 296,369 $ 329,172 $ 256,166 Germany 90,874 116,379 93,945 United States 82,080 64,926 24,568 Other 51,002 36,172 24,093 $ 520,325 $ 546,649 $ 398,772 Disaggregation of long-lived tangible assets by geographic area: March 31, March 31, 2022 2021 Canada $ 827,591 $ 847,678 United States 63,247 143,747 Other 51,942 83,112 $ 942,780 $ 1,074,537 For the year ended March 31, 2022, one customer represented more than 10% of the Company’s net revenue (years ended March 31, 2021 and 2020, none and one, respectively).

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	36. SUBSEQUENT EVENTS Plan to Acquire Jetty On May 18, 2022, the Company and Lemurian, Inc. (“Jetty”), a California-based producer of high-quality cannabis extracts and clean vape technology, announced that they entered into definitive agreements (the “Jetty Agreements”) providing Canopy Growth, by way of a wholly-owned subsidiary, the right to acquire, upon federal permissibility of THC in the U.S. or earlier at our election, up to 100% of the outstanding capital stock of Jetty. Under the Jetty Agreements, the Company will make aggregate upfront payments in the amount of approximately US$69,000, payable through a combination of cash and Canopy Growth common shares, a majority of which will be in Canopy Growth common shares, in exchange for approximately 75% of the equity interests in Jetty, subject to certain adjustments. Upon exercise of the rights to acquire up to 100% of the equity interests in Jetty covered by the first option agreement, the Company will make an additional payment pursuant to the terms of the Jetty Agreements, also to be satisfied through a combination of cash and Canopy Growth common shares. Until such time as the Company elects to exercise its rights to acquire Jetty, the Company will have no direct or indirect economic or voting interests in Jetty, the Company will not directly or indirectly control Jetty, and the Company, on the one hand, and Jetty, on the other hand, will continue to operate independently of one another.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation.
Variable interest entities	Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under Accounting Standards Codification (“ASC”) 810 – Consolidations
Equity method investments	Equity method investments Investments accounted for using the equity method include those investments where the Company (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods.
Use of estimates	Use of estimates The preparation of these consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.
Foreign currency translation	Foreign currency translation In preparing the financial statements of individual entities, transactions in currencies other than the entity’s functional currency are recognized at exchange rates in effect on the date of the transactions. At each reporting date monetary assets and liabilities denominated in foreign currencies are re-translated at the exchange rates applicable at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary assets and liabilities that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Realized and unrealized exchange gains and losses are recognized through net income (loss). For the purposes of presenting consolidated financial statements, the assets and liabilities of foreign operations are translated into Canadian dollars at the exchange rates applicable at the balance sheet date. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in accumulated other comprehensive income (loss).
Cash equivalents and short-term investments	Cash equivalents and short-term investments Cash equivalents consist of highly liquid investments with original maturities of three months or less. Investments with maturities greater than 90 days but less than one year at the date of purchase are included in short-term investments. The Company’s investments in debt securities, which consist primarily of U.S. government securities and U.S. commercial paper, have been classified and accounted for using the fair value option. Unrealized gains and losses on debt securities are recognized in net income (loss). All other short-term investments are recorded at fair value with gains or losses recognized in net income (loss).
Inventory	Inventory Inventory consists of raw materials, supplies and consumables used in the inventory process, merchandise for sale, finished goods and work-in-process such as pre-harvested cannabis plants, by-products to be extracted, oils, gel capsules and edible products. Inventory is valued at the lower of cost and net realizable value. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead costs. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, age of inventory, historical experience and application of the specific identification method. The Company classifies cannabis inventory as a current asset, although part of such inventory, because of the duration of the cultivation, drying, and conversion process, ordinarily would not be utilized within one year.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment is recorded at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in net income (loss). Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 Estimates of useful life and residual value, and the method of depreciation, are reviewed only when events or changes in circumstances indicate that the current estimates or depreciation method are no longer appropriate. Any changes are accounted for on a prospective basis as a change in estimate.
Intangible assets	Intangible assets Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 8 Software and domain names 3 - 5 Brands 2 - 5 The estimated useful life and amortization method are reviewed at the end of each reporting year, with the effect of any changes in estimate being accounted for on a prospective basis.
Goodwill and indefinite lived intangible assets	Goodwill and indefinite lived intangible assets Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company reviews goodwill and indefinite lived intangible assets annually for impairment in the fourth quarter, or sooner, if events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If factors indicate this is the case, then a quantitative test is performed and an impairment is recorded for any excess carrying value above the reporting unit’s fair value, not to exceed the amount of goodwill. Until the three months ended March 31, 2021, the Company had two operating segments, which were also its reportable segments: (i) cannabis, hemp and other consumer products; and (ii) RIV Capital. The goodwill associated with all acquisitions was allocated to the one reporting unit within the cannabis, hemp and other consumer products operating and reportable segment, as this reporting unit held the acquired entities. The Company changed the structure of its internal management reporting in the fourth quarter of the year ended March 31, 2021 (refer to Note 35), and accordingly, identified two operating and reportable segments: (i) global cannabis; and (ii) other consumer products. The reorganization of the Company’s reporting structure changed the composition of its reporting units and required that goodwill be reassigned to the reporting units using a relative fair value allocation approach. Assets and liabilities were also reassigned to the reporting units affected based on the assets that would be employed in, or the liabilities related to, the operations of each reporting unit, and the assets or liabilities that would be considered in determining the fair value of each reporting unit. After this reorganization, the Company’s reporting units with goodwill in the global cannabis segment included (i) cannabis operations, and (ii) C 3 3 In the three months ended March 31, 2022, the Company further changed the composition of its reporting units within the global cannabis segment as a result of (i) the completion of the Company’s divestiture (the “C 3 3 The Company performed its annual goodwill impairment test in the fourth quarter of the year ended March 31, 2022, and recognized an impairment loss in relation to its KeyLeaf and This Works reporting units. Refer to Note 15 for further details. Indefinite lived intangible assets are comprised of certain acquired brand names and operating licenses, which are carried at cost less accumulated impairment losses. The Company reviews the classification each reporting period to decide whether the assessment made about the useful life as indefinite or finite is still appropriate. Any change is accounted for on a prospective basis as a change in estimate.
Impairment of long-lived assets	Impairment of long-lived assets The Company evaluates the recoverability of long-lived assets, including property, plant and equipment and finite lived intangible assets whenever events or changes in circumstances indicate a potential impairment exists. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. When indicators of potential impairment are present the Company prepares a projected undiscounted cash flow analysis for the respective asset or asset group. If the sum of the undiscounted cash flow is less than the carrying value of the asset or asset group, an impairment loss is recognized equal to the excess of the carrying value over the fair value, if any.
Restricted short-term investments	Restricted short-term investments The Company considers short-term investments to be restricted when withdrawal or general use is legally restricted. The Company records restricted short-term investments as current or non-current in the consolidated balance sheets based on the classification of the underlying securities.
Redeemable noncontrolling interest	Redeemable noncontrolling interest Redeemable noncontrolling interest is presented as mezzanine equity. The balance of the redeemable noncontrolling interest is reported at the greater of the initial carrying amount adjusted for the redeemable noncontrolling interest's share of earnings or losses and other comprehensive income or loss, or its estimated redemption value. The Company adjusts the carrying amount of the redeemable interest to the redemption amount each period, assuming the interest was redeemable at the balance sheet date with changes in fair value recorded in equity.
Revenue recognition	Revenue recognition The Company’s cannabis revenue is comprised of sales of (i) recreational cannabis products in Canada, either to government agencies or third-party retailers under a “business-to-business” wholesale model, or directly to consumers through the Company’s network of retail stores and e-commerce platforms; and (ii) medical and other cannabis products in Canada and certain other countries. The Company’s other revenue is comprised of sales of vaporizers, beauty, wellness and sleep products, sports nutrition beverages, merchandise, and revenue from other sources. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. In accordance with contracts with certain of the Company’s Canadian provincial customers, the Company fulfills its obligations only when the customer transfers control of the product to the end consumer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts, most notably those with the Canadian provincial and territorial agencies, may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. The Company estimates this variable consideration by taking into account factors such as historical information, current trends, forecasts, provincial and territorial inventory levels, availability of actual results and expectations of demand. The Company recognizes a liability for sales refunds within other current liabilities, and an asset for the value of inventory which is expected to be returned is recognized within prepaid expenses and other assets on the consolidated balance sheets. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.
Cost of goods sold	Cost of goods sold The types of costs included in cost of goods sold are raw materials, packaging materials, manufacturing costs, plant facilities administrative support and overheads, and freight and warehouse costs, including distribution costs.
Advertising	Advertising Advertising costs are expensed as incurred. Advertising expenses totaled $104,221, $72,377 and $78,474 in the years ended March 31, 2022, 2021, and 2020, respectively.
Research and development	Research and development Research and development costs are expensed as incurred. Research and development expenses totaled $32,344, $57,582, and $61,812 in the years ended March 31, 2022, 2021, and 2020, respectively.
Asset impairment and restructuring costs	Asset impairment and restructuring costs Asset impairment and restructuring costs consist of property, plant and equipment, intangible asset and goodwill impairment charges, asset abandonment costs, contractual and other settlement costs, and employee-related and other restructuring costs recognized in connection with (i) the restructuring of the Company’s global operations that commenced in the year ended March 31, 2020 and continued during the years ended March 31, 2021 and March 31, 2022; and (ii) other impairments. When a long-lived asset is abandoned its carrying amount is adjusted to its salvage value, if any. In determining the salvage value of our long-lived assets, management considers information from manufacturers, historical data, and industry standards. In certain cases, management may obtain third party appraisals to estimate salvage value.
Share-based compensation	Share-based compensation The Company accounts for share-based compensation using the fair value method. With the exception of a limited number of share-based awards subject to market-based performance conditions that are valued using the Monte Carlo simulation model, the fair value of awards granted is estimated at the date of grant using the Black-Scholes model. The share-based compensation expense is based on the fair value of share-based awards at the grant date and the expense is recognized over the related service period following a graded vesting expense schedule. Forfeitures are estimated at the time of grant and revised in subsequent periods if there is a difference in actual forfeitures and the estimate. Effective April 1, 2018, the Company early-adopted ASU 2018-07 – Compensation - Stock Compensation (Topic 718) For awards with service and/or non-market based performance conditions, the amount of compensation expense recognized is based on the number of awards expected to vest, reflecting estimated expected forfeitures, and is adjusted to reflect those awards that do ultimately vest. For awards with performance conditions, the Company recognizes the compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of achieving the performance condition at each reporting date. Restricted stock units (“RSUs”) that are settled in cash or common stock at the election of the employee are remeasured to fair value at the end of each reporting period until settlement. This fair value is based on the closing price of the Company's common shares on the last business day before each period end.
Income taxes	Income taxes Income taxes are comprised of current and deferred taxes. These taxes are accounted for using the liability method. Current tax is recognized in connection with income for tax purposes, unrealized tax benefits and the recovery of tax paid in a prior period and measured using the enacted tax rates and laws applicable to the taxation period during which the income for tax purposes arose. Deferred tax is recognized on the difference between the carrying amount of an asset or a liability, as reflected in the financial statements, and the corresponding tax base, used in the computation of income for tax purposes (“temporary difference”) and measured using the enacted tax rates and laws as at the balance sheet date that are expected to apply to the income that the Company expects to arise for tax purposes in the period during which the difference is expected to reverse. Management assesses the likelihood that a deferred tax asset will be realized and a valuation allowance is provided to the extent that it is more likely than not that all or a portion of a deferred tax asset will not be realized. The determination of both current and deferred taxes reflects the Company's interpretation of the relevant tax rules and judgement. An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs. Income taxes are recognized in the consolidated statement of operations, except when they relate to a pre-tax item that is recognized in other comprehensive income (loss) or directly in equity, respectively. Income taxes recognized in other comprehensive income (loss) or equity are reclassified to the consolidated statement of operations if the corresponding pre-tax item is reclassified to the consolidated statement of operations. Where income taxes arise from the initial accounting for a business combination, these are embedded in the pre-tax accounting for the business combination. Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share is computed by dividing earnings (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common shares of the Company during the reporting periods. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of warrants, vested share options, RSUs and the incremental shares issuable upon conversion of the convertible senior notes. As at March 31, 2022, March 31, 2021, and March 31, 2020, all instruments were anti-dilutive.
Fair value measurements	Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company calculates the estimated fair value of financial instruments using quoted market prices whenever available. When quoted market prices are not available, the Company uses standard pricing models. For other financial assets measured at fair value that earn interest, the Company has elected to present interest income as part of the fair value change in other income (expense), net.
COVID-19 estimation uncertainty	COVID-19 estimation uncertainty In March 2020, the World Health Organization recognized the outbreak of COVID-19 as a global pandemic. Government measures to limit the spread of COVID-19, including the closure of non-essential businesses, did not materially impact the Company’s operations during the years ended March 31, 2022, March 31, 2021 and March 31, 2020. The production and sale of cannabis have been recognized as essential services in Canada and across Europe. Due to the rapid developments and uncertainty surrounding COVID-19, it is not possible to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in the future. Additionally, it is possible that estimates in the Company’s consolidated financial statements will change in the near term as a result of COVID-19. The Company is closely monitoring the impact of the pandemic on all aspects of its business.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Accounting Guidance not yet adopted Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 The components of property, plant and equipment are as follows: March 31, March 31, 2022 2021 Buildings and greenhouses $ 766,931 $ 651,166 Production and warehouse equipment 159,314 216,925 Leasehold improvements 69,304 106,837 Office and lab equipment 29,879 30,546 Computer equipment 22,293 26,431 Land 18,917 34,747 Right-of-use-assets Buildings and greenhouses 89,228 100,517 Production and warehouse equipment 55 530 Assets in process 19,771 129,428 1,175,692 1,297,127 Less: Accumulated depreciation (232,912 ) (222,590 ) $ 942,780 $ 1,074,537
Summary of Finite Lived Intangible Assets Useful Life	Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 8 Software and domain names 3 - 5 Brands 2 - 5

Asset Impairment and Restruct_2

Asset Impairment and Restructuring Costs (Tables)	12 Months Ended
	Mar. 31, 2022
Restructuring And Related Activities [Abstract]
Summary of Pre-tax Charges Recognized in Restructuring Actions and Other Impairments	A summary of the pre-tax charges totaling $496,623 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2022 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 123,669 $ - $ 123,669 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 224,726 - 224,726 Impairment and abandonment of intangible assets 41,404 26,065 67,469 Impairment of goodwill - 40,748 40,748 Contractual and other settlement obligations 6,610 - 6,610 Employee-related and other restructuring costs 29,786 - 29,786 Asset impairment and restructuring costs 302,526 66,813 369,339 Acceleration of share-based compensation expense related to acquisition milestones 3,615 - 3,615 Share-based compensation expense 3,615 - 3,615 Total restructuring, asset impairments and related costs $ 429,810 $ 66,813 $ 496,623 A summary of the pre-tax charges totaling $570,683 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2021 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 25,985 $ - $ 25,985 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 426,748 - 426,748 Impairment and abandonment of intangible assets 54,511 6,634 61,145 Contractual and other settlement obligations 22,352 - 22,352 Employee-related and other restructuring costs 24,153 - 24,153 Asset impairment and restructuring costs 527,764 6,634 534,398 Costs recorded in loss from equity method investments: Impairment of equity method investments 10,300 - 10,300 Total restructuring, asset impairments and related costs $ 564,049 $ 6,634 $ 570,683 A summary of the pre-tax charges totaling $843,275 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2020 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 132,089 $ - $ 132,089 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 334,964 - 334,964 Impairment and abandonment of intangible assets 192,987 54,020 247,007 Contractual and other settlement obligations 18,712 6,000 24,712 Employee-related and other restructuring costs 16,583 - 16,583 Asset impairment and restructuring costs 563,246 60,020 623,266 Acceleration of share-based compensation expense related to acquisition milestones 32,694 - 32,694 Share-based compensation expense 32,694 - 32,694 Costs recorded in loss from equity method investments: Impairment of equity method investments 14,900 40,326 55,226 Total restructuring, asset impairments and related costs $ 742,929 $ 100,346 $ 843,275

Plan Of Arrangement With Riv _2

Plan Of Arrangement With Riv Capital (Tables)	12 Months Ended
	Mar. 31, 2022
Divestiture [Abstract]
Schedule Of Derecognized Assets And Liabilities	The derecognized assets and liabilities on February 23, 2021, were as follows: Acquired assets TerrAscend Exchangeable Shares $ 291,500 TerrAscend warrants 32,000 Preferred shares in Vert Mirabel 22,600 Settlement of Tweed NB obligations to RCC 15,000 TerrAscend loan 10,000 Common shares in Vert Mirabel 9,075 Total acquired assets $ 380,175 Consideration paid in shares (170,284 ) Consideration paid in cash (115,000 ) $ 94,891 Derecognition of RIV Capital net assets Cash and cash equivalents $ 37,801 Amounts receivable, net 4,327 Prepaid expenses and other assets 995 Equity method investments 5,114 Other financial assets 417,256 Property, plant and equipment 729 Intangible assets 86 Accounts payable (22,038 ) Other accrued expenses and liabilities (1,703 ) Other current liabilities (32,653 ) Other long-term liabilities (303 ) Noncontrolling interests and other (315,144 ) $ 94,467 Gain on completion of RIV Arrangement $ 424

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Mar. 31, 2022
Cash And Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	The components of cash and cash equivalents are as follows: March 31, March 31, 2022 2021 Cash $ 470,682 $ 436,588 Cash equivalents 305,323 718,065 $ 776,005 $ 1,154,653

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Mar. 31, 2022
Short Term Investments [Abstract]
Components of Short-term Investments	The components of short-term investments are as follows: March 31, March 31, 2022 2021 Term deposits $ 319,092 $ 463,824 Government securities 22,253 136,620 Asset-backed securities 21,905 16,342 Commercial paper and other 232,401 527,777 $ 595,651 $ 1,144,563

Amounts Receivable, Net (Tables

Amounts Receivable, Net (Tables)	12 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Components of Amounts Receivable, Net	The components of amounts receivable, net are as follows: March 31, March 31, 2022 2021 Accounts receivable, net $ 78,059 $ 67,106 Indirect taxes receivable 7,524 8,281 Interest receivable 4,406 5,140 Other receivables 6,454 11,908 $ 96,443 $ 92,435

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows: March 31, March 31, 2022 2021 Raw materials, packaging supplies and consumables $ 26,821 $ 55,554 Work in progress 65,245 223,652 Finished goods 112,321 88,773 $ 204,387 $ 367,979

Prepaid Expenses and Other As_2

Prepaid Expenses and Other Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Components of Prepaid and Other Assets	The components of prepaid and other assets are as follows: March 31, March 31, 2022 2021 Prepaid expenses $ 23,041 $ 28,349 Deposits 10,145 18,316 Prepaid inventory 449 1,496 Other assets 19,065 19,071 $ 52,700 $ 67,232

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Schedule Of Investments [Abstract]
Summary of Changes in Other Financial Assets	The following tables outline changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 24. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal March 31, Entity Instrument 2021 Additions changes adjustments income of shares 2022 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ (156,000 ) $ - $ - $ - $ 229,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 835 - (795 ) - 10,280 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - (1,528 ) - (4,912 ) - 49,890 Arise Bioscience Term loan / debenture 13,077 - 308 (42 ) - - 13,343 TerrAscend - October 2019 Warrants 17,250 - (13,520 ) - - - 3,730 TerrAscend - March 2020 Warrants 152,910 - (92,170 ) - - - 60,740 TerrAscend - December 2020 Warrants 13,240 - (9,780 ) - - - 3,460 TerrAscend Option 10,600 - (4,300 ) - - - 6,300 Wana Option - 442,227 (74,639 ) 4,755 - - 372,343 Acreage Hempco 1 Debenture 27,448 - 5,337 (94 ) (3,867 ) - 28,824 Other - at fair value through net income (loss) Various 14,887 6,457 (10,652 ) (204 ) - (92 ) 10,396 Other - classified as held for investment Loan receivable 7,185 5,000 - - - (163 ) 12,022 $ 708,167 $ 453,684 $ (356,109 ) $ 4,415 $ (9,574 ) $ (255 ) $ 800,328 1 Exercise of Foreign options / Balance at currency Allowance disposal Derecognition Balance at March 31, Fair value translation for expected of shares / of March 31, Entity Instrument 2020 Additions changes adjustments credit losses repayments RIV Capital 1 2021 TerrAscend Exchangeable Shares Exchangeable shares $ 47,000 $ - $ 338,000 $ - $ - $ - $ - $ 385,000 TerrAscend Canada - October 2019 Term loan / debenture 9,520 8,579 (7,859 ) - - - - 10,240 TerrAscend Canada - March 2020 Term loan / debenture 44,300 - 16,942 - - (4,912 ) - 56,330 Arise Bioscience Term loan / debenture - 11,758 1,489 (170 ) - - - 13,077 TerrAscend - October 2019 Warrants 804 4,315 12,131 - - - - 17,250 TerrAscend - March 2020 Warrants 24,200 - 128,710 - - - - 152,910 TerrAscend - December 2020 Warrants - 13,720 (480 ) - - - - 13,240 TerrAscend Option - 13,445 (2,845 ) - - - - 10,600 Acreage Hempco 2 Debenture - 66,995 (37,026 ) (2,521 ) - - - 27,448 SLANG Warrants 3,500 - 5,900 - - - - 9,400 PharmHouse 3 Loan receivable 40,000 - - - (40,000 ) - - - ZeaKal Shares 14,186 - (1,486 ) - - - (12,700 ) - Agripharm Royalty interest 12,600 - (7,200 ) - - - (5,400 ) - Greenhouse Convertible debenture 10,517 - (4,117 ) - - (1,300 ) (5,100 ) - Other - at fair value through net income (loss) Various 28,478 11,251 (7,052 ) - - (4,234 ) (22,956 ) 5,487 Other - classified as held for investment Loan receivable 14,148 11,106 - - (12,956 ) (5,113 ) - 7,185 $ 249,253 $ 141,169 $ 435,107 $ (2,691 ) $ (52,956 ) $ (15,559 ) $ (46,156 ) $ 708,167 1 2 3

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 The components of property, plant and equipment are as follows: March 31, March 31, 2022 2021 Buildings and greenhouses $ 766,931 $ 651,166 Production and warehouse equipment 159,314 216,925 Leasehold improvements 69,304 106,837 Office and lab equipment 29,879 30,546 Computer equipment 22,293 26,431 Land 18,917 34,747 Right-of-use-assets Buildings and greenhouses 89,228 100,517 Production and warehouse equipment 55 530 Assets in process 19,771 129,428 1,175,692 1,297,127 Less: Accumulated depreciation (232,912 ) (222,590 ) $ 942,780 $ 1,074,537

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Summary of Components of Intangible Assets	The components of intangible assets are as follows: March 31, 2022 March 31, 2021 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 138,170 $ 97,638 $ 212,100 $ 168,655 Distribution channel 72,642 24,834 73,756 35,176 Operating licenses 24,400 22,052 - - Software and domain names 29,822 14,206 27,836 18,149 Brands 5,547 3,680 21,812 8,894 Amortizable intangibles in process 5,476 5,476 1,952 1,952 Total $ 276,057 $ 167,886 $ 337,456 $ 232,826 Indefinite lived intangible assets Acquired brands $ 74,809 $ 67,341 Operating licenses 10,000 8,000 Total intangible assets $ 252,695 $ 308,167
Summary of Estimated Amortization Expense	Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows: 2023 $ 25,318 2024 $ 24,660 2025 $ 21,040 2026 $ 18,472 2027 $ 17,727 Thereafter $ 60,669

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2020 $ 1,954,471 Foreign currency translation adjustments (65,117 ) Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities (58,786 ) Impairment losses (40,748 ) Foreign currency translation adjustments (28,640 ) Balance, March 31, 2022 $ 1,866,503

Other Accrued Expenses and Li_2

Other Accrued Expenses and Liabilities (Tables)	12 Months Ended
	Mar. 31, 2022
Accounts Payable And Accrued Liabilities Current [Abstract]
Components of Other Accrued Expenses and Liabilities	The components of other accrued expenses and liabilities are as follows: March 31, March 31, 2022 2021 Employee compensation $ 24,873 $ 47,237 Inventory 10,096 5,426 Professional fees 7,640 11,544 Taxes and government fees 7,144 13,550 Other 25,525 23,056 $ 75,278 $ 100,813

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of Components of Debt	The components of debt are as follows: March 31, March 31, Maturity Date 2022 2021 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 5,958 5,664 Non-credit risk fair value adjustment 7,140 109,710 Credit risk fair value adjustment (49,140 ) (27,960 ) 563,958 687,414 Convertible debentures September 10, 2025 32,858 - Accretion debentures September 10, 2025 7,720 - Credit facility March 18, 2026 893,647 891,677 Other revolving debt facility, loan, and financings 2,808 3,872 1,500,991 1,582,963 Less: current portion (9,296 ) (9,827 ) Long-term portion $ 1,491,695 $ 1,573,136
Summary of Required Principal Repayments Under Long-term Debt Obligations	As of March 31, 2022, the required principal repayments under long-term debt obligations for each of the five succeeding fiscal years and thereafter are as follows: 2023 $ 865 2024 603,865 2025 6,865 2026 966,470 2027 - Thereafter - $ 1,578,065

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	The components of other liabilities are as follows: As at March 31, 2022 As at March 31, 2021 Current Long-term Total Current Long-term Total Lease liabilities $ 38,035 $ 101,125 $ 139,160 $ 42,061 $ 94,164 $ 136,225 Acquisition consideration and other investment related liabilities 4,020 77,834 81,854 16,577 7,808 24,385 Refund liability 3,437 - 3,437 6,441 - 6,441 Settlement liabilities and other 18,562 11,090 29,652 41,349 5,268 46,617 $ 64,054 $ 190,049 $ 254,103 $ 106,428 $ 107,240 $ 213,668

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Tables)	12 Months Ended
	Mar. 31, 2022
Temporary Equity Disclosure [Abstract]
Summary of Net Change in Redeemable Noncontrolling Interests	The net change in the redeemable noncontrolling interests is as follows: Vert Mirabel BioSteel Total As at March 31, 2019 $ 6,400 $ - $ 6,400 Initial recognition of noncontrolling interest - 18,733 18,733 Income (loss) attributable to noncontrolling interest 8,220 (1,731 ) 6,489 Adjustments to redemption amount 5,630 32,498 38,128 As at March 31, 2020 20,250 49,500 69,750 Net loss attributable to redeemable noncontrolling interest (11,906 ) (6,171 ) (18,077 ) Adjustments to redemption amount 3,156 80,471 83,627 As at March 31, 2021 11,500 123,800 135,300 Net loss attributable to redeemable noncontrolling interest (3,165 ) (13,932 ) (17,097 ) Adjustments to redemption amount (7,335 ) (69,559 ) (76,894 ) Redemption of redeemable noncontrolling interest - (5,109 ) (5,109 ) As at March 31, 2022 $ 1,000 $ 35,200 $ 36,200

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of Issuances of Stock Other	During the year ended March 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 (29,721 ) Other issuances 492,741 8,201 (736 ) Total 10,801,426 $ 298,145 $ (30,457 ) During the year ended March 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Completion of acquisition milestones 2,598,978 $ 46,903 $ (19,059 ) Other issuances 449,729 14,906 (14,894 ) Total 3,048,707 $ 61,809 $ (33,953 ) During the year ended March 31, 2020, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share capital Share based reserve Acquisition of BC Tweed NCI release from escrow 6,940,531 $ 223,036 $ (223,036 ) Completion of acquisition milestones 1,121,605 29,561 (29,687 ) Other issuances 597,936 19,369 (19,511 ) Total 8,660,072 $ 271,966 $ (272,234 )
Summary of Warrants	Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2019 107,848,322 $ 43.80 $ 1,589,925 Tranche A warrant modification - - 1,049,153 Issuance of Tranche B warrants 38,454,444 76.68 - Other issuance of warrants 9,200 32.83 359 Exercise of warrants (12,523 ) 35.55 (486 ) Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,882,927 ) 12.98 (70,513 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants (145,831 ) 32.61 - Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Outstanding Stock Options	The following is a summary of the outstanding stock options as at March 31, 2022: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices March 31, 2022 (years) March 31, 2022 (years) $0.06 - $24.62 3,705,144 4.05 1,312,215 2.12 $24.63 - $33.53 4,036,819 3.25 2,285,789 2.68 $33.54 - $36.80 2,984,264 2.24 2,984,264 2.24 $36.81 - $42.84 2,641,567 2.85 2,488,993 2.65 $42.85 - $67.64 3,415,168 2.88 3,005,487 2.83 16,782,962 3.11 12,076,748 2.54
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	the Company uses the Black-Scholes option pricing model to establish the fair value of options granted during the years ended March 31, 2022, 2021 and 2020 on their measurement date by applying the following assumptions: March 31, March 31, March 31, 2022 2021 2020 Risk-free interest rate 1.09% 0.36% 1.38% Expected life of options (years) 3 - 5 1 - 7 3 - 5 Expected volatility 75% 76% 73% Expected forfeiture rate 18% 17% 12% Expected dividend yield nil nil nil Black-Scholes value of each option $9.69 $15.24 $19.83
Summary of Changes in RSUs	The following is a summary of changes in the Company’s RSUs during the years ended March 31, 2020, 2021 and 2022: Number of RSUs and PSUs Balance outstanding at March 31, 2019 137,228 RSUs granted 875,673 RSUs released (29,892 ) RSUs cancelled and forfeited (100,000 ) Balance outstanding at March 31, 2020 883,009 RSUs granted 142,826 RSUs released (120,399 ) RSUs cancelled and forfeited (152,126 ) Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 3,253,671 RSUs and PSUs released (300,319 ) RSUs and PSUs cancelled and forfeited (229,370 ) Balance outstanding at March 31, 2022 3,477,292
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	The following is a summary of the changes in the Company’s Omnibus Plan employee options during the years ended March 31, 2020, 2021 and 2022: Options issued Weighted average exercise price Balance outstanding at March 31, 2019 32,831,895 $ 34.10 Options granted 9,454,714 33.87 Options exercised (3,900,032 ) 10.63 Options forfeited/cancelled (5,878,182 ) 44.95 Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 478,215 28.15 Options exercised (7,062,317 ) 22.22 Options forfeited (8,219,982 ) 41.27 Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,537,290 17.40 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised (445,680 ) 12.27 Options forfeited (3,153,118 ) 42.03 Balance outstanding at March 31, 2022 16,782,962 $ 33.89

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2019 $ 41,225 $ (47,130 ) $ (5,905 ) Other comprehensive income 85,498 175,260 260,758 Income tax expense - (33,954 ) (33,954 ) As at March 31, 2020 126,723 94,176 220,899 Other comprehensive loss (154,969 ) (100,170 ) (255,139 ) As at March 31, 2021 (28,246 ) (5,994 ) (34,240 ) Disposal of consolidated entities 16,130 - 16,130 Other comprehensive income (loss) (45,352 ) 21,180 (24,172 ) As at March 31, 2022 $ (57,468 ) $ 15,186 $ (42,282 )

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	12 Months Ended
	Mar. 31, 2022
Noncontrolling Interest [Abstract]
Summary of Net Change in Noncontrolling Interests	The net change in the noncontrolling interests is as follows: RIV Capital Vert Mirabel BioSteel Other Total As at March 31, 2019 $ 280,012 $ 2,422 $ - $ 3,051 $ 285,485 Comprehensive (loss) income (77,313 ) 12,930 (1,731 ) - (66,114 ) Net (loss) income loss attributable to redeemable noncontrolling interest - (8,220 ) 1,731 - (6,489 ) Share-based compensation 6,857 - 489 - 7,346 Ownership changes 1,530 - - - 1,530 As at March 31, 2020 211,086 7,132 489 3,051 221,758 Comprehensive income (loss) 94,532 (14,261 ) (6,171 ) - 74,100 Net loss attributable to redeemable noncontrolling interest - 11,906 6,171 - 18,077 Share-based compensation 2,659 - 1,169 - 3,828 Ownership changes (308,527 ) (4,777 ) - - (313,304 ) Warrants 250 - - - 250 As at March 31, 2021 - - 1,658 3,051 4,709 Comprehensive loss - (3,165 ) (13,932 ) (1,207 ) (18,304 ) Net loss attributable to redeemable noncontrolling interest - 3,165 13,932 - 17,097 Share-based compensation - - 839 - 839 Ownership changes - - - - - Warrants - - - - - As at March 31, 2022 $ - $ - $ 2,497 $ 1,844 $ 4,341 1

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Mar. 31, 2022
Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis	The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Convertible senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066 March 31, 2021 Assets: Short-term investments $ 1,144,563 $ - $ - $ 1,144,563 Restricted short-term investments 11,332 - - 11,332 Other financial assets 254 - 700,728 700,982 Liabilities: Convertible senior notes - 687,414 - 687,414 Liability arising from Acreage Arrangement - - 600,000 600,000 Warrant derivative liability - - 615,575 615,575
Level 2
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior notes Convertible note pricing model Quoted prices in over-the-counter broker market
Level 3
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - October 2019, March 2020 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Arise Bioscience term loan, TerrAscend Canada term loan - Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value October 2019, March 2020 Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Call Option Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	Revenue is dissaggregated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Canadian recreational cannabis net revenue Business-to-business 1 $ 143,732 $ 163,585 $ 121,605 Business-to-consumer 61,570 66,016 52,044 205,302 229,601 173,649 Canadian medical cannabis net revenue 2 52,608 55,448 51,647 257,910 285,049 225,296 International and other revenue C 3 36,113 62,335 53,770 Other 43,193 31,296 15,869 79,306 93,631 69,639 Global cannabis net revenue 337,216 378,680 294,935 Other consumer products Storz & Bickel 85,410 80,998 48,329 This Works 32,296 33,314 24,725 BioSteel 44,626 28,530 4,589 Other 20,777 25,127 26,194 Other consumer products revenue 183,109 167,969 103,837 Net revenue $ 520,325 $ 546,649 $ 398,772 1 - $54,928, and year ended March 31, 2020 - $35,649). 2

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	12 Months Ended
	Mar. 31, 2022
Other Income And Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net is dissaggregated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Fair value changes on other financial assets (356,109 ) $ 435,107 $ (243,965 ) Fair value changes on liability arising from Acreage Arrangement 553,000 (399,849 ) (645,190 ) Fair value changes on convertible senior notes 76,776 (162,540 ) 184,740 Fair value changes on warrant derivative liability 588,655 (293,084 ) 795,149 Fair value changes on acquisition related contingent consideration and other 4,417 39,608 12,293 Interest income 6,601 21,367 66,327 Interest expense (103,944 ) (8,459 ) (6,716 ) Foreign currency gain (loss) 5,415 (18,013 ) (1,245 ) (Loss) gain on disposal/acquisition of consolidated entity (6,762 ) 634 61,775 Other income (expense), net (14,708 ) (2,647 ) 1,161 $ 753,341 $ (387,876 ) $ 224,329

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Summary of Net Loss Before Income Taxes	Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Domestic - Canada $ (163,888 ) $ (1,611,210 ) $ (1,167,000 ) Foreign - outside of Canada (165,545 ) (72,751 ) (342,054 ) $ (329,433 ) $ (1,683,961 ) $ (1,509,054 )
Summary of Income Tax Recovery	The income tax recovery consists of the following: Years ended March 31, March 31, March 31, 2022 2021 2020 Current Domestic - Canada $ 895 $ (19,318 ) $ (12,342 ) Foreign - outside of Canada 1,476 (2,091 ) (4,356 ) $ 2,371 $ (21,409 ) $ (16,698 ) Deferred Domestic - Canada $ 6,353 $ 36,505 $ 78,624 Foreign - outside of Canada 224 (1,955 ) 59,688 6,577 34,550 138,312 Income tax recovery $ 8,948 $ 13,141 $ 121,614
Summary of Reconciliation of Amount of Income Taxes Compared to Expected Income Taxes Calculated at Combined Federal and Provincial Enacted Statutory Tax Rate	A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5% for each of the three years ended March 31, 2022, 2021 and 2020 is as follows: Years ended March 31, March 31, March 31, 2022 2021 2020 Net loss before income taxes $ (329,433 ) $ (1,683,961 ) $ (1,509,054 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 87,300 446,250 399,899 Non-deductible and non-taxable items 17,557 81,883 22,947 Fair value changes on Acreage Arrangement 146,545 (105,960 ) (170,975 ) Fair value changes on warrant derivative liability 155,964 (77,663 ) 210,715 Share-based compensation (9,908 ) (21,121 ) (84,873 ) Change in valuation allowance (361,283 ) (358,964 ) (215,975 ) Effect of tax rates outside of Canada 8,459 10,870 (3,248 ) Non-taxable portion of capital gains and losses (38,440 ) 38,705 (34,961 ) Other 2,754 (859 ) (1,915 ) Income tax recovery $ 8,948 $ 13,141 $ 121,614
Summary of Significant Compenents of Deferred Income Tax Assets (Liabilities)	Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2022 2021 Deferred income tax assets Property, plant and equipment $ 78,023 $ 74,603 Intangible assets 671 5,063 Inventory reserves and write-downs 40,324 39,893 Other reserves and accruals 5,939 7,957 Losses carried forward 917,283 608,002 Equity method investments and other financial assets 10,512 14,900 Deferred financing costs 2,740 3,587 Other 5,635 6,226 Gross deferred income tax assets 1,061,127 760,231 Valuation allowances (1,039,130 ) (677,847 ) Total deferred income tax assets, net $ 21,997 $ 82,384 Deferred income tax liabilities Property, plant and equipment $ (4,182 ) $ (25,864 ) Intangible assets (29,832 ) (43,449 ) Equity method investments and other financial assets - (31,176 ) Deferred financing costs (3,353 ) (2,785 ) Other (621 ) (489 ) Total deferred income tax liabilities (37,988 ) (103,763 ) Net deferred income tax assets (liabilities) $ (15,991 ) $ (21,379 )
Summary of Losses Carried Forward Available to Reduce Future Years' Taxable Income	As at March 31, 2022 the Company has the following losses carried forward available to reduce future years' taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 1,031 Expiring between 10 and 15 years 156,420 Expiring between 15 and 20 years 2,394,542 Indefinite 377,120 $ 2,929,113 Total in Canada $ 2,547,844 Total in United States 278,458 Total in Europe 55,440 Total in other jurisdictions 47,371 $ 2,929,113 Total operating losses $ 2,929,113 Total capital losses (carried forward indefinitely) 892,360 $ 3,821,473

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Mar. 31, 2022
Business Acquisition [Line Items]
Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations	The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities (1,724 ) (12,935 ) (30 ) (14,689 ) Debt and other liabilities - (88,324 ) (1,037 ) (89,361 ) Deferred income tax liabilities (1,899 ) (5,545 ) (540 ) (7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired (1,544 ) (41,306 ) (1,227 ) (44,077 ) Net cash outflow (inflow) $ 50,292 $ (41,222 ) $ 5,877 $ 14,947 There were no acquisitions during the year ended March 31, 2021. The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2020: Spectrum Storz & C 3 This Works BioSteel BCT UK Bickel (i) (ii) (iii) (iv) (iv) 30(c)(v) Total Cash and cash equivalents $ 2,818 $ 1,619 $ 225 $ 7,886 $ - $ - $ 12,548 Other current assets 15,140 8,239 12,972 2,296 67 - 38,714 Property, plant and equipment 8,345 478 391 5 895 - 10,114 Intangible assets Brands 10,613 22,114 3,600 - - - 36,327 Distribution channel 4,058 12,988 14,700 - - - 31,746 Operating licenses - - - - 1,158 - 1,158 Intellectual property 36,520 16,848 20,900 5,267 - 24,990 104,525 Software and domain names 8 176 541 - - - 725 Goodwill 287,010 22,214 35,939 85,700 12,861 (24,990 ) 418,734 Accounts payable and other accrued expenses and liabilities (3,652 ) (4,100 ) (3,852 ) (2,176 ) (922 ) - (14,702 ) Debt and other liabilities (3,942 ) - (3,659 ) - - - (7,601 ) Deferred income tax liabilities (11,219 ) (7,911 ) (3,817 ) (838 ) (36 ) - (23,821 ) Net assets $ 345,699 $ 72,665 $ 77,940 $ 98,140 $ 14,023 $ - $ 608,467 Noncontrolling interests - - (18,733 ) - - - (18,733 ) Net assets acquired $ 345,699 $ 72,665 $ 59,207 $ 98,140 $ 14,023 $ - $ 589,734 Consideration paid in cash $ 345,699 $ 72,665 $ 47,924 $ 45,098 $ - $ - $ 511,386 Fair value of previously held equity interest - - - 37,919 14,023 - 51,942 Replacement options - - - 1,885 - - 1,885 Other consideration - - 11,283 13,238 - - 24,521 Total consideration $ 345,699 $ 72,665 $ 59,207 $ 98,140 $ 14,023 $ - $ 589,734 Consideration paid in cash $ 345,699 $ 72,665 $ 47,924 $ 45,098 $ - $ - $ 511,386 Less: Cash and cash equivalents acquired (2,818 ) (1,619 ) (225 ) (7,886 ) - - (12,548 ) Net cash outflow $ 342,881 $ 71,046 $ 47,699 $ 37,212 $ - $ - $ 498,838
Summary of Derecognized Assets and Liabilities	Following this transaction, the Company no longer controlled 1955625 Ontario Inc. and the Company derecognized the assets and liabilities of 1955625 Ontario Inc. from its consolidated financial statements at their carrying amounts. Management has concluded that the subsidiary does not meet the definition of an operation and no goodwill was allocated. The derecognized assets and liabilities on November 7, 2019, were as follows: Current assets $ 100 Intangible assets 2,810 Net assets disposed $ 2,910 Fair value of retained interest 25,200 Gain on disposal of consolidated entity $ 22,290
C3
Business Acquisition [Line Items]
Summary of Measurement Period Adjustments	In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Distribution channel $ 4,058 10 Income approach Intellectual property 36,520 10 Relief-from-royalty Licensed brands 10,613 2 Relief-from-royalty Other adjustments Inventory step-up 1,814 Deferred income tax liabilities (11,219 ) Net impact to goodwill $ (41,786 )
This Works
Business Acquisition [Line Items]
Summary of Measurement Period Adjustments	In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Acquired brands $ 19,130 Indefinite Relief-from-royalty Distribution channel 12,988 10 Income approach using a multi-period excess earnings method Intellectual property 16,848 10 Replacement cost Licensed brands 2,984 5 Income approach using a multi-period excess earnings method Other adjustments Inventory step-up 1,755 Deferred income tax liabilities (7,911 ) Net Impact to Goodwill $ (45,794 )
BioSteel
Business Acquisition [Line Items]
Summary of Measurement Period Adjustments	In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Acquired brands $ 3,600 Indefinite Relief-from-royalty Distribution channel 14,700 11 Income approach using a multi-period excess earnings method Intellectual property 20,900 11 Relief-from-royalty, net of product migration Other adjustments Inventory step-up 2,710 Deferred income tax liabilities (3,817 ) Net impact to goodwill $ (38,093 )
BCT and Spectrum UK
Business Acquisition [Line Items]
Summary of Measurement Period Adjustments	In the year ended March 31, 2020, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The measurement period adjustments include: Useful life Measurement period impact Adjustments (years) Valuation methodology Acquisition related intangible assets Intellectual property $ 5,267 1 Replacement cost Operating license 1,158 1 Replacement cost Other adjustments Deferred income tax liabilities (874 ) Net impact to goodwill $ (5,551 )

C3 Divestiture (Tables)

C3 Divestiture (Tables)	12 Months Ended
	Mar. 31, 2022
Discontinued Operations And Disposal Groups [Abstract]
Summary of Derecognized Assets and Liabilities Transferred	Current assets 1 $ 44,568 Property, plant and equipment 9,216 Intangible assets 15,548 Goodwill 53,541 Current liabilities (3,089 ) Deferred income tax liabilities (6,029 ) Cumulative translation adjustment 19,178 Net assets disposed $ 132,933 Consideration received in cash $ 128,316 Future cash consideration 7,233 Costs to sell (1,153 ) Total consideration $ 134,396 Gain on disposal of consolidated entity $ 1,463 1

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Summary of Lease Right-of-use Assets and Liabilities	A summary of lease right-of-use assets and liabilities are as follows: March 31, March 31, 2022 2021 Property, plant and equipment Operating lease $ 39,571 $ 47,522 Finance lease 34,333 39,427 $ 73,904 $ 86,949 Other current liabilities: Operating lease $ 11,752 $ 11,491 Finance lease 26,283 30,570 Other long-term liabilities: Operating lease 58,031 62,285 Finance lease 43,094 31,879 $ 139,160 $ 136,225
Summary of Components of Total Lease Expense	The components of total lease expense are as follows: Years ended March 31, March 31, 2022 2021 Operating lease expense $ 5,245 $ 10,846 Finance lease expense: Amortization of right-of-use assets 3,883 2,303 Interest on lease liabilities 1,667 1,674 $ 10,795 $ 14,823
Summary of Minimum Payments Due for Lease Liabilities	As of March 31, 2022, the minimum payments due for lease liabilities for each of the five succeeding fiscal years and thereafter are as follows: Operating Leases Finance Leases 2023 $ 12,004 $ 8,023 2024 11,402 8,116 2025 10,923 8,200 2026 9,892 38,476 2027 9,525 3,388 Thereafter 17,761 6,262 Total lease payments $ 71,507 $ 72,465 Less: Interest 1,724 3,088 Total lease liabilities $ 69,783 $ 69,377
Summary of Supplemental Information of Leases	Supplemental information Years ended March 31, March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,905 $ 18,792 Operating cash flows from finance leases 1,667 1,674 Financing cash flows from finance leases 1,494 2,303 Right-of-use assets obtained in exchange for new lease liabilities: Operating leases $ 9,019 $ 13,592 Finance leases 3,720 1,428 March 31, March 31, 2022 2021 Weighted-average remaining lease term: Operating leases 6 7 Finance leases 4 4 Weighted-average discount rate Operating leases 4.50 % 4.50 % Finance leases 4.50 % 4.50 %

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Summary of Annual Minimum Commitments Associated with Contractual Agreements	The Company has entered into agreements in which it has committed to purchase a minimum amount of inventory, pay a minimum amount of royalty expenses, incur expenditures for property, plant and equipment and procure various other goods or services. The following summarizes the Company’s annual minimum commitments associated with its contractual agreements as of March 31, 2022. This amount excludes the Company’s debt and lease related commitments which are disclosed elsewhere in Notes 17 and 32, respectively in these consolidated financial statements. 2023 $ 130,453 2024 72,653 2025 33,641 2026 24,347 2027 16,936 Thereafter 57,773 $ 335,803

Segmented Information (Tables)

Segmented Information (Tables)	12 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Years ended March 31, March 31, March 31, 2022 2021 2020 Segmented net revenue Global cannabis $ 337,216 $ 378,680 $ 294,935 Other consumer products 183,109 167,969 103,837 $ 520,325 $ 546,649 $ 398,772 Segmented gross margin: Global cannabis $ (251,235 ) $ 7,045 $ (76,836 ) Other consumer products 58,181 59,915 45,152 (193,054 ) 66,960 (31,684 ) Selling, general and administrative expenses 472,756 575,389 693,737 Share-based compensation 47,525 91,149 320,276 Expected credit losses on financial assets and relates charges - 109,480 - Asset impairment and restructuring costs 369,339 534,398 623,266 Operating loss (1,082,674 ) (1,243,456 ) (1,668,963 ) Loss from equity method investments (100 ) (52,629 ) (64,420 ) Other income (expense), net 753,341 (387,876 ) 224,329 Loss before incomes taxes $ (329,433 ) $ (1,683,961 ) $ (1,509,054 )
Summary of Disaggregation of Net Revenue by Geographic Area	Disaggregation of net revenue by geographic area: Years ended March 31, March 31, March 31, 2022 2021 2020 Canada $ 296,369 $ 329,172 $ 256,166 Germany 90,874 116,379 93,945 United States 82,080 64,926 24,568 Other 51,002 36,172 24,093 $ 520,325 $ 546,649 $ 398,772
Summary of Disaggregation of Long-lived Assets by Geographic Areas	Disaggregation of long-lived tangible assets by geographic area: March 31, March 31, 2022 2021 Canada $ 827,591 $ 847,678 United States 63,247 143,747 Other 51,942 83,112 $ 942,780 $ 1,074,537

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Expected Useful Life of Property, Plant and Equipment (Details)	12 Months Ended
	Mar. 31, 2022
Buildings and Greenhouses | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	20 years
Buildings and Greenhouses | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	50 years
Leasehold Improvements | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Leasehold Improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	20 years
Production and Warehouse Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	5 years
Production and Warehouse Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	30 years
Computer Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Computer Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	10 years
Office and Lab Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Office and Lab Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	10 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Finite Lived Intangible Assets Useful Life (Details)	12 Months Ended
	Mar. 31, 2022
Distribution Channel | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Distribution Channel | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	11 years
Operating Licenses
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	8 years
Intellectual Property | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Intellectual Property | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	15 years
Brands | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	2 years
Brands | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Software and Domain Names | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	3 years
Software and Domain Names | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021UnitSegment	Mar. 31, 2022CAD ($)	Mar. 31, 2021CAD ($)Segment	Mar. 31, 2020CAD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment	2		2
Advertising expenses		$ 104,221	$ 72,377	$ 78,474
Research and development expenses		$ 32,344	$ 57,582	$ 61,812
Cannabis, Hemp and Other Consumer Products
Summary Of Significant Accounting Policies [Line Items]
Number of reporting units | Unit	1

Asset Impairment and Restruct_3

Asset Impairment and Restructuring Costs - Additional Information (Details) $ in Thousands	Mar. 01, 2021CAD ($)	Mar. 31, 2022CAD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2020CAD ($)	Mar. 31, 2022CAD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2020CAD ($)
Restructuring Cost And Reserve [Line Items]
Inventory write-downs					$ 237,147	$ 79,859
Aggregate pre-tax charges					$ 429,810	564,049	$ 742,929
Number of full time positions eliminated					250		600
Goodwill impairment loss		$ 40,748			$ 40,748
Total restructuring, asset impairment and related costs					496,623	570,683	$ 843,275
Share-based compensation					47,525	91,149	320,276
Additional amounts of deemed excess				$ 76,199
Canadian And International Production Facilities
Restructuring Cost And Reserve [Line Items]
Inventory write-downs						25,985
Third Party
Restructuring Cost And Reserve [Line Items]
Derecognized royalty obligations			$ 18,810
More Life
Restructuring Cost And Reserve [Line Items]
Impairment of equity method investments			$ 10,300			10,300	14,900
Derecognized royalty obligations	$ 33,681
Aldergrove and Delta
Restructuring Cost And Reserve [Line Items]
Proceeds from sale of assets						40,650
Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					224,726	426,748	334,964
This Work
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss		18,393
KeyLeaf
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss		$ 22,355
Asset Impairment and Restructuring Costs | Brand and License
Restructuring Cost And Reserve [Line Items]
Brand and license impairment charges						6,634	60,020
Asset Impairment and Restructuring Costs | KeyLeaf | Brand and License
Restructuring Cost And Reserve [Line Items]
Brand and license impairment charges					26,065
Costs Recorded in Operating Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					302,526	527,764	563,246
Impairment losses					266,130	481,259	527,951
Share-based compensation					3,615		32,694
Costs Recorded in Operating Expenses | Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					224,726	426,748	334,964
Impairment losses					224,726	426,748	334,964
Costs Recorded in Operating Expenses | Brand, Intellectual Property and License Intangible Assets
Restructuring Cost And Reserve [Line Items]
Impairment losses					41,404	54,511	192,987
Costs Recorded in Operating Expenses | Contractual And Other Settlement Obligations
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					6,610	22,352	18,712
Costs Recorded in Operating Expenses | Employee-related and Other Restructuring Costs
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					29,786	24,153	16,583
Other Income (Expense) | Other Financial Assets and Equity Method Investments
Restructuring Cost And Reserve [Line Items]
Impairment of equity method investments							40,326
Costs Recorded in Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Inventory write-downs				$ 55,890	123,669	25,985	132,089
Restructuring and other charges					$ 123,669	$ 25,985	$ 132,089

Asset Impairment and Restruct_4

Asset Impairment and Restructuring Costs - Summary of Pre-tax Charges Recognized in Restructuring Actions and Other Impairments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Restructuring Cost And Reserve [Line Items]
Share-based compensation	$ 47,525	$ 91,149	$ 320,276
Restructuring and share-based compensation	429,810	564,049	742,929
Asset impairment and restructuring costs	332,949	519,209	571,719
Other impairments	66,813	6,634	100,346
Total asset impairment and restructuring costs	369,339	534,398	623,266
Total restructuring, asset impairment and related costs	496,623	570,683	843,275
Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	224,726	426,748	334,964
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	41,404	54,511	192,987
Asset impairment and restructuring costs	26,065	6,634	54,020
Costs Recorded in Operating Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	302,526	527,764	563,246
Share-based compensation	3,615		32,694
Asset impairment and restructuring costs	66,813	6,634	60,020
Total asset impairment and restructuring costs	369,339	534,398	623,266
Costs Recorded in Operating Expenses | Spectrum Columbia and Canindica Acquisitions
Restructuring Cost And Reserve [Line Items]
Acceleration of share-based compensation expense related to acquisition milestones			32,694
Costs Recorded in Operating Expenses | Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	224,726	426,748	334,964
Total asset impairment and restructuring costs	224,726	426,748	334,964
Costs Recorded in Operating Expenses | Intangible Assets
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	41,404	54,511	192,987
Asset impairment and restructuring costs	26,065	6,634	54,020
Total asset impairment and restructuring costs	67,469	61,145	247,007
Costs Recorded in Operating Expenses | Goodwill
Restructuring Cost And Reserve [Line Items]
Asset impairment and restructuring costs	40,748
Total asset impairment and restructuring costs	40,748
Costs Recorded in Operating Expenses | Contractual And Other Settlement Obligations
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	6,610	22,352	18,712
Asset impairment and restructuring costs			6,000
Total asset impairment and restructuring costs	6,610	22,352	24,712
Costs Recorded in Operating Expenses | Employee-related and Other Restructuring Costs
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	29,786	24,153	16,583
Total asset impairment and restructuring costs	29,786	24,153	16,583
Costs Recorded in Operating Expenses | Spectrum Columbia and Canindica Acquisitions
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	3,615
Total asset impairment and restructuring costs	3,615
Costs Recorded in Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	123,669	25,985	132,089
Total asset impairment and restructuring costs	$ 123,669	25,985	132,089
Costs Recorded in Loss from Equity Method Investments
Restructuring Cost And Reserve [Line Items]
Impairment of equity method investments restructuring		10,300	14,900
Impairment of equity method investments			40,326
Impairment of equity method investments cost		$ 10,300	$ 55,226

Plan Of Arrangement With Riv _3

Plan Of Arrangement With Riv Capital - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands	Dec. 21, 2020$ / sharesshares	Mar. 31, 2022CAD ($)$ / sharesshares	Mar. 31, 2022USD ($)shares	Mar. 31, 2021CAD ($)shares
Class Of Stock [Line Items]
Common stock, shares issued		394,422,604	394,422,604	382,875,179
Cash payment | $		$ 470,682		$ 436,588
Tweed N B
Class Of Stock [Line Items]
Ownership percentage		15.00%	15.00%
Canopy Rivers
Class Of Stock [Line Items]
Common stock, shares issued		3,647,902	3,647,902
Cash payment | $			$ 115,000
Canopy Rivers | Multiple Voting Shares
Class Of Stock [Line Items]
Exchangeable shares in the capital		36,468,318	36,468,318
Canopy Rivers | Subordinated Voting Shares
Class Of Stock [Line Items]
Exchangeable shares in the capital		15,223,938	15,223,938
RIV Arrangement
Class Of Stock [Line Items]
Exchangeable shares in the capital		19,445,285	19,445,285
Common share purchase warrants in the capital	333,723	2,225,714
Warrant price per share | $ / shares	$ 5.95	$ 6.49
RIV Arrangement | Tweed N B
Class Of Stock [Line Items]
Exchangeable shares in the capital		38,890,570	38,890,570
Common share purchase warrants in the capital		22,474,130
Acquired shares of common stock		1,072,450	1,072,450
Maximum | RIV Arrangement
Class Of Stock [Line Items]
Percentage of ownership increase in common shares outstanding		55.00%

Plan Of Arrangement With Riv _4

Plan Of Arrangement With Riv Capital - Schedule of Derecognized Assets and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2021	Feb. 23, 2021	Mar. 31, 2020	Mar. 31, 2019
Class Of Stock [Line Items]
Warrant value	$ 2,581,788		$ 2,568,438		$ 2,638,951	$ 1,589,925
Preferred shares in Vert Mirabel				$ 22,600
Common shares in Vert Mirabel				9,075
Total acquired assets				380,175
Consideration paid in shares				170,284
Consideration paid in cash				115,000
Total Assets and Liabilities				94,891
Cash and cash equivalents		$ 19,338		37,801
Amounts receivable, net				4,327
Prepaid expenses and other assets				995
Equity method investments				5,114
Other financial assets				417,256
Property, plant and equipment				729
Intangible assets				86
Accounts payable				(22,038)
Other accrued expenses and liabilities				(1,703)
Other current liabilities				(32,653)
Other long-term liabilities				(303)
Noncontrolling interests and other				(315,144)
Disposal Group, Including Discontinued Operation, Liabilities				94,467
Gain on completion of RIV Arrangement				424
TerrAscend
Class Of Stock [Line Items]
TerrAscend Exchangeable Shares				291,500
Warrant value				32,000
TerrAscend loan				10,000
Tweed N B
Class Of Stock [Line Items]
Settlement of Tweed NB obligations to RCC				$ 15,000

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Cash	$ 470,682	$ 436,588
Cash equivalents	305,323	718,065
Cash and cash equivalents	$ 776,005	$ 1,154,653

Short-term Investments - Compon

Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Marketable Securities [Line Items]
Short-term investments	$ 595,651	$ 1,144,563
Term Deposits
Marketable Securities [Line Items]
Short-term investments	319,092	463,824
Government securities
Marketable Securities [Line Items]
Short-term investments	22,253	136,620
Asset-backed securities
Marketable Securities [Line Items]
Short-term investments	21,905	16,342
Commercial paper and other
Marketable Securities [Line Items]
Short-term investments	$ 232,401	$ 527,777

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Short Term Investments [Abstract]
Amortized cost of short-term investments	$ 599,862	$ 1,145,364

Amounts Receivable, Net - Compo

Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Receivables [Abstract]
Accounts receivable, net	$ 78,059	$ 67,106
Indirect taxes receivable	7,524	8,281
Interest receivable	4,406	5,140
Other receivables	6,454	11,908
Amounts receivable, net	$ 96,443	$ 92,435

Amounts Receivable, Net - Addit

Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Receivables [Abstract]
Allowance for doubtful accounts	$ 4,764	$ 1,411

Inventory - Components of Inven

Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Inventory Disclosure [Abstract]
Raw materials, packaging supplies and consumables	$ 26,821	$ 55,554
Work in progress	65,245	223,652
Finished goods	112,321	88,773
Inventory	$ 204,387	$ 367,979

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Inventory [Line Items]
Inventory write-downs	$ 237,147	$ 79,859
Inventory write-downs
Inventory [Line Items]
Charges associated with strategic review	$ 116,770	$ 25,985

Prepaid Expenses and Other As_3

Prepaid Expenses and Other Assets - Components of Prepaid and Other Assets (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 23,041	$ 28,349
Deposits	10,145	18,316
Prepaid inventory	449	1,496
Other assets	19,065	19,071
Prepaid and other assets	$ 52,700	$ 67,232

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule Of Investments [Line Items]
Beginning balance	$ 708,167	$ 249,253
Additions	453,684	141,169
Fair value changes	(356,109)	435,107
Foreign currency translation adjustments	4,415	(2,691)
Interest income	(9,574)
Allowance for expected credit losses		(52,956)
Exercise of options / disposal of shares	(255)	(15,559)
Derecognition of RIV Capital		(46,156)
Ending balance	800,328	708,167
TerrAscend Exchangeable Shares | Exchangeable Shares
Schedule Of Investments [Line Items]
Beginning balance	385,000	47,000
Fair value changes	(156,000)	338,000
Ending balance	229,000	385,000
TerrAscend Canada - October 2019 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	10,240	9,520
Additions		8,579
Fair value changes	835	(7,859)
Interest income	(795)
Ending balance	10,280	10,240
TerrAscend Canada March 2020 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	56,330	44,300
Fair value changes	(1,528)	16,942
Interest income	(4,912)
Exercise of options / disposal of shares		(4,912)
Ending balance	49,890	56,330
Arise Bioscience | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	13,077
Additions		11,758
Fair value changes	308	1,489
Foreign currency translation adjustments	(42)	(170)
Ending balance	13,343	13,077
TerrAscend - October 2019 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	17,250	804
Additions		4,315
Fair value changes	(13,520)	12,131
Ending balance	3,730	17,250
TerrAscend - March 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	152,910	24,200
Fair value changes	(92,170)	128,710
Ending balance	60,740	152,910
TerrAscend - December 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	13,240
Additions		13,720
Fair value changes	(9,780)	(480)
Ending balance	3,460	13,240
TerrAscend | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	10,600
Additions		13,445
Fair value changes	(4,300)	(2,845)
Ending balance	6,300	10,600
Wana | Equity Option
Schedule Of Investments [Line Items]
Additions	442,227
Fair value changes	(74,639)
Foreign currency translation adjustments	4,755
Ending balance	372,343
Acreage Hempco2 | Debenture
Schedule Of Investments [Line Items]
Beginning balance	27,448
Additions		66,995
Fair value changes	5,337	(37,026)
Foreign currency translation adjustments	(94)	(2,521)
Interest income	(3,867)
Ending balance	28,824	27,448
Other At Fair Value Through Net Income (Loss) | Various
Schedule Of Investments [Line Items]
Beginning balance	14,887
Additions	6,457
Fair value changes	(10,652)
Foreign currency translation adjustments	(204)
Exercise of options / disposal of shares	(92)
Ending balance	10,396	14,887
Other - Classified as Held for Investment | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	7,185	14,148
Additions	5,000	11,106
Allowance for expected credit losses		(12,956)
Exercise of options / disposal of shares	(163)	(5,113)
Ending balance	12,022	7,185
SLANG | Warrants
Schedule Of Investments [Line Items]
Beginning balance	9,400	3,500
Fair value changes		5,900
Ending balance		9,400
Pharm House | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance		40,000
Allowance for expected credit losses		(40,000)
Zea Kal Inc | Shares
Schedule Of Investments [Line Items]
Beginning balance		14,186
Fair value changes		(1,486)
Derecognition of RIV Capital		(12,700)
Agripharm | Royalty Interest
Schedule Of Investments [Line Items]
Beginning balance		12,600
Fair value changes		(7,200)
Derecognition of RIV Capital		(5,400)
Greenhouse | Convertible Debenture
Schedule Of Investments [Line Items]
Beginning balance		10,517
Fair value changes		(4,117)
Exercise of options / disposal of shares		(1,300)
Derecognition of RIV Capital		(5,100)
Other At Fair Value Through Net Income (Loss) | Various
Schedule Of Investments [Line Items]
Beginning balance	$ 5,487	28,478
Additions		11,251
Fair value changes		(7,052)
Exercise of options / disposal of shares		(4,234)
Derecognition of RIV Capital		(22,956)
Ending balance		$ 5,487

Other Financial Assets -Additio

Other Financial Assets -Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands	Oct. 14, 2021CAD ($)Number	Dec. 10, 2020CAD ($)$ / sharesshares	Mar. 11, 2020CAD ($)Tranche$ / sharesshares	Mar. 31, 2022CAD ($)	Mar. 31, 2021CAD ($)	Oct. 14, 2021USD ($)Number	Jan. 13, 2021CAD ($)shares	Jan. 13, 2021USD ($)shares	Dec. 10, 2020USD ($)	Oct. 02, 2019CAD ($)	Oct. 02, 2019USD ($)
Schedule Of Investments [Line Items]
Investment in the exchangeable shares fair value				$ 229,000	$ 385,000
Deferred Payment1
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised	25.00%
Estimate Fair Value Anniversary Year	2 years 6 months
Deferred Payment2
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised	25.00%
Estimate Fair Value Anniversary Year	5 years
Wana
Schedule Of Investments [Line Items]
Outstanding Membership Interests	100.00%					100.00%
Number of option agreements | Number	3					3
Ownership percentage	100.00%					100.00%
Proceeds from Warrant Exercises	$ 368,067
Percentage of Fair Value at the time of Option Exercised	15.00%
Debt Instrument, Fair Value Disclosure	$ 442,227			$ 372,343
Estimated Deferred Payments	$ 74,160
Percentage Of Outstanding Membership Interest Acquired	100.00%
Wana | Deferred Payment1
Schedule Of Investments [Line Items]
Upfront payment anniversary years	2 years 6 months
Wana | Deferred Payment2
Schedule Of Investments [Line Items]
Upfront payment anniversary years	5 years
Wana | U S D
Schedule Of Investments [Line Items]
Proceeds from Warrant Exercises						$ 297,500
TerrAscend Canada
Schedule Of Investments [Line Items]
Loans, warrants and options			$ 80,526
Number of tranches of warrants issued | Tranche			2
Investment transaction costs			$ 100
TerrAscend Canada | First Tranche
Schedule Of Investments [Line Items]
Warrants exercisable | shares			15,656,242
Warrant exercisable price per share | $ / shares			$ 5.41
Warrants exercisable description				They are exercisable upon the occurrence or waiver of TerrAscend the Triggering Event until the earliest of (i) March 10, 2030 and (ii) the later of (A) March 10, 2025 and (B) the date that is 24 months following the occurrence of the TerrAscend Triggering Event.
TerrAscend Canada | Second Tranche
Schedule Of Investments [Line Items]
Warrants exercisable | shares			2,152,733
Warrant exercisable price per share | $ / shares			$ 3.74
Warrants exercisable description				They are exercisable upon the occurrence or waiver of the TerrAscend Triggering Event until the earliest of (i) March 10, 2031 and (ii) the later of (A) March 10, 2026 and (B) the date that is 36 months following the occurrence of the TerrAscend Triggering Event.
TerrAscend Canada | Warrants
Schedule Of Investments [Line Items]
Loans, warrants and options			$ 25,626	$ 60,740	152,910
Number of additional shares invested | shares			17,808,975
TerrAscend Canada | Term Loan
Schedule Of Investments [Line Items]
Loans, warrants and options			$ 54,800	$ 49,890	56,330
TerrAscend Canada | Secured Debenture
Schedule Of Investments [Line Items]
Loans, warrants and options			$ 80,526
Debt instrument, maturity date, description				matures the earliest of (i) March 10, 2030 and (ii) the later of March 10, 2025 and the date that is 24 months following the date that is the TerrAscend Triggering Event.
Annual interest rate			6.10%
Debt instrument, frequency of periodic payment				annually
TerrAscend Canada | RIV Capital
Schedule Of Investments [Line Items]
Loans, warrants and options										$ 13,243	$ 10,000
TerrAscend Canada | RIV Capital | TerrAscend Warrants
Schedule Of Investments [Line Items]
Loans, warrants and options				$ 3,730	17,250					2,390
TerrAscend Canada | RIV Capital | Term Loan
Schedule Of Investments [Line Items]
Loans, warrants and options				10,280	10,240					$ 10,853
Arise Bioscience | First Tranche
Schedule Of Investments [Line Items]
Warrants exercisable | shares		1,926,983
Warrant exercisable price per share | $ / shares		$ 15.28
Warrants exercisable expiration date		Dec. 10, 2030
Arise Bioscience | Second Tranche
Schedule Of Investments [Line Items]
Warrants exercisable | shares		178,735
Warrant exercisable price per share | $ / shares		$ 17.19
Warrants exercisable expiration date		Dec. 10, 2031
Arise Bioscience | TerrAscend Warrants
Schedule Of Investments [Line Items]
Loans, warrants and options		$ 13,720		3,460	13,240
Number of additional shares invested | shares		2,105,718
Arise Bioscience | Secured Debenture
Schedule Of Investments [Line Items]
Loans, warrants and options		$ 11,758		13,343	13,077
Arise Bioscience | Secured Debenture | Loans
Schedule Of Investments [Line Items]
Loans, warrants and options		$ 25,478							$ 20,000
Annual interest rate		6.10%							6.10%
Debenture maturity date		Dec. 10, 2030
TerrAscend Option | Equity Option
Schedule Of Investments [Line Items]
Loans, warrants and options							$ 13,445	$ 10,529
Business acquisition additional number of shares issuable | shares							1,072,450	1,072,450
Investment in subsidiary				$ 6,300	$ 10,600

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,175,692	$ 1,297,127
Less: Accumulated depreciation	(232,912)	(222,590)
Property, plant and equipment, net	942,780	1,074,537
Buildings and Greenhouses
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	766,931	651,166
Buildings and Greenhouses | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	89,228	100,517
Production and Warehouse Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	159,314	216,925
Production and Warehouse Equipment | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	55	530
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	69,304	106,837
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	18,917	34,747
Office and Lab Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	29,879	30,546
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	22,293	26,431
Assets in Process
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 19,771	$ 129,428

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 76,247	$ 70,914	$ 73,716
Property, Plant and Equipment
Property Plant And Equipment [Line Items]
Charges associated with strategic review	224,726	426,748	334,964
Costs Recorded in Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	50,200	51,737	52,249
Charges associated with strategic review	123,669	25,985	132,089
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 26,047	$ 19,177	$ 21,467

Intangible Assets - Summary of

Intangible Assets - Summary of Components of Intangible Assets (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	$ 276,057	$ 337,456
Net Carrying Amount	167,886	232,826
Total intangible assets	252,695	308,167
Intellectual Property
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	138,170	212,100
Net Carrying Amount	97,638	168,655
Distribution Channel
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	72,642	73,756
Net Carrying Amount	24,834	35,176
Software and Domain Names
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	29,822	27,836
Net Carrying Amount	14,206	18,149
Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	24,400	0
Net Carrying Amount	22,052	0
Indefinite lived intangible assets	10,000	8,000
Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	5,547	21,812
Net Carrying Amount	3,680	8,894
Amortizable Intangibles in Process
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	5,476	1,952
Net Carrying Amount	5,476	1,952
Acquired Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	$ 74,809	$ 67,341

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 38,171	$ 56,204	$ 51,297
Asset impairment and restructuring costs	332,949	519,209	571,719
Intangible Assets
Finite Lived Intangible Assets [Line Items]
Restructuring and other charges	41,404	54,511	192,987
Asset impairment and restructuring costs	26,065	6,634	54,020
Costs Recorded in Cost of Goods Sold
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	81	80	1,030
Restructuring and other charges	123,669	25,985	132,089
Selling, General and Administrative Expenses
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 38,090	$ 56,124	$ 50,267

Intangible Assets - Summary o_2

Intangible Assets - Summary of Estimated Amortization Expense (Details) $ in Thousands	Mar. 31, 2022CAD ($)
Finite Lived Intangible Assets Future Amortization Expense Current And Five Succeeding Fiscal Years [Abstract]
2023	$ 25,318
2024	24,660
2025	21,040
2026	18,472
2027	17,727
Thereafter	$ 60,669

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Line Items]
Beginning Balance		$ 1,889,354	$ 1,954,471
Purchase accounting allocations		105,323
Impairment losses	$ (40,748)	(40,748)
Foreign currency translation adjustments		(28,640)	(65,117)
Ending Balance	1,866,503	1,866,503	$ 1,889,354
Consolidated Entities
Goodwill [Line Items]
Disposal of consolidated entities	$ (58,786)	$ (58,786)

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Goodwill [Line Items]
Goodwill impairment loss	$ 40,748	$ 40,748
Goodwill	1,866,503	1,866,503	$ 1,889,354	$ 1,954,471
Key Leaf Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss		22,355
This Works Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss		18,393
Goodwill	$ 2,289	$ 2,289
Cannabis Operations Reporting Unit
Goodwill [Line Items]
Estimated fair value decrease percentage		15.00%
Share price decrease percentage		10.00%
Cannabis Operations Reporting Unit | Minimum
Goodwill [Line Items]
Goodwill percentage of fair value in excess of carrying value	5.00%	5.00%
Cannabis Operations Reporting Unit | Maximum
Goodwill [Line Items]
Goodwill percentage of fair value in excess of carrying value	10.00%	10.00%
Cannabis Operations Reporting Unit | Estimated Control Premium Decreased by 100 Basis Points
Goodwill [Line Items]
Goodwill	$ 1,727,848	$ 1,727,848
Decrease in estimated control premium		5.00%
Estimated fair value decrease percentage		7.00%
BioSteel Reporting Unit | Discount Rate Increased by 50 Basis Points
Goodwill [Line Items]
Goodwill	57,339	$ 57,339
Estimated fair value decrease percentage		8.00%
Increase in discount rate		0.50%
BioSteel Reporting Unit | Annual Cash Flow Projections Decreased By 250 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage		5.00%
Decrease in annual cash flow projections		2.50%
BioSteel Reporting Unit | Long Term Growth Rate Decreased By50 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage		3.00%
Decrease in long-term growth rate		0.50%
Storz & Bickel Reporting Unit | Discount Rate Increased by 50 Basis Points
Goodwill [Line Items]
Goodwill	$ 79,027	$ 79,027
Estimated fair value decrease percentage		6.00%
Increase in discount rate		0.50%
Storz & Bickel Reporting Unit | Annual Cash Flow Projections Decreased By 250 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage		3.00%
Decrease in annual cash flow projections		2.50%
Storz & Bickel Reporting Unit | Long Term Growth Rate Decreased By50 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage		4.00%
Decrease in long-term growth rate		0.50%

Other Accrued Expenses and Li_3

Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Accounts Payable And Accrued Liabilities Current [Abstract]
Employee compensation	$ 24,873	$ 47,237
Inventory	10,096	5,426
Professional fees	7,640	11,544
Taxes and government fees	7,144	13,550
Other	25,525	23,056
Other accrued expenses and liabilities	$ 75,278	$ 100,813

Debt - Summary of Components of

Debt - Summary of Components of Debt (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Other revolving debt facility, loan, and financings	$ 2,808	$ 3,872
Long Term Debt	1,500,991	1,582,963
Current portion of long-term debt	9,296	9,827
Long-term debt	1,491,695	1,573,136
Debt	1,500,991	1,582,963
Less: current portion	(9,296)	(9,827)
Long-term portion	$ 1,491,695	1,573,136
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debenture maturity date	Jul. 15, 2023
Principal amount	$ 600,000	600,000
Accrued interest	5,958	5,664
Non-credit risk fair value adjustment	7,140	109,710
Credit risk fair value adjustment	(49,140)	(27,960)
Senior Notes	$ 563,958	687,414
Convertible Debentures
Debt Instrument [Line Items]
Convertible debentures	Sep. 10, 2025
Convertible debentures	$ 32,858	0
Accretion debentures
Debt Instrument [Line Items]
Convertible debentures	Sep. 10, 2025
Accretion debentures	$ 7,720	0
Revolving Credit Facility
Debt Instrument [Line Items]
Convertible debentures	Mar. 18, 2026
Credit facility	$ 893,647	$ 891,677

Debt - Summary of Components _2

Debt - Summary of Components of Debt (Parenthetical) (Details)	Mar. 31, 2022
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	4.25%

Debt - Additional Information (

Debt - Additional Information (Details)	Mar. 18, 2021CAD ($)	Mar. 18, 2021USD ($)	Sep. 09, 2020CAD ($)	Aug. 13, 2019CAD ($)	Jun. 20, 2018CAD ($)Trading_Day$ / shares	Sep. 09, 2020CAD ($)	Oct. 19, 2018CAD ($)$ / shares	Mar. 31, 2022CAD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2020CAD ($)
Debt Instrument [Line Items]
Issuance of long-term debt	$ 893,160,000							$ 0	$ 893,160,000	$ 14,761,000
Accretion Rate						11.06%
Conversion Of Outstanding Debentures Description						In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures
Supreme Cannabis
Debt Instrument [Line Items]
Annual interest rate							6.00%
Interest at a rate							6.00%
Maturity date							Sep. 10, 2025
Conversion price | $ / shares							$ 0.285
Proceeds from the Credit Facility							$ 100,000,000
Cancellation of Debt			$ 63,500,000
Debenture maturity date							Sep. 10, 2025
Monthly Interest Rate			1.00%			1.00%
Farm Credit Canada | Tweed Farms Inc | Revolving Credit Facility
Debt Instrument [Line Items]
Annual interest rate								3.70%
Interest at a rate								3.70%
Maturity date								Sep. 3, 2024
Debenture maturity date								Sep. 3, 2024
Line of credit facility, maximum borrowing capacity				$ 40,000,000
Extinguishment of debt, amount				$ 4,912,000
Debt Instrument, Description of Variable Rate Basis								prime rate plus 1.0%
Debt Instrument, Basis Spread on Variable Rate								1.00%
Minimum | Supreme Cannabis
Debt Instrument [Line Items]
Proceeds from the Credit Facility						$ 13,500,000
Maximum | Supreme Cannabis
Debt Instrument [Line Items]
Annual interest rate							8.00%
Interest at a rate							8.00%
Proceeds from the Credit Facility						$ 36,500,000
Minimum
Debt Instrument [Line Items]
Minimum liquidity, each fiscal quarter		$ 200,000,000
Credit Facility
Debt Instrument [Line Items]
Senior secured debt, Term		5 years
Principal amount		$ 750,000
Senior credit facility		$ 500,000
Loan amortization payment	$ 0
Convertible debentures		Mar. 18, 2026
Principal amount		$ 750,000
L I B O R Plus
Debt Instrument [Line Items]
Annual interest rate		8.50%
Interest at a rate		8.50%
L I B O R Floor
Debt Instrument [Line Items]
Annual interest rate		1.00%
Interest at a rate		1.00%
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal amount					$ 600,000,000
Annual interest rate					4.25%
Principal amount					$ 600,000,000
Interest at a rate					4.25%
Frequency of periodic payment team								semi-annually on January 15th and July 15th of each year commencing from January 15, 2019
Maturity date					Jul. 15, 2023
Convertible senior notes conversion time start from					Jan. 15, 2023
Conversion rate for every dollar one of principal amount of notes | $ / shares					$ 20.7577
Convertible, If-converted value in excess of principal					$ 1,000
Conversion price | $ / shares					$ 48.18
Debt Conversion, Description					(i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith.
Conversion price percentage					130.00%			130.00%
Convertible measurement period threshold trading days					5 days
Convertible measurement period threshold consecutive trading days					5 days
Convertible conversion price | $ / shares					$ 1
Maximum discount to last reported sales price					98.00%
Debt instrument, redemption, description								Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law.
Debt instrument, redemption period, start date								Jul. 20, 2021
Debt instrument, redemption threshold trading days								20 days
Debt instrument, redemption threshold consecutive trading days								30 days
Number of trading days to provide notice of redemption								5 days
Debt instrument, redemption price, percentage								100.00%
Debt instrument, change in fair value of notes								$ (123,456,000)	237,210,000
Debt instrument, change in fair value of notes from contractual interest								$ 25,794,000	$ 25,710,000
Debenture maturity date					Jul. 15, 2023
4.25% Convertible Senior Notes [Member] | Minimum
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day					20
4.25% Convertible Senior Notes [Member] | Maximum
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day					30

Debt - Summary of Required Prin

Debt - Summary of Required Principal Repayments Under Long-term Debt Obligations (Details) $ in Thousands	Mar. 31, 2022CAD ($)
Long Term Debt By Maturity [Abstract]
2023	$ 865
2024	603,865
2025	6,865
2026	966,470
Long-term debt obligations	$ 1,578,065

Other Liabilities - Components

Other Liabilities - Components of Other Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Oct. 14, 2021	Mar. 31, 2021
Current
Lease liabilities	$ 38,035		$ 42,061
Acquisition consideration and other investment related liabilities	4,020		16,577
Refund liability	3,437		6,441
Settlement liabilities and other	18,562		41,349
Other Liabilities Current	64,054		106,428
Long-term
Lease liabilities, long-term	101,125		94,164
Acquisition consideration and other investment related liabilities	77,834		7,808
Settlement liabilities and other	11,090		5,268
Other liabilities, long-term	190,049		107,240
Total
Lease liabilities	139,160		136,225
Acquisition consideration and other investment related liabilities	81,854	$ 74,160	24,385
Refund liability	3,437		6,441
Settlement liabilities and other	29,652		46,617
Other liabilities	$ 254,103		$ 213,668

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Oct. 14, 2021	Mar. 31, 2021
Other Liabilities Disclosure [Abstract]
Acquisition consideration and other investment related liabilities	$ 81,854	$ 74,160	$ 24,385
Estimated fair value of deferred payments	$ 70,066

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interest - Summary of Net Change in Redeemable Noncontrolling Interests (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	$ 135,300	$ 69,750	$ 6,400
Initial recognition of noncontrolling interest			18,733
Income (loss) attributable to noncontrolling interest	(17,097)	(18,077)	6,489
Adjustments to redemption amount	(76,894)	83,627	38,128
Ending balance	36,200	135,300	69,750
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	(5,109)
Vert Mirabel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	11,500	20,250	6,400
Income (loss) attributable to noncontrolling interest	(3,165)	(11,906)	8,220
Adjustments to redemption amount	(7,335)	3,156	5,630
Ending balance	1,000	11,500	20,250
BioSteel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	123,800	49,500
Initial recognition of noncontrolling interest			18,733
Income (loss) attributable to noncontrolling interest	(13,932)	(6,171)	(1,731)
Adjustments to redemption amount	(69,559)	80,471	32,498
Ending balance	35,200	$ 123,800	$ 49,500
BioSteel | Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	$ (5,109)

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ / shares in Units, $ in Thousands	Apr. 02, 2020shares	Feb. 23, 2021CAD ($)$ / sharesshares	Mar. 31, 2020CAD ($)shares	Mar. 31, 2022shares	Mar. 31, 2021
Class Of Stock [Line Items]
Number of equity financing			0	0	0
Financings | $		$ 0	$ 0
Subordinated Voting Shares
Class Of Stock [Line Items]
Daily purchases of common shares, limit	70,653
Average daily trading volume	25.00%
RIV Capital [Member]
Class Of Stock [Line Items]
Ownership percentage			27.30%
Voting rights percentage			84.40%
RIV Capital [Member] | Subordinated Voting Shares
Class Of Stock [Line Items]
Treasury shares		15,223,938	15,223,938	0
Maximum number of shares authorized to be repurchased	10,409,961
Percentage of subordinated voting shares issuable from treasury	10.00%
NCIB expiration date	Apr. 1, 2021
Stock repurchased and cancelled, shares		273,300
Stock repurchased and cancelled, value | $		$ 307
Weighted Average price, per share | $ / shares		$ 1.11
RIV Capital [Member] | Multiple Voting Shares
Class Of Stock [Line Items]
Treasury shares		36,468,318	36,468,318	0

Share Capital - Summary of Issu

Share Capital - Summary of Issuances of Stock Other (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones, Number of shares	1,295,285	2,598,978	1,121,605
Completion of acquisition milestones, Number of shares	1,295,285	2,598,978	1,121,605
Share Capital
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ 29,276	$ 46,903	$ 29,561
Share-based Reserve
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ (29,721)	$ (19,059)	$ (29,687)
Acquisition Of Supreme Cannabis [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	9,013,400
Share capital	$ 260,668
Number of common shares	9,013,400
Other Issuances [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	492,741	449,729	597,936
Share capital	$ 8,201	$ 14,906	$ 19,369
Share based reserve	$ (736)	$ (14,894)	$ (19,511)
Number of common shares	492,741	449,729	597,936
Total [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	10,801,426	3,048,707	8,660,072
Share capital	$ 298,145	$ 61,809	$ 271,966
Share based reserve	$ (30,457)	$ (33,953)	$ (272,234)
Number of common shares	10,801,426	3,048,707	8,660,072
BC Tweed NCI [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares			6,940,531
Share capital			$ 223,036
Share based reserve			$ (223,036)
Number of common shares			6,940,531

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details) - CAD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Class Of Warrant Or Right [Line Items]
Number of whole warrants, Beginning balance	127,073,136	146,299,443	107,848,322
Number of whole warrants, Other issuance of warrants			9,200
Number of whole warrants, Exercise of warrants		(18,882,927)	(12,523)
Number of whole warrants,Supreme Cannabis Warrants	1,265,742
Number of whole warrants, Expiry of warrants	(145,831)	(343,380)
Number of whole warrants, Ending balance	128,193,047	127,073,136	146,299,443
Average exercise price, Beginning balance	$ 58.33	$ 52.44	$ 43.80
Average exercise price, Other issuance of warrants			32.83
Average exercise price, Exercise of warrants		12.98	35.55
Average exercise price,Supreme Cannabis warrants	25.61
Average exercise price, Expiry of warrants	$ 32.61	41.49
Average exercise price, Ending balance	$ 58.04	$ 58.33	$ 52.44
Warrant value, Beginning balance	$ 2,568,438	$ 2,638,951	$ 1,589,925
Warrant value, Other issuance of warrants			359
Warrant value, Exercise of warrants		(70,513)	(486)
Warrant Value, Supreme Cannabis warrants	13,350
Warrant value, Ending balance	$ 2,581,788	$ 2,568,438	2,638,951
Tranche A
Class Of Warrant Or Right [Line Items]
Warrant value, Warrant modification			$ 1,049,153
Tranche B
Class Of Warrant Or Right [Line Items]
Number of whole warrants, Issuance of warrants			38,454,444
Average exercise price, Issuance of warrants			$ 76.68

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands	May 27, 2021	Sep. 21, 2020	Feb. 23, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jun. 22, 2021	Oct. 01, 2019	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options extended period		10 years
Options maximum period		6 years
Weighted average exercise price of options outstanding				$ 33.89	$ 36.79
Weighted average exercise price of options exercisable				$ 38.33	$ 36.97
Stock options outstanding				16,782,962
Proceeds from exercise of stock options				$ 5,567	$ 156,897	$ 41,413
Share-based compensation				$ 47,525	$ 91,149	$ 320,276
Number of shares released on completion of acquisition milestones				1,295,285	2,598,978	1,121,605
Number of shares to be issued on completion of acquisition and asset purchase milestones				275,468
RIV Capital [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 2,659			$ 6,857
Acquisition Milestones
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation				$ 7,991	$ 8,136	62,172
Costs Recorded in Operating Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation				3,615		$ 32,694
Supreme Cannabis
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense				$ 823
Percentage of outstanding shares purchased							100.00%
Bio Steel Sports Nutrition Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options outstanding				1,565,300	1,581,000	1,008,000
Share-based compensation				$ 839	$ 1,169	$ 489
Percentage of outstanding shares purchased								72.00%
Vesting period					5 years
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense				$ 27,163	$ 67,737	$ 248,450
Stock Option Subject To Performance Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, options subject to performance conditions				1,336,249	2,152,938	2,160,068
Options with Market Based Performance Conditions and Valued Using Monte Carlo Simulation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options outstanding				0	17,559	571,689
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense				$ 10,709	$ 11,448	$ 2,308
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for Awards				39,442,260	57,431,277
Options expiration period		10 years
Weighted average exercise price of options outstanding				$ 33.89	$ 36.79	$ 34.89			$ 34.10
Stock options outstanding				16,782,962	17,704,311	32,508,395			32,831,895
Options exercised				445,680	7,062,317	3,900,032
Exercise price				$ 12.27	$ 22.22	$ 10.63
Proceeds from exercise of stock options				$ 5,567	$ 156,897	$ 41,413
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of awards vesting on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of awards vesting on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of awards vesting on each anniversaries from date of grant		33.33%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of common shares authorized		600,000
Equity shares issued to shareholders				198,501	37,312
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	15.00%
Maximum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price				$ 36.34	$ 67.64	$ 40.68
Maximum | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity shares issued to shareholders		300,000		235,813	37,312
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	10.00%
Minimum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price				$ 0.06	$ 0.06	$ 0.06

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Changes in Omnibus Plan Employee Options (Details) - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance	16,782,962
Weighted average exercise price outstanding, beginning balance	$ 36.79
Weighted average exercise price outstanding, ending balance	$ 33.89	$ 36.79
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	17,704,311	32,508,395	32,831,895
Options granted	2,537,290	478,215	9,454,714
Replacement options issued as a result of the acquisition of Supreme Cannabis	140,159
Options exercised	(445,680)	(7,062,317)	(3,900,032)
Options forfeited/cancelled	(3,153,118)	(8,219,982)	(5,878,182)
Options outstanding, ending balance	16,782,962	17,704,311	32,508,395
Weighted average exercise price outstanding, beginning balance	$ 36.79	$ 34.89	$ 34.10
Weighted average exercise price, Options granted	17.40	28.15	33.87
Weighted average exercise price, Replacement options issued as a result of the acquisition of Supreme Cannabis	80.53
Weighted average exercise price, Options exercised	12.27	22.22	10.63
Weighted average exercise price, Options forfeited/cancelled	42.03	41.27	44.95
Weighted average exercise price outstanding, ending balance	$ 33.89	$ 36.79	$ 34.89

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Outstanding Stock Options (Details)	12 Months Ended
	Mar. 31, 2022$ / sharesshares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding	16,782,962
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 1 month 9 days
Options Exercisable	12,076,748
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 6 months 14 days
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 0.06
Range of Exercise Prices, Upper Range | $ / shares	$ 24.62
Options Outstanding	3,705,144
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 18 days
Options Exercisable	1,312,215
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 1 month 13 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 24.63
Range of Exercise Prices, Upper Range | $ / shares	$ 33.53
Options Outstanding	4,036,819
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 3 months
Options Exercisable	2,285,789
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 8 months 4 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 33.54
Range of Exercise Prices, Upper Range | $ / shares	$ 36.80
Options Outstanding	2,984,264
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 2 months 26 days
Options Exercisable	2,984,264
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 2 months 26 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 36.81
Range of Exercise Prices, Upper Range | $ / shares	$ 42.84
Options Outstanding	2,641,567
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 10 months 6 days
Options Exercisable	2,488,993
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 7 months 24 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 42.85
Range of Exercise Prices, Upper Range | $ / shares	$ 67.64
Options Outstanding	3,415,168
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 10 months 17 days
Options Exercisable	3,005,487
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 9 months 29 days

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.09%	0.36%	1.38%
Expected volatility	75.00%	76.00%	73.00%
Expected forfeiture rate	18.00%	17.00%	12.00%
Black-Scholes value of each option	$ 9.69	$ 15.24	$ 19.83
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	3 years	1 year	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	5 years	7 years	5 years

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Changes in RSUs (Details) - Restricted Stock Units (RSUs) - shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	753,310	883,009	137,228
RSUs and PSUs granted	3,253,671	142,826	875,673
RSUs and PSUs released	(300,319)	(120,399)	(29,892)
RSUs and PSUs cancelled and forfeited	(229,370)	(152,126)	(100,000)
Ending balance	3,477,292	753,310	883,009

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 3,486,520	$ 5,108,120	$ 7,065,708
Disposal of consolidated entities	16,130
Other comprehensive income (loss)	(24,172)	(255,139)	260,758
Income tax expense			(33,954)
Ending balance	3,594,297	3,486,520	5,108,120
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(28,246)	126,723	41,225
Other comprehensive income (loss)	(45,352)	(154,969)	85,498
Ending balance	(57,468)	(28,246)	126,723
Changes of Own Credit Risk of Financial Liabilities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(5,994)	94,176	(47,130)
Other comprehensive income (loss)	21,180	(100,170)	175,260
Income tax expense			(33,954)
Ending balance	15,186	(5,994)	94,176
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(34,240)	220,899	(5,905)
Ending balance	$ (42,282)	$ (34,240)	$ 220,899

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Minority Interest [Line Items]
Beginning balance	$ 3,486,520	$ 5,108,120	$ 7,065,708
Comprehensive (loss) income	(18,304)	74,100	(66,114)
Net (loss) income loss attributable to redeemable noncontrolling interest	17,097	18,077	(6,489)
Share-based compensation	47,525	91,149	320,276
Ending balance	3,594,297	3,486,520	5,108,120
Noncontrolling Interests
Minority Interest [Line Items]
Beginning balance	4,709	221,758	285,485
Comprehensive (loss) income	(18,304)	74,100	(66,114)
Net (loss) income loss attributable to redeemable noncontrolling interest	17,097	18,077	(6,489)
Share-based compensation	839	3,828	7,346
Ownership changes		(313,304)	1,530
Warrants		250
Ending balance	4,341	4,709	221,758
RIV Capital
Minority Interest [Line Items]
Beginning balance		211,086	280,012
Comprehensive (loss) income		94,532	(77,313)
Share-based compensation		2,659	6,857
Ownership changes		(308,527)	1,530
Warrants		250
Ending balance			211,086
Vert Mirabel
Minority Interest [Line Items]
Beginning balance		7,132	2,422
Comprehensive (loss) income	(3,165)	(14,261)	12,930
Net (loss) income loss attributable to redeemable noncontrolling interest	3,165	11,906	(8,220)
Ownership changes		(4,777)
Ending balance			7,132
BioSteel
Minority Interest [Line Items]
Beginning balance	1,658	489
Comprehensive (loss) income	(13,932)	(6,171)	(1,731)
Net (loss) income loss attributable to redeemable noncontrolling interest	13,932	6,171	1,731
Share-based compensation	839	1,169	489
Ending balance	2,497	1,658	489
Other
Minority Interest [Line Items]
Beginning balance	3,051	3,051	3,051
Comprehensive (loss) income	(1,207)
Ending balance	$ 1,844	$ 3,051	$ 3,051

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Assets:
Short-term investments	$ 595,651	$ 1,144,563
Restricted short-term investments	12,216	11,332
Other financial assets	788,306	700,982
Liabilities:
Convertible senior notes	563,958	687,414
Other liabilities	70,066
Acreage
Liabilities:
Derivative liability	47,000	600,000
Warrant
Liabilities:
Derivative liability	26,920	615,575
Level 1
Assets:
Short-term investments	595,651	1,144,563
Restricted short-term investments	12,216	11,332
Other financial assets	490	254
Level 2
Liabilities:
Convertible senior notes	563,958	687,414
Level 3
Assets:
Other financial assets	787,816	700,728
Liabilities:
Other liabilities	70,066
Level 3 | Acreage
Liabilities:
Derivative liability	47,000	600,000
Level 3 | Warrant
Liabilities:
Derivative liability	$ 26,920	$ 615,575

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) - Level 2 - Convertible Senior Notes	12 Months Ended
	Mar. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Convertible note pricing model
Key inputs	Quoted prices in over-the-counter broker market

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) - Level 3	12 Months Ended
	Mar. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Probability of Each Scenario
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Financial Instrument Value and Number of Canopy Shares Issued
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Number of common shares to be issued
Relationship of unobservable inputs to fair value	Increase or decrease in value and number of common shares will result in a decrease or increase in fair value
Acreage Financial Instrument Intrinsic Value of Acreage
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Estimated premium on US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Estimated Premium on US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Control premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated control premium will result in an increase or decrease in fair value
Acreage Financial Instrument Control Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Market access premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated market access premium will result in an increase or decrease in fair value
TerrAscend Canada Term Loan - October 2019 March 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend Exchangeable Shares, TerrAscend Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Put option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Hempco Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Terr Ascend Warrants - December 2019, March 2020, December 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Black-Sholes option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Arise Bioscience Term Loan
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument - Call Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Expected future Wana cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value
BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Expected future BioSteel cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value
Wana Financial Instrument - Call Option, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Wana Financial Instrument - Deferred Payments, Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Wana
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility of Canopy Growth Share Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of Canopy Growth share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Wana Financial Instrument - Deferred Payments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
BioSteel Redeemable Noncontrolling Interest Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - CAD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Gross revenue		$ 582,218	$ 607,198	$ 439,626
Net revenue		520,325	546,649	398,772
Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		205,302	229,601	173,649
Canadian Medical Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[1]	52,608	55,448	51,647
Canadian Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		257,910	285,049	225,296
International and Other Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		79,306	93,631	69,639
Global Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		337,216	378,680	294,935
Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Gross revenue		183,109	167,969	103,837
C3 | International and Other Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		36,113	62,335	53,770
Business to Business | Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[2]	143,732	163,585	121,605
Business to Consumer | Canadian Recreational Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		61,570	66,016	52,044
Other | International and Other Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		43,193	31,296	15,869
Other | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Gross revenue		20,777	25,127	26,194
Storz & Bickel | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Gross revenue		85,410	80,998	48,329
This Work | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Gross revenue		32,296	33,314	24,725
BioSteel | Consumer Products and Other
Disaggregation Of Revenue [Line Items]
Gross revenue		$ 44,626	$ 28,530	$ 4,589
[1]	Canadian medical cannabis net revenue reflects excise taxes of $5,227 (year ended March 31, 2021 - $5,621, and year ended March 31, 2020 - $5,205).
[2]	Canadian recreational business-to-business net revenue reflects excise taxes of $56,666 (year ended March 31, 2021

Revenue - Summary of Disaggre_2

Revenue - Summary of Disaggregation of Revenue (Parenthetical) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenue	$ 520,325	$ 546,649	$ 398,772
CANADA
Disaggregation Of Revenue [Line Items]
Net revenue	296,369	329,172	256,166
CANADA | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	56,666	54,928	35,649
CANADA | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	$ 5,227	$ 5,621	$ 5,205

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Revenue From Contract With Customer [Abstract]
Allowance for estimated returns and price adjustments	$ 21,464	$ 23,935	$ 51,500
Liability for estimated returns and price adjustments	$ 3,437	$ 6,441

Pharmhouse - Additional informa

Pharmhouse - Additional information (Details) - PharmHouse $ in Thousands	12 Months Ended
	Mar. 31, 2022CAD ($)
Schedule Of Equity Method Investments [Line Items]
Date of formation of joint venture entity	May 7, 2018
Recoverable amount of assets on liquidation	$ 57,500

Pharmhouse - Pharmhouse financi

Pharmhouse - Pharmhouse financial guarantee - Additional information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Feb. 23, 2021
Line Of Credit Facility [Line Items]
Financial liabilities	$ 1,984,553	$ 3,201,660
Expected credit loss in net income (loss)	$ (302,181)	(1,744,920)	$ (1,321,326)
Pharmhouse Credit Agreement
Line Of Credit Facility [Line Items]
Non - revolving credit facility, maximum Principle amount				$ 90,000
Expected credit loss				$ (32,500)
Expected credit loss in net income (loss)		$ 32,500

Pharmhouse - Other financial as

Pharmhouse - Other financial assets, including loans receivable - Additional information (Details) - CAD ($) $ in Thousands	Aug. 04, 2020	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Feb. 23, 2021
Schedule Of Equity Method Investments [Line Items]
Expected credit losses on financial assets and related charges			$ 0	$ 109,480	$ 0
PharmHouse
Schedule Of Equity Method Investments [Line Items]
Loss in interest receivable in relation to the financial instruments				8,989
Advances written off		$ 35,000		15,000,000
Expected credit losses on financial assets and related charges				109,480
PharmHouse | Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Secured debt					40,000	$ 40,000
PharmHouse | Debtor In Possession
Schedule Of Equity Method Investments [Line Items]
Line of credit facility, pursuant to the agreement						9,300
Contingent irrecoverable credit losses				9,300
PharmHouse | Pharmhouse Credit Agreement
Schedule Of Equity Method Investments [Line Items]
Expected credit losses on financial assets				32,500
PharmHouse | Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Contingent irrecoverable credit losses				40,000
PharmHouse | Secured Demand Promissory Note
Schedule Of Equity Method Investments [Line Items]
Secured debt					$ 2,450	2,450
Contingent irrecoverable credit losses				2,450
PharmHouse | Unsecured Demand Promissory Note
Schedule Of Equity Method Investments [Line Items]
Debt financing pursuant to a unsecured demand promisory note	$ 1,206
Contingent irrecoverable credit losses				$ 1,206
PharmHouse | Financial Asset Past Due
Schedule Of Equity Method Investments [Line Items]
Financing increased amount						$ 9,700

Pharmhouse - PharmHouse equity

Pharmhouse - PharmHouse equity method investment - Additional information (Details) - PharmHouse - CAD ($) $ in Thousands	Feb. 23, 2021	Mar. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Common shares owned in joint venture	10,998,660	10,998,660
Ownership percentage	49.00%
Equity method investments	$ 32,369

Other Income (Expense), Net - S

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Other Income And Expenses [Abstract]
Fair value changes on other financial assets	$ (356,109)	$ 435,107	$ (243,965)
Fair value changes on liability arising from Acreage Arrangement	553,000	(399,849)	(645,190)
Fair value changes on convertible senior notes	76,776	(162,540)	184,740
Fair value changes on warrant derivative liability	588,655	(293,084)	795,149
Fair value changes on acquisition related contingent consideration and other	4,417	39,608	12,293
Interest income	6,601	21,367	66,327
Interest expense	(103,944)	(8,459)	(6,716)
Foreign currency gain (loss)	5,415	(18,013)	(1,245)
(Loss) gain on disposal/acquisition of consolidated entity	(6,762)	634	61,775
Other income (expense), net	(14,708)	(2,647)	1,161
Other income (expense), net	$ 753,341	$ (387,876)	$ 224,329

Income Taxes - Summary of Net L

Income Taxes - Summary of Net Loss Before Income Taxes (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Domestic - Canada	$ (163,888)	$ (1,611,210)	$ (1,167,000)
Foreign - outside of Canada	(165,545)	(72,751)	(342,054)
Loss before income taxes	$ (329,433)	$ (1,683,961)	$ (1,509,054)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Recovery (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Domestic - Canada	$ 895	$ (19,318)	$ (12,342)
Foreign - outside of Canada	1,476	(2,091)	(4,356)
Current income tax recovery	2,371	(21,409)	(16,698)
Domestic - Canada	6,353	36,505	78,624
Foreign - outside of Canada	224	(1,955)	59,688
Deferred income tax recovery	6,577	34,550	138,312
Income tax recovery	$ 8,948	$ 13,141	$ 121,614

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Tax Examination [Line Items]
Combined Canadian federal and provincial enacted statutory tax rate	26.50%	26.50%	26.50%
Other Accounts Receivable
Income Tax Examination [Line Items]
Current income taxes receivable	$ 6,018	$ 5,259
Accounts Payable
Income Tax Examination [Line Items]
Current income taxes payable	$ 1,927	$ 5,267

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Amount of Income Taxes Compared to Expected Income Taxes Calculated at Combined Federal and Provincial Enacted Statutory Tax Rate (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (329,433)	$ (1,683,961)	$ (1,509,054)
Expected tax rate	26.50%	26.50%	26.50%
Expected income tax recovery	$ 87,300	$ 446,250	$ 399,899
Non-deductible and non-taxable items	17,557	81,883	22,947
Fair value changes on Acreage Arrangement	146,545	(105,960)	(170,975)
Fair value changes on warrant derivative liability	155,964	(77,663)	210,715
Share-based compensation	(9,908)	(21,121)	(84,873)
Change in valuation allowance	(361,283)	(358,964)	(215,975)
Effect of tax rates outside of Canada	8,459	10,870	(3,248)
Non-taxable portion of capital gains and losses	(38,440)	38,705	(34,961)
Other	2,754	(859)	(1,915)
Income tax recovery	$ 8,948	$ 13,141	$ 121,614

Income Taxes - Summary of Signi

Income Taxes - Summary of Significant Compenents of Deferred Income Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Deferred income tax assets
Property, plant and equipment	$ 78,023	$ 74,603
Intangible assets	671	5,063
Inventory reserves and write-downs	40,324	39,893
Other reserves and accruals	5,939	7,957
Losses carried forward	917,283	608,002
Equity method investments and other financial assets	10,512	14,900
Deferred financing costs	2,740	3,587
Other	5,635	6,226
Gross deferred income tax assets	1,061,127	760,231
Valuation allowances	(1,039,130)	(677,847)
Total deferred income tax assets, net	21,997	82,384
Deferred income tax liabilities
Property, plant and equipment	(4,182)	(25,864)
Intangible assets	(29,832)	(43,449)
Equity method investments and other financial assets		(31,176)
Deferred financing costs	(3,353)	(2,785)
Other	(621)	(489)
Total deferred income tax liabilities	(37,988)	(103,763)
Net deferred income tax assets (liabilities)	$ (15,991)	$ (21,379)

Income Taxes - Summary of Losse

Income Taxes - Summary of Losses Carried Forward Available to Reduce Future Years' Taxable Income (Details) $ in Thousands	Mar. 31, 2022CAD ($)
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	$ 2,929,113
Losses carried forward available to reduce future years' taxable income	3,821,473
Expiring between 5 and 10 Years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	1,031
Expiring between 10 and 15 Years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	156,420
Expiring between 15 and 20 years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	2,394,542
Indefinite
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	377,120
Indefinite | Capital Loss Carry forward
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	892,360
CANADA
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	2,547,844
United States
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	278,458
Europe
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	55,440
Other Jurisdictions
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	$ 47,371

Acquisitions - Summary of Conso

Acquisitions - Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations (Details) £ in Thousands, $ in Thousands	Oct. 01, 2021CAD ($)	Jun. 22, 2021CAD ($)	Apr. 01, 2021CAD ($)	Oct. 11, 2019CAD ($)	Oct. 01, 2019CAD ($)	Sep. 29, 2019CAD ($)	May 21, 2019CAD ($)	May 21, 2019GBP (£)	Apr. 30, 2019CAD ($)	Oct. 31, 2020CAD ($)	Mar. 31, 2022CAD ($)shares	Mar. 31, 2020CAD ($)	Mar. 31, 2021CAD ($)
Business Acquisition [Line Items]
Goodwill											$ 1,866,503	$ 1,954,471	$ 1,889,354
Ace Valley
Business Acquisition [Line Items]
Cash and cash equivalents											1,544
Inventory											878
Other current assets											2,249
Property, plant and equipment											105
Goodwill											39,152
Accounts payable and other accrued expenses and liabilities											(1,724)
Deferred income tax liabilities											(1,899)
Net assets acquired											54,305
Consideration paid in cash											51,836
Other consideration											2,469
Total consideration			$ 51,836								54,305
Less: Cash and cash equivalents acquired											(1,544)
Net cash outflow (inflow)											50,292
Supreme Cannabis
Business Acquisition [Line Items]
Cash and cash equivalents											41,306
Inventory											33,426
Other current assets											14,791
Property, plant and equipment											187,407
Goodwill											58,842
Accounts payable and other accrued expenses and liabilities											(12,935)
Debt and other liabilities											(88,324)
Deferred income tax liabilities											(5,545)
Net assets acquired											279,668
Consideration paid in cash		$ 84									$ 84
Consideration paid in shares | shares											260,668
Replacement options		$ 140,159									$ 629
Replacement warrants											13,350
Other consideration											4,937
Total consideration											279,668
Less: Cash and cash equivalents acquired											(41,306)
Net cash outflow (inflow)											(41,222)
Other
Business Acquisition [Line Items]
Cash and cash equivalents											1,227
Inventory											362
Other current assets											335
Property, plant and equipment											1,510
Goodwill											7,329
Accounts payable and other accrued expenses and liabilities											(30)
Debt and other liabilities											(1,037)
Deferred income tax liabilities											(540)
Net assets acquired											11,156
Consideration paid in cash											$ 7,104
Consideration paid in shares | shares											4,052
Total consideration											$ 11,156
Less: Cash and cash equivalents acquired											(1,227)
Net cash outflow (inflow)											5,877
2022 Acquisitions
Business Acquisition [Line Items]
Cash and cash equivalents											44,077
Inventory											34,666
Other current assets											17,375
Property, plant and equipment											189,022
Goodwill											105,323
Accounts payable and other accrued expenses and liabilities											(14,689)
Debt and other liabilities											(89,361)
Deferred income tax liabilities											(7,984)
Net assets acquired											345,129
Consideration paid in cash											$ 59,024
Consideration paid in shares | shares											264,720
Replacement options											$ 629
Replacement warrants											13,350
Other consideration											7,406
Total consideration											345,129
Less: Cash and cash equivalents acquired											(44,077)
Net cash outflow (inflow)											14,947
C3
Business Acquisition [Line Items]
Cash and cash equivalents												2,818
Inventory									$ 1,814
Other current assets												15,140
Property, plant and equipment												8,345
Goodwill									(41,786)			287,010
Accounts payable and other accrued expenses and liabilities												(3,652)
Debt and other liabilities												(3,942)
Deferred income tax liabilities									(11,219)			(11,219)
Net assets acquired												345,699
Consideration paid in cash												345,699
Total consideration									$ 345,699			345,699
Less: Cash and cash equivalents acquired												(2,818)
Net cash outflow (inflow)												342,881
Net assets												345,699
This Works
Business Acquisition [Line Items]
Cash and cash equivalents												1,619
Inventory							$ 1,755
Other current assets												8,239
Property, plant and equipment												478
Goodwill							(45,794)					22,214
Accounts payable and other accrued expenses and liabilities												(4,100)
Deferred income tax liabilities							(7,911)					(7,911)
Net assets acquired												72,665
Consideration paid in cash												72,665
Total consideration							$ 72,665	£ 43,296				72,665
Less: Cash and cash equivalents acquired												(1,619)
Net cash outflow (inflow)												71,046
Net assets												72,665
BioSteel
Business Acquisition [Line Items]
Cash and cash equivalents												225
Inventory					$ 2,710
Other current assets												12,972
Property, plant and equipment												391
Goodwill					(38,093)							35,939
Accounts payable and other accrued expenses and liabilities												(3,852)
Debt and other liabilities												(3,659)
Deferred income tax liabilities					(3,817)							(3,817)
Net assets acquired												59,207
Consideration paid in cash					47,924							47,924
Other consideration						$ 8,500						11,283
Total consideration												59,207
Less: Cash and cash equivalents acquired												(225)
Net cash outflow (inflow)												47,699
Net assets												77,940
Noncontrolling interests					(18,733)							(18,733)
Contingent consideration					$ 10,000
BCT
Business Acquisition [Line Items]
Cash and cash equivalents												7,886
Other current assets												2,296
Property, plant and equipment												5
Goodwill												85,700
Accounts payable and other accrued expenses and liabilities												(2,176)
Deferred income tax liabilities												(838)
Net assets acquired												98,140
Consideration paid in cash												45,098
Fair value of previously held equity interest	$ 5,746											37,919
Replacement options												1,885
Other consideration												13,238
Total consideration												98,140
Less: Cash and cash equivalents acquired												(7,886)
Net cash outflow (inflow)												37,212
Net assets												98,140
Noncontrolling interests				$ (51,942)
Contingent consideration	$ 5,861			$ 45,098						$ 8,750
Spectrum UK
Business Acquisition [Line Items]
Other current assets												67
Property, plant and equipment												895
Goodwill												12,861
Accounts payable and other accrued expenses and liabilities												(922)
Deferred income tax liabilities												(36)
Net assets acquired												14,023
Fair value of previously held equity interest												14,023
Total consideration												14,023
Net assets												14,023
Storz & Bickel
Business Acquisition [Line Items]
Goodwill												(24,990)
2020 Acquisitions
Business Acquisition [Line Items]
Cash and cash equivalents												12,548
Other current assets												38,714
Property, plant and equipment												10,114
Goodwill												418,734
Accounts payable and other accrued expenses and liabilities												(14,702)
Debt and other liabilities												(7,601)
Deferred income tax liabilities												(23,821)
Net assets acquired												589,734
Consideration paid in cash												511,386
Fair value of previously held equity interest												51,942
Replacement options												1,885
Other consideration												24,521
Total consideration												589,734
Less: Cash and cash equivalents acquired												(12,548)
Net cash outflow (inflow)												498,838
Net assets												608,467
Noncontrolling interests												(18,733)
Brands | Ace Valley
Business Acquisition [Line Items]
Intangible assets											14,000
Brands | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets											22,800
Brands | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets											36,800
Brands | C3
Business Acquisition [Line Items]
Intangible assets												10,613
Brands | This Works
Business Acquisition [Line Items]
Intangible assets												22,114
Brands | BioSteel
Business Acquisition [Line Items]
Intangible assets												3,600
Brands | 2020 Acquisitions
Business Acquisition [Line Items]
Intangible assets												36,327
Distribution Channel | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets											3,500
Distribution Channel | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets											3,500
Distribution Channel | C3
Business Acquisition [Line Items]
Intangible assets												4,058
Distribution Channel | This Works
Business Acquisition [Line Items]
Intangible assets												12,988
Distribution Channel | BioSteel
Business Acquisition [Line Items]
Intangible assets												14,700
Distribution Channel | 2020 Acquisitions
Business Acquisition [Line Items]
Intangible assets												31,746
Operating Licenses | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets											24,400
Operating Licenses | Other
Business Acquisition [Line Items]
Intangible assets											2,000
Operating Licenses | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets											$ 26,400
Operating Licenses | Spectrum UK
Business Acquisition [Line Items]
Intangible assets												1,158
Operating Licenses | 2020 Acquisitions
Business Acquisition [Line Items]
Intangible assets												1,158
Intellectual Property | C3
Business Acquisition [Line Items]
Intangible assets												36,520
Intellectual Property | This Works
Business Acquisition [Line Items]
Intangible assets												16,848
Intellectual Property | BioSteel
Business Acquisition [Line Items]
Intangible assets												20,900
Intellectual Property | BCT
Business Acquisition [Line Items]
Intangible assets												5,267
Intellectual Property | Storz & Bickel
Business Acquisition [Line Items]
Intangible assets												24,990
Intellectual Property | 2020 Acquisitions
Business Acquisition [Line Items]
Intangible assets												104,525
Software and Domain Names | C3
Business Acquisition [Line Items]
Intangible assets												8
Software and Domain Names | This Works
Business Acquisition [Line Items]
Intangible assets												176
Software and Domain Names | BioSteel
Business Acquisition [Line Items]
Intangible assets												541
Software and Domain Names | 2020 Acquisitions
Business Acquisition [Line Items]
Intangible assets												$ 725

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - CAD ($)	Mar. 31, 2022	Mar. 31, 2020
C3
Business Acquisition [Line Items]
Goodwill expected to be deductible for income tax purposes	$ 0	$ 0

Acquisitions - Ace Valley - Add

Acquisitions - Ace Valley - Additional Information (Details) - Ace Valley - CAD ($) $ in Thousands	Apr. 01, 2021	Mar. 31, 2022
Business Acquisition [Line Items]
Business acquisition, acquisition date	Apr. 1, 2021
Percentage of outstanding shares purchased	100.00%
Business acquisition, total purchase consideration	$ 51,836	$ 54,305
Business Combination, Contingent Consideration, Liability	$ 2,469

Acquisitions - Supreme Cannabis

Acquisitions - Supreme Cannabis - Additional Information (Details) - Supreme Cannabis $ in Thousands	Jun. 22, 2021CAD ($)Instrumentshares	Mar. 31, 2022CAD ($)
Business Acquisition [Line Items]
Name of acquiree	Supreme Cannabis
Date of acquisition	Jun. 22, 2021
Percentage of outstanding shares purchased	100.00%
Number of common shares | shares	9,013,400
Shares issued, value	$ 260,668
Consideration paid in cash	84	$ 84
Replacement options	140,159	$ 629
Fair value of outstanding warrant	13,350
Fair value of replacement options	1,452
Fair value of replacement options included as consideration paid	629
Fair value of replacement options recognized as share-based compensation expense	823
Debentures Subject to Mandatory Redemption
Business Acquisition [Line Items]
Principal amount of convertible debt	$ 27,045
Number of shares convertible | Instrument	94,895,649
Share exchange ratio	0.011659
Debt Instrument, Fair Value Disclosure	$ 36,593
Conversion feature of debt	4,937
Debt component	$ 31,656
Warrant
Business Acquisition [Line Items]
Number of common shares | shares	1,265,742

Acquisitions - C3 - Additional

Acquisitions - C3 - Additional Information (Details) - C3 - CAD ($) $ in Thousands	Apr. 30, 2019	Mar. 31, 2020
Business Acquisition [Line Items]
Business acquisition, acquisition date	Apr. 30, 2019
Percentage of outstanding shares purchased	100.00%
Business acquisition, total purchase consideration	$ 345,699	$ 345,699
Business cooperation agreement term	5 years
Business cooperation agreement, cash paid	$ 7,804

Acquisitions - C3 - Summary of

Acquisitions - C3 - Summary of Measurement Period Adjustments (Details) - CAD ($) $ in Thousands	Apr. 30, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Net impact to goodwill		$ 1,866,503	$ 1,889,354	$ 1,954,471
C3
Business Acquisition [Line Items]
Inventory step-up	$ 1,814
Deferred income tax liabilities	(11,219)			(11,219)
Net impact to goodwill	(41,786)			$ 287,010
C3 | Distribution Channel | Income Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 4,058
Acquisition related intangible assets, Useful life (years)	10 years
C3 | Intellectual Property | Relief-from-Royalty
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 36,520
C3 | Intellectual Property | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Useful life (years)	10 years
C3 | Licensed Brands | Relief-from-Royalty
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 10,613
C3 | Licensed Brands | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Useful life (years)	2 years

Acquisitions - This Works - Add

Acquisitions - This Works - Additional Information (Details) - This Works £ in Thousands, $ in Thousands	May 21, 2019CAD ($)	May 21, 2019GBP (£)	Mar. 31, 2020CAD ($)
Business Acquisition [Line Items]
Business acquisition, acquisition date	May 21, 2019	May 21, 2019
Percentage of outstanding shares purchased	100.00%	100.00%
Business acquisition, total purchase consideration	$ 72,665	£ 43,296	$ 72,665

Acquisitions - This Works - Sum

Acquisitions - This Works - Summary of Measurement Period Adjustments (Details) - CAD ($) $ in Thousands	May 21, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Net impact to goodwill		$ 1,866,503	$ 1,889,354	$ 1,954,471
This Works
Business Acquisition [Line Items]
Inventory	$ 1,755
Deferred income tax liabilities	(7,911)			(7,911)
Net impact to goodwill	(45,794)			$ 22,214
This Works | Acquired Brands | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	19,130
This Works | Distribution Channel | Income Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 12,988
Acquisition related intangible assets, Useful life (years)	10 years
This Works | Intellectual Property | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 16,848
Acquisition related intangible assets, Useful life (years)	10 years
This Works | Licensed Brands | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Useful life (years)	5 years
This Works | Licensed Brands | Income Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 2,984

Acquisitions - BioSteel - Addit

Acquisitions - BioSteel - Additional Information (Details) - CAD ($) $ in Thousands	Oct. 01, 2019	Sep. 29, 2019	Mar. 31, 2020
BioSteel
Business Acquisition [Line Items]
Ownership interest	76.70%
BioSteel
Business Acquisition [Line Items]
Percentage of outstanding shares purchased	72.00%
Business combination, initial cash consideration	$ 50,707
Consideration paid in cash	47,924		$ 47,924
Business combination, noncontrolling interests	18,733		18,733
Secured loan agreement		$ 8,500
Other consideration		$ 8,500	$ 11,283
Business acquisition, total purchase consideration	14,000
Business combination, consideration cash paid in advance	10,000
Business combination, consideration payable	$ 4,000
Maximum Rollover Period			5 years

Acquisitions - BioSteel - Summa

Acquisitions - BioSteel - Summary of Measurement Period Adjustments (Details) - CAD ($) $ in Thousands	Oct. 01, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Net impact to goodwill		$ 1,866,503	$ 1,889,354	$ 1,954,471
BioSteel
Business Acquisition [Line Items]
Inventory step-up	$ 2,710
Deferred income tax liabilities	(3,817)			(3,817)
Net impact to goodwill	(38,093)			$ 35,939
BioSteel | Acquired Brands | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	3,600
BioSteel | Distribution Channel | Income Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 14,700
Acquisition related intangible assets, Useful life (years)	11 years
BioSteel | Intellectual Property | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 20,900
Acquisition related intangible assets, Useful life (years)	11 years

Acquisitions - BCT and Spectrum

Acquisitions - BCT and Spectrum UK - Additional Information (Details) - CAD ($) $ in Thousands	Oct. 01, 2021	Oct. 11, 2019	Oct. 31, 2020	Mar. 31, 2019	Mar. 31, 2020
BCT
Business Acquisition [Line Items]
VIE's, of not primary beneficiary		42.00%		42.00%
Percentage ownership of wholly owned subsidiaries		100.00%
Business acquisition, total purchase consideration		$ 58,336
Contingent consideration	$ 5,861	$ 45,098	$ 8,750
Fair value of previously held equity interest	$ 5,746				$ 37,919
Business acquisition, replacement options		155,565
Fair value of replacement options		$ 1,885
Business acquisition, compensation expense		1,987
Business acquisition, Remeasurement Gain (Loss)		39,485
Business acquisition, carrying value of unowned interest		12,457
Business combination, noncontrolling interests		$ 51,942
Business Combination Percentage of Estimated Control Premium		5.00%
Consideration paid in cash					45,098
BCT | Key Management Personnel
Business Acquisition [Line Items]
Consideration paid in cash		$ 250
BCT | Replacement Options | Management
Business Acquisition [Line Items]
Number of common shares		16,430
Spectrum UK
Business Acquisition [Line Items]
VIE's, of not primary beneficiary		67.00%		67.00%
Fair value of previously held equity interest					$ 14,023

Acquisitions - BCT and Spectr_2

Acquisitions - BCT and Spectrum UK - Summary of Measurement Period Adjustments (Details) - CAD ($) $ in Thousands	Oct. 11, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Net impact to goodwill		$ 1,866,503	$ 1,889,354	$ 1,954,471
BCT and Spectrum UK
Business Acquisition [Line Items]
Net impact to goodwill	$ (5,551)
BCT and Spectrum UK | Intellectual Property | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 5,267
Acquisition related intangible assets, Useful life (years)	1 year
BCT and Spectrum UK | Operating License | Valuation, Cost Approach
Business Acquisition [Line Items]
Acquisition related intangible assets, Value	$ 1,158
Acquisition related intangible assets, Useful life (years)	1 year
B C T And Spectrum U K
Business Acquisition [Line Items]
Deferred income tax liabilities	$ (874)

Loss From Equity Method Investm

Loss From Equity Method Investments - More Life - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 01, 2021	Nov. 07, 2019	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2022
Schedule Of Equity Method Investments [Line Items]
Goodwill			$ 1,889,354	$ 1,889,354	$ 1,954,471	$ 1,866,503
More Life
Schedule Of Equity Method Investments [Line Items]
Ownership interest		60.00%
Fair value of retained interest					10,300
Impairment charge related to remaining intangible assets					32,717
Derecognized royalty obligations	$ 33,681
Fair value of equity method investments						$ 25,200
Impairment of equity method investments			$ 10,300	$ 10,300	$ 14,900
More Life | Drake
Schedule Of Equity Method Investments [Line Items]
Ownership percentage		40.00%
Ownership interest		60.00%
More Life | 1955625 Ontario Inc.
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership to be sold		100.00%
Goodwill		$ 0
Fair value of retained interest		$ 25,200

Loss From Equity Method Inves_2

Loss From Equity Method Investments - Summary of Derecognized Assets and Liabilities (Details) - CAD ($) $ in Thousands	Nov. 07, 2019	Feb. 23, 2021
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Intangible assets		$ 86
1955625 Ontario Inc.
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Current assets	$ 100
Intangible assets	2,810
Net assets disposed	2,910
Fair value of retained interest	25,200
Gain on disposal of consolidated entity	$ 22,290

C3 Divestiture - Additional Inf

C3 Divestiture - Additional Information (Details) - Jan. 31, 2022 - C3 € in Thousands, $ in Thousands	CAD ($)	EUR (€)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 128,316	€ 88,698
Earnout Payment Receivable | €		€ 42,600
Disposal of consolidated entities | $	$ 53,541

C3 Divestiture - Summary of Der

C3 Divestiture - Summary of Derecognized Assets and Liabilities Transferred (Details) € in Thousands, $ in Thousands	Jan. 31, 2022CAD ($)	Jan. 31, 2022EUR (€)	Feb. 23, 2021CAD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Property, plant and equipment			$ 729
C3
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Current assets	$ 44,568
Property, plant and equipment	9,216
Intangible assets	15,548
Disposal of consolidated entities	53,541
Current liabilities	(3,089)
Deferred income tax liabilities	(6,029)
Cumulative translation adjustment	19,178
Net assets disposed	132,933
Consideration received in cash	128,316	€ 88,698
Future cash consideration	7,233
Costs to sell	(1,153)
Total consideration	134,396
Gain on disposal of consolidated entity	$ 1,463

C3 Divestiture - Summary of D_2

C3 Divestiture - Summary of Derecognized Assets and Liabilities Transferred (Parenthetical) (Details) - CAD ($) $ in Thousands	Jan. 31, 2022	Feb. 23, 2021
Discontinued Operations And Disposal Groups [Abstract]
Cash and cash equivalents	$ 19,338	$ 37,801

Acreage Arrangement and Amend_2

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands	Jun. 24, 2020CAD ($)shares	Jun. 24, 2020USD ($)$ / sharesshares	Jun. 27, 2019CAD ($)	Jun. 27, 2019USD ($)	Mar. 31, 2022CAD ($)shares	Mar. 31, 2022USD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2020CAD ($)	Apr. 18, 2019$ / sharesshares
Business Acquisition [Line Items]
Derivative, financial liability					$ 26,920,000		$ 615,575,000
Debentures bear interest rate per annum					6.10%
Warrant expiration date									Nov. 1, 2023
Estimated fair value					$ (588,655,000)		293,084,000	$ (795,149,000)
Tranche A Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares									88,500,000
Warrant price per share | $ / shares									$ 50.40
Tranche B Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares									38,500,000
Warrant price per share | $ / shares									$ 76.68
Tranche C Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares									12,800,000
Derivative liability					$ 0
Tranche B and C Warrants | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Number of common stock shares to be repurchased to avoid providing repurchase credit | shares					27,378,866
Value of common stock to be repurchased to avoid providing repurchase credit					$ 1,583,000,000
Derivative liability					0
Debenture
Business Acquisition [Line Items]
Payments to acquire investments					66,995,000	$ 50,000
Estimated fair value					28,824,000		27,448,000
Additional payment upon satisfaction of certain conditions						$ 50,000
Warrants
Business Acquisition [Line Items]
Derivative, financial liability					26,920,000		615,575,000
Maximum | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Share repurchase credit limit					1,583,000,000
Acreage
Business Acquisition [Line Items]
Aggregate payment	$ 49,849,000	$ 37,500	$ 395,190,000	$ 300,000
Acreage | Acreage Financial Instrument
Business Acquisition [Line Items]
Derivative, financial liability					$ 47,000,000		$ 600,000,000
Acreage | Maximum
Business Acquisition [Line Items]
Number Of Fixed And Floating Shares Issued | shares	32,700,000	32,700,000
Acreage | Class E Subordinated Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3048	0.3048
Acreage | Class D Subordinated Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Minimum call price | $ / shares		$ 6.41

Leases - Additional Information

Leases - Additional Information (Details) - Maximum	Mar. 31, 2022
Lessee Lease [Line Items]
Lessee, operating lease, term	30 years
Lessee, finance lease, term	30 years

Leases - Summary of Lease Right

Leases - Summary of Lease Right-of-use Assets and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating lease	$ 39,571	$ 47,522
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment	Property, plant and equipment
Finance lease	$ 34,333	$ 39,427
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment	Property, plant and equipment
Operating and finance lease right of use asset	$ 73,904	$ 86,949
Operating lease	$ 11,752	$ 11,491
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance lease	$ 26,283	$ 30,570
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Operating lease	$ 58,031	$ 62,285
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance lease	$ 43,094	$ 31,879
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Total finance lease liability, noncurrent	$ 139,160	$ 136,225

Leases - Summary of Components

Leases - Summary of Components of Total Lease Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating lease expense	$ 5,245	$ 10,846
Amortization of right-of-use assets	3,883	2,303
Interest on lease liabilities	1,667	1,674
Total lease expense	$ 10,795	$ 14,823

Leases - Summary of Minimum Pay

Leases - Summary of Minimum Payments Due for Lease Liabilities (Details) $ in Thousands	Mar. 31, 2022CAD ($)
Lessee Disclosure [Abstract]
2023	$ 12,004
2024	11,402
2025	10,923
2026	9,892
2027	9,525
Thereafter	17,761
Total lease payments	71,507
Less: Interest	1,724
Total lease liabilities	$ 69,783
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities
2023	$ 8,023
2024	8,116
2025	8,200
2026	38,476
2027	3,388
Thereafter	6,262
Total lease payments	72,465
Less: Interest	3,088
Total lease liabilities	$ 69,377

Leases - Summary of Measurement

Leases - Summary of Measurement of Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating cash flows from operating leases	$ 12,905	$ 18,792
Operating cash flows from finance leases	1,667	1,674
Financing cash flows from finance leases	$ 1,494	$ 2,303

Leases - Summary of Right-of-us

Leases - Summary of Right-of-use Assets Obtained in Exchange for New Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating leases	$ 9,019	$ 13,592
Finance leases	$ 3,720	$ 1,428

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Remaining Lease Term (Details)	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating leases	7 years	7 years
Finance leases	4 years	4 years

Leases - Summary of Weighted _2

Leases - Summary of Weighted Average Discount Rate (Details)	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Operating leases	4.50%	4.50%
Finance leases	4.50%	4.50%

Commitments - Summary of Annual

Commitments - Summary of Annual Minimum Commitments Associated with Contractual Agreements (Details) $ in Thousands	Mar. 31, 2022CAD ($)
Commitments And Contingencies Disclosure [Abstract]
2023	$ 130,453
2024	72,653
2025	33,641
2026	24,347
2027	16,936
Thereafter	57,773
Total annual minimum commitment associated with contractual agreements	$ 335,803

Segmented Information - Additio

Segmented Information - Additional Information (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021Segment	Mar. 31, 2022Customer	Mar. 31, 2021SegmentCustomer	Mar. 31, 2020Customer
Segment Reporting Information [Line Items]
Number of operating segments | Segment	2		2
Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk customer number of customers | Customer		1	0	1

Segmented Information - Summary

Segmented Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 520,325	$ 546,649	$ 398,772
Gross margin	(193,054)	66,960	(31,684)
Selling, general and administrative expenses	472,756	575,389	693,737
Share-based compensation	47,525	91,149	320,276
Expected credit losses on financial assets and related charges	0	109,480	0
Asset impairment and restructuring costs	369,339	534,398	623,266
Operating loss	(1,082,674)	(1,243,456)	(1,668,963)
Loss from equity method investments	(100)	(52,629)	(64,420)
Other income (expense), net	753,341	(387,876)	224,329
Net loss before income taxes	(329,433)	(1,683,961)	(1,509,054)
Global Cannabis
Segment Reporting Information [Line Items]
Net revenue	337,216	378,680	294,935
Gross margin	(251,235)	7,045	(76,836)
Other Consumer Products
Segment Reporting Information [Line Items]
Net revenue	183,109	167,969	103,837
Gross margin	$ 58,181	$ 59,915	$ 45,152

Segmented Information - Summa_2

Segmented Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 520,325	$ 546,649	$ 398,772
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	296,369	329,172	256,166
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	90,874	116,379	93,945
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	82,080	64,926	24,568
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 51,002	$ 36,172	$ 24,093

Segmented Information - Summa_3

Segmented Information - Summary of Disaggregation of Long-lived Tangible Assets by Geographic Areas (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 942,780	$ 1,074,537
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	827,591	847,678
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	63,247	143,747
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 51,942	$ 83,112

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Company and Lemurian, Inc. (Jetty) - Subsequent Event $ in Thousands	May 18, 2022CAD ($)
Subsequent Event [Line Items]
Acquisition of outstanding capital stock	100.00%
Upfront payments	$ 69,000
Ownership percentage	75.00%
Percentage of ownership increase in common shares outstanding	100.00%